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ABSTRACT
Understanding the metabolic fate of drug candidates in vitro and in vivo is a key 
component of drug development. Structural characterisation of drug candidate 
metabolites is important early in drug discovery to identify unwanted metabolic 
liabilities such as reactive, active, toxic or human specific metabolites. Reactive 
metabolite (RM) liability is a major concern for pharmaceutical companies 
during drug design, with most of the industry running primary RM trapping 
screens.
This thesis investigates Fenclozic acid, homopiperazine reactivity, 
homomorphyline reactive aldehyde and methanol adduct formation, where RMs 
were not detected through routine glutathione/cyanide trapping assays.
Fenclozic acid was withdrawn from clinical development due to hepatotoxicity; 
the mechanism of hepatotoxicity was never determined. In vitro covalent 
binding studies indicated phase I bioactivation in human liver microsomes, 
however no RMs were identified from in vitro experiments. As a part of this 
PhD thesis the metabolism of Fenclozic acid was investigated in bile duct 
cannulated rats using modern analytical techniques. Several new metabolites 
including glutathione related adducts formed through an epoxide RM were 
identified.
A series of homopiperazine compounds were found to react with endogenous 
formaldehyde during rat in vivo studies. This thesis describes a detailed 
investigation into the identification and mechanism of formation of the resulting 
product, a bridged homopiperazine formed through a reactive Schiff base 
intermediate.
A cysteineglycine conjugate observed for a series of homomorpholine 
compounds trapped by glutathione in human liver microsomes has been 
investigated in this thesis. NMR, detailed MS and methoxyamine trapping 
confirmed formation of a thiazolidine glycine product via a reactive aldehyde 
and subsequent glutathione rearrangement.
A compound series in an early drug discovery programme formed unusual 
methanol adducts post incubation in human liver microsomes. The work 
undertaken in this thesis revealed the generation of a reactive aldehyde 
metabolite that did not form an adduct with glutathione, but reacted with the 
methanol mobile phase to form a pair of hemiacetal diastereoisomers.
These examples would not have been detected using routine glutathione RM 
screening assays, this thesis highlights limitations of a screening approach, and 
where detailed metabolite identification studies employing modern LC-MS 
techniques are critical in understanding RM formation.
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1. INTRODUCTION
1.1 Drug metabolism and pharmacokinetics in drug discovery
and development
Drug metabolism and pharmacokinetics (DMPK) is concerned with the fate of 
administered drug in the body. In the 1990s 40% of drug attrition was due to 
poor DMPK properties, and investment in DMPK had improved this statistic so 
that by the 2000s this had reduced to less than 10% attrition. However overall 
drug approval rates remained low1. Pharmacokinetics (PK) examines drug 
concentrations over time, and is influenced by the drug’s absorption, 
distribution, metabolism and excretion (ADME) properties. Both the rate and 
extent of absorption can be of concern, especially for orally administered drugs. 
When a drug is absorbed it passes through the liver first where metabolism of 
xenobiotics occurs and this is often described as first pass metabolism. Once in 
the systemic circulation the drug may become bound to plasma proteins or as 
free drug it is able to distribute into tissues/cells. Ultimately the drug will be 
excreted via urine or faeces unchanged or as a metabolite.
The rate of removal of active drug from the body can be referred to as 
Clearance (CL), which describes the volume of drug cleared per unit of time. It 
is important to understand the CL of a drug together with its volume of 
distribution to determine its plasma half-life. The optimisation of plasma half-life 
is critical (together with dose) to achieve sufficient duration of exposure of a 
drug to illicit efficacy for the desired therapeutic indication. Systemic CL can be 
due to metabolism, excretion of drug or a combination of both. It is therefore 
important to understand the routes of metabolism and elimination, which are 
studied in both in vitro and in vivo systems.
1.1.1 Drug/Xenobiotic metabolism
Xenobiotic metabolism is the biochemical modification of a drug or foreign 
compound by living organisms, typically to more polar water soluble metabolites 
which are more readily excreted from the body. Drug metabolism can generally 
be divided into two phases; Phase I and Phase II. Phase I metabolism involves 
oxidation, hydrolysis or reduction that typically increases the polarity of the drug.
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These metabolites often maintain some parent drug activity, in the case of pro­
drugs become more active, or they can be chemically reactive through 
bioactivation.
There are a number of enzymes that are known to catalyze Phase I 
biotransformation reactions such as the cytochrome P450 family (CYP), flavin- 
containing monooxygenases, aldehyde oxidase, alcohol dehydrogenase and 
monoamine oxidases. The most important of these for xenobiotic metabolism 
in humans is the CYP family2"5 which are responsible about 75% of all Phase I 
dependent drug metabolism4.
The human CYP family consists of numerous enzymes, however for drug 
metabolism; enzyme families 1-3 are the most important and are responsible for 
10-80% of all phase I dependent metabolism of clinically used drugs4. These 
families can be divided up into sub families e.g. CYP3A and CYP3B and each 
individual member of a subfamily is labeled with Arabic numerals (e.g. 
CYP1A2)3. CYP3A4 is the most abundant CYP in the human liver and is the 
most important CYP for drug metabolism, responsible for about 50% of the 
metabolism of clinically used drugs4,6. Drug metabolism by cytochrome P450s 
is a major cause of drug-drug interactions where co-administration of more than 
one drug leads to change in the exposure of one or more of the drugs and their 
metabolites. For example co-administration of a strong inhibitor of CYP3A4 
such as ketoconazole with a drug that is primarily metabolized by CYP3A4 
could lead to accumulation and increased exposure of that drug. This can have 
potentially dire consequences, such as life-threatening arrhythmias which 
occurred when 3A4 inhibitors were co-administered with terfenadine an anti­
histamine), which was later withdrawn7.
Phase II drug metabolism involves conjugation of small polar endogenous 
molecules (such as glutathione, sulphate, acetyl, glucuronic acid and amino 
acids) with specific functional groups on a drug, either directly to the drug or 
more often to a phase I metabolite . In contrast to phase I metabolism, phase II 
metabolism generally results in metabolites that are deactivated and or less 
reactive than the substrate, the exception being acyl-glucuronides where 
metabolites can be more chemically reactive.
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1.1.2 Metabolite identification
Metabolite identification studies are fundamental to the discovery, refinement, 
optimization and development of small molecule therapeutics (xenobiotics) for 
humans. Metabolite identification studies are conducted from early design all 
the way through to life cycle management of a drug. Early discovery metabolite 
identification work focuses on drug design such as ‘soft spot analysis’ or 
identification of reactive/toxic metabolite liabilities to direct iterative synthetic 
chemistry make test cycles towards structures with favourable DMPK and 
safety profiles. Later drug development activities are more focused on 
quantifying and identifying metabolites in man, with a focus on major circulating 
metabolites. It is vital to avoid any unexpected occurrences such as the 
formation of reactive, active or circulating human specific/disproportionate 
metabolites in clinical trials, so it is important to identify, avoid or evaluate these 
issues during drug design.
1.1.2.1 Metabolite identification soft spot analysis
Metabolism studies begin early in drug discovery at lead identification or earlier, 
where large numbers of compounds are investigated to identify a promising 
series of compounds. At this stage it is important that there is sufficient 
exposure of a test compound in the efficacy species to be able to measure it’s 
in vivo efficacy. There are two important considerations to achieve good 
exposure of an orally administered drug; absorption and CL. It would be 
expensive and inefficient to dose large numbers of compounds to animals to 
optimise absorption and CL in vivo and would be against the 3 R’s principles 
(Refine, reduce, replace animal usage), which all pharmaceutical companies 
are committed to. One way to reduce the number of compounds dosed to 
animals, is to optimise the CL in vitro first.
Metabolism is a major CL mechanism that primarily occurs in the liver, so 
measuring a test compound’s metabolic stability or intrinsic CL (Clint) will help 
understand the in vivo CL. These measurements can be determined in vitro 
using liver microsomes and/or hepatocytes, which contain enzymes for the most 
prevalent metabolic processes in the liver. Compounds are incubated in liver 
microsomes or hepatocytes where samples are taken at set times and
16
compound disappearance is measured allowing a Clint to be determined6. 
These in vitro experiments are high throughput and high numbers of 
compounds can be tested quickly and cheaply compared to in vivo testing.
One way to help reduce the Clint for a chemical series is to identify the major 
sites of metabolic liability on structure by in vitro soft spot metabolite 
identification. This metabolite identification is relatively simple, often only the 
top 2 or 3 metabolites are identified from the microsomal or hepatocytes 
incubation. Absolute confirmation of the metabolite structure is not always 
required and often just an idea of the site of metabolism is sufficient. Therefore 
the data can be generated quickly to direct iterative synthetic chemistry make- 
test cycles towards better compounds (Figure 1). Probe compounds with 
favourable Clint and potency are dosed to animals (rodents) to generate in vivo 
pharmacokinetic (PK) data to determine exposure.
Figure 1 Compound optimisation by soft spot analysis and structural 
modification to block metabolism
DMT
structure
Modified
O —  DMT 
I Structure 
/  modified
Major site of metabolism Major site of metabolism
Cljnt <300 pL/mL/mg >10 pL/mL/mg
 >
Increasing metabolic stability
DMT = Design make test
1.1.2.2 In vitro-in vivo extrapolation disconnect
Optimising Clint in vitro for a chemical series does not always correlate to the in 
vivo situation and there can be a significant disconnect in the in vitro/in vivo 
extrapolation (IVIVe) of CL. When this occurs, it is likely there is a CL 
mechanism in vivo that is not represented in vitro in microsomes or 
hepatocytes. This can be metabolic or non-metabolic, often the best way to 
identify the problem is to intravenously (i.v.) dose a bile cannulated animal (the 
species with the disconnect) and collect bile and urine. The parent drug is then 
quantified in the collected bile and urine (normally over a time course) and the 
% of dose excreted as parent compound can be calculated. If the majority of
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the dose is excreted as parent compound then major CL mechanism is likely to 
be non-metabolic. If very little parent drug is quantified then the major CL 
mechanism is metabolic, which is not likely not to be represented in 
hepatocytes or microsomes and therefore potentially non-hepatic metabolism.
Non-hepatic metabolism was observed for compound AZX discussed in 
Chapter 4, where an unusual carbon hydrogen addition metabolite was 
observed in vivo in the rat, but not formed in rat microsomal or hepatocytes 
incubations. It is important to identify the exact metabolite to identify the 
structural liability so it can be avoided for future drug discovery programmes.
1.1.2.3 Reactive metabolites and toxicity
Metabolic processes normally transform xenobiotics into harmless, inactive 
water-soluble products to improve excretion from the body. However some 
metabolic transformations can result in products that are considerably more 
chemically reactive than the parent test compound or drug, this process is 
known as bioactivation. The product is referred to as a reactive metabolite 
(RM), but is in fact a reactive intermediate that undergoes further reaction. The 
most common of these reactive intermediates are electrophiles which can vary 
in nature from soft to hard. RMs may cause toxicity by binding to nucleophilic 
groups on macromolecules in the body such as protein, lipids and nucleic acids.
Glutathione (GSH), a tripeptide consisting of cysteine (Cys), glycine and 
glutamyl, present in animal cells, offers some protection from reactive/toxic 
compounds/metabolites8. It contains a thiol group which acts as a competing 
nucleophilic site for RMs to bind to rather than nucleophiles present on 
endogenous macromolecules. A good example of the protective properties of 
GSH is the bioactivation of paracetamol, a small molecule analgesic drug. 
Paracetamol is metabolized in man to a quinoneimine electrophilic RM that 
covalently binds to macromolecules which can cause hepatotoxicity. GSH 
protects against this covalent binding (CVB) by reacting with the quinoneimine 
metabolite/intermediate forming a non-reactive GSH adduct (Figure 2)9.
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Figure 2 Bioactivation of paracetamol and detoxification of the resulting 
RM by GSH
This defensive mechanism is not always completely successful, and in some 
cases reactive electrophilic intermediates are not efficiently detoxified by GSH 
or in other cases may deplete GSH both resulting in CVB to cellular 
macromolecules. This type of in vivo CVB can lead to toxicity and adverse drug 
reactions (ADR) in the clinic10,11.
1.1.2.3.1 Adverse drug reactions
The World Health Organization defines an adverse reaction as ‘a response to a 
drug which is noxious and unintended, and which occurs at doses normally 
used in man for the prophylaxis, diagnosis, therapy of disease, or the 
modifications of physiological function’12. ADRs are a serious concern for 
pharmaceutical companies, they are one of the most common causes for 
withdrawing a drug for the market and are estimated to be the 4th most common 
cause of death in the United States (US)13. It is estimated that about 2 million 
patients in the US experience serious ADRs each year from drugs on the 
market, which results in 100,000 deaths. In the United Kingdom, there were 
557,978 ADR associated hospital admissions from 1999 to 2008, with 
approximately 5% mortality14.
ADRs are often classified into two important categories Type A and Type B, 
however there is an extended categorization that includes Type C, Type D and 
Type E15. Type A reactions are the result of a drugs primary or secondary 
pharmacological actions when given at the therapeutic dose and account
Bioactivation +GSH
Detoxification
Paracetamol
i oGlutathione adduct
Covalent binding to 
Macromolecules and 
toxicity
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approximately 80% of all ADR’s. These reactions are rarely life threatening and 
are normally dose dependent, so they are reversible on reducing dose or by 
withdrawing the drug16. Type A ADRs are generally predictable and can be 
identified from the pre-clinical toxicological studies in animals. Type B reactions 
are not related to the known pharmacology of the drug and are primarily related 
to the patient or individual dosed so are not predictable. They are referred to as 
an idiosyncratic adverse drug reaction (IADR) or idiosyncratic drug reaction 
(IDR). It is not currently possible to predict who will develop an IDR to a drug 
and there are no general animal models to predict the occurrence of IDR’s. 
They can be dose dependent for the susceptible individuals; however most 
dosed patients will not have an IDR from a specific drug at any dose, so 
increasing the dose does not necessarily increase the risk or frequency of 
IDRs17. IDRs are rarer than type A with frequencies ranging from as high as 5% 
of users to as low as 1 in 10000 or 1 in 100,00018, however they are more 
serious and can be life-threatening. Due to the frequency and unpredictability 
these events are often only seen late in the development program or when the 
drug is licensed, both are likely to be after significant investment in its 
development.
1.1.2.3.2 RMs link to IDRs
IDRs can affect a number of different organs in the body, however drug induced 
liver injury (DILI) is the type that most commonly leads to drug withdrawals or 
failure to obtain market approval17,19. DILI can be predictable (non- 
idiosyncratic, Type A), these are generally dose related and a result of direct 
toxicity of the parent drug or its metabolites, for example in the case of 
paracetamol9. This non-idiosyncratic DILI is more likely to be detected during 
the pre-clinical toxicological studies and therefore drugs generating these rarely 
get to market. In contrast, idiosyncratic (unpredictable, type B) DILI related 
events often materialize late in a drugs development or when the drug has been 
licensed, hence is responsible for most of the DILI related drug withdrawals17,19' 
21. Withdrawing a drug late in its development or from the market is very 
expensive and can significantly damage a company’s reputation, as well as 
putting patient health at risk, so idiosyncratic DILI is a serious concern for 
pharmaceutical companies.
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The liver metabolizes xenobiotics in order to make them more polar to aid 
excretion, so will be exposed to high concentrations of drug and its 
corresponding metabolites after dosing. Bioactivation of the drug to a RM is 
believed to be the first step towards DILI and hepatotoxicity for most 
drugs17,19,21,22; they can covalently bind to protein, lipids or nucleic acids. All of 
these have a direct effect on cell function, which can cause hepatic cell death 
leading to liver injury. A good way to reduce the risk of idiosyncratic DILI in the 
clinic is to try to avoid compounds that can generate RMs in man.
Over the last 15-20 years pharmaceutical companies have tried to identify 
compounds that generate RMs in early drug discovery and where possible 
modify chemistry to remove the liability. There are a number of ways to identify 
and avoid RMs, including in silico prediction, metabolite identification and in 
vitro trappinglin vitro trapping screens. The in silico metabolite predictive tools 
are beyond the scope of this thesis and are not discussed. Metabolite 
identification studies are generally low throughput and time consuming, so 
cannot be used to assess large numbers of compounds early in drug discovery, 
but can be applied sensibly by analyzing a selected compound representing a 
chemical series. In vitro trapping experiments are a tool that can be used by a 
metabolite identification scientist to help detect RMs and investigate their 
mechanism of formation. They can also be applied in a higher throughput 
manner using appropriate automation and analytical techniques (Section 1.5.1).
It is important to note that not all compounds that form a RM will lead to toxicity 
in man and that there are other factors that are important such as disease area, 
patient population and importantly the predicted human daily dose. In addition, 
it is not always possible to remove the RM liability by chemically altering 
compounds as the liability could be embedded in the pharmacophore, where 
structural changes would significantly impact its potency.
1.1.2.4 Active metabolites
Generally metabolism of an active drug leads to the formation of considerably 
less active or inactive metabolites. However, occasionally biotransformation of 
an active drug can lead to the generation of metabolites with equal or greater 
pharmacological activity (active metabolite). Active metabolites can be of
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concern to drug discovery programmes due to the added complexity of 
understanding the metabolite contribution to the safety and efficacy profile of 
the drug, so are often avoided.
However, a metabolite identified in drug discovery may have superior 
pharmacological, pharmacokinetic, and safety profiles compared to its parent 
compound. In this case the metabolite may be developed in to a drug and there 
are several examples of this reported including oxyphenbutazone, oxazepam, 
cetirizine, fexofenadine and desloratadine23. Confirming a metabolite has 
activity requires identifying its exact structure to enable metabolite synthesis for 
subsequent activity testing. Therefore it is important to try and determine the 
exact structure of metabolites when they are formed in high quantities from 
human in vitro experiments for promising compounds approaching 
development.
The pro-drug approach to drug design is where an inactive compound with 
favourable bioavailability is designed to be metabolised to an active drug via 
first pass metabolism. This is different to active metabolites, which have been 
defined as a pharmacologically active metabolic product with activity against the 
same pharmacological target as the parent molecule23,24.
1.1.2.5 Metabolites in Safety testing
Non-clinical toxicological studies generally include the assessment of circulating 
concentrations of drug, which are used to compare the systemic exposure of 
the drug in the toxicological animal species with systemic exposure in humans 
to help guide clinical trials. This is likely to be sufficient if the metabolic profile in 
humans is similar to at least one of the animals used in the study, however 
metabolites can vary across species both quantitatively and qualitatively. 
Safety testing of drug metabolites is a serious consideration for drug 
development programmes and is concerned specifically with drug metabolites 
circulating in human plasma.
Circulating human metabolites can contribute to the primary target 
pharmacology, off target pharmacology/secondary pharmacology and/or toxicity 
of a drug through active, reactive and toxic metabolites. These metabolites
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could represent a significant proportion of the dose or even be present at higher 
concentrations than the parent drug in plasma or tissues. In this circumstance it 
is important to understand if these metabolites are represented in one of the 
toxicological species and whether the metabolite exposure is equivalent to or 
high compared to humans.
In 2008 the Food and Drug Administration (FDA) centre for drug evaluation and 
research (CDER) issued ‘the safety testing of metabolites’ guidance also known 
as metabolites in safety testing (MIST)25. Further guidance was published in 
2009 following the International Conference on Harmonisation (ICH) of technical 
requirements for regulations of pharmaceuticals for human use26. Both 
documents define levels of metabolite exposure in humans and pre-clinical 
species that would assure regulators.
The FDA guidance states that ‘generally, metabolites identified only in human 
plasma or metabolites at disproportionately higher levels in humans than in any 
of the animal test species should be considered for safety assessment’. Human 
metabolites that can raise a safety concern are those formed at greater than 
10% of parent drug systemic exposure at steady state27. Both the FDA and ICH 
guidance documents26,27 recommend the same 10% threshold value; however 
the ICH guidance refers to percentage of total drug related material (tDRM) 
rather than a percentage of parent drug. Percentage of tDRM is more 
commonly adopted within the pharmaceutical industry. Therefore metabolites 
that are unique or disproportionate in humans are not of concern if they are 
<10% relative to tDRM at steady state, and metabolites >10% are not of 
concern if there is equal or greater exposure of the metabolite in the 
toxicological species. Hence, it is necessary to either demonstrate there are no 
metabolites greater than 10% (quantification of circulating human metabolites) 
or to confirm equal exposure in the toxicological species (in vivo cross species 
comparison). Metabolite profile comparisons in vitro (hepatocytes or 
microsomes) are not sufficient to determine if a test compound has a 
unique/disproportionate metabolite26,27, so both approaches require the analysis 
of human plasma and/or plasma from the toxicological species.
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Radiolabelled ADME studies provide the most definitive metabolite identification 
and quantification in vivo in humans and pre-clinical toxicological species28. 
Therefore a human radiolabelled ADME metabolite profiling study would 
determine if any metabolites were circulating greater than 10%. Comparison of 
the metabolite profiles from the radiolabelled ADME studies in human and the 
toxicological species, confirms if any of the human metabolites are unique or 
disproportionate. Human ADME studies are very expensive and often 
pharmaceutical companies prefer to backload these studies until there has been 
proof of concept around Phase lib clinical trials. To perform this analysis earlier 
numerous non-radiolabelled methodologies have been reported in the literature 
for quantification, metabolite detection and profiling comparison.
1.1.2.5.1 Area under the curve pooling of samples for total metabolite 
exposure quantification or comparison
To quantify or compare the total exposure of all metabolites and drug plasma, 
concentrations can be determined from samples taken at several time-points 
during a dosing interval (typically 24 hours). The area under the curve (AUC) 
integrates concentrations over time and is used as a measure of total drug or 
metabolite exposure, unlike maximal concentration (Cmax) that only compares 
amounts at a snapshot in time. The AUC of a metabolite can be used to judge 
whether there is a disproportionate amount in human to other species or if it 
represents more than 10% of tDRM. It would be time consuming and labour 
intensive to identify and quantify metabolites at each time-point, so the time- 
points available are pooled in order to construct a single sample for analysis. 
The volumes of each time point are pooled to reflect the relative proportions 
based on the PK profile needed to assess the AUC, and this is known as an 
AUC pooling as reported by Hamilton et al.29.
1.1.2.5.2 Quantification of metabolites in human plasma for MIST  
assessments
This approach is to first identify and quantify all plasma circulating metabolites 
in an AUC pooled human plasma sample to determine if the exposure of any of 
the metabolites detected is greater than 10% of the tDRM. Quantification is not 
possible by mass spectrometry (MS) without a standard (Section 1.2.4), so
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alternative techniques such as UV and nuclear magnetic resonance (NMR) 
have been used30. Yu et a/.31 reported the quantification of metabolites using a 
radiolabelled compound to generate in vitro metabolites, then determined a 
MS/radioactivity response factor to quantify human in vivo metabolites. If there 
are any metabolites at or above the 10% threshold then these are assessed to 
ensure their exposure in the toxicological species is at least equal to their 
exposure in humans. Due to this arbitrary 10% cut off and the accuracy of 
bioanalytical methodology metabolites slightly below this percentage will also 
likely be investigated.
1.1.2.5.3 In vivo cross species metabolite comparison of circulating 
metabolites in human versus the toxicological species
This approach focuses on determining if the toxicological species have been 
exposed in equal or greater levels to metabolites observed in humans. This is 
done by comparing the metabolite plasma profiles in a human AUC pooled 
sample with the metabolite profiles from the toxicological species. Comparison 
of all human metabolites with the equivalent metabolites (if formed) in the 
toxicological species is used to determine if any are disproportionate or unique 
to humans. This can be done using the techniques discussed in Section
1.1.2.5.2 or simply by liquid chromatography mass spectrometry (LC-MS) 
comparing the MS peak areas of each metabolite in human with the peak area 
of the equivalent metabolite in the toxicological species. Matrix matching of the 
human and animal samples is done to equalise any matrix or ion suppression 
effects (Section 1.2.4). Only the MS responses (peak area) of identical 
metabolites are compared with each other, so there should not be any variation 
in ionisation efficiency due to structural differences. If any metabolites are 
disproportionate or unique to humans then accurate quantification of these 
metabolites in humans is required to determine if they are greater than 10% of 
the total circulating drug related material. If no metabolites are human unique 
or disproportionate then no further work is required.
1.1.2.5.4 MIST strategy summary
It is important to understand the metabolism of a drug in humans before it is 
tested on large numbers of patients. The best way to ensure there are no
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problems later on in the clinic is to have synthetic standards for the major 
human circulating metabolites available before humans are dosed. Metabolites 
with analytical standards can be accurately quantified, tested for activity and 
dosed to toxicological species if specific or disproportionate in humans. 
Therefore identifying the exact structures of human metabolites in vitro and/or 
identifying them in other test species prior to the clinic is very important.
1.1.3 Drug discovery/development process
An overall view of the small molecule pharmacuetical drug discovery and 
delevlopment process is illustrated in Figure 3. Drug discovery is focused on 
the identification of a safe, potent, small molecule (from multiple potential 
compounds) to progress into clinical trials. Development studies are primarily to 
determine and understand the drugs effects on the human body including 
clinical toxicity and efficacy. The further a compound progresses in 
development the large the number of patients/volunteers used, hence the 
increasing cost.
Figure 3 Drug discovery process (top) leading into drug development 
process (bottom).
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1.2 LC-MS
LC-MS is the most widely used analytical technique in drug research and is 
generally applied to the separation, quantification and/or structural 
characterisation of molecules from mixtures. It has become the predominant
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analytical tool for the detection quantification and characterisation of drugs and 
metabolites in biological matrices32,33. MS instruments for metabolite 
identification studies are normally coupled to a high performance liquid 
chromatography (HPLC) system or ultra high performance liquid 
chromatography (UHPLC) system, see Figure 4 for a block diagram of a typical 
set up for these systems.
Figure 4 Block diagram of a typical UHPLC or HPLC system connected to 
a mass spectrometer
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It is not uncommon for drugs to form multiple metabolites with the same 
accurate mass; such as multiple +0 (hydroxylated) metabolites, therefore it is 
important to separate these by chromatography prior to MS analysis.
1.2.1 Liquid chromatography
Liquid chromatography (LC) is a technique used to separate components within 
a mixture through interactions with 2 phases; a mobile phase and a stationary 
phase. Components in a mixture are separated if they interact through 
hydrogen bonding, van der Waals forces or/and electrostatic forces to different 
extents with the mobile and/or stationary phases. There are different modes of 
liquid chromatography that include: normal-phase liquid chromatography, 
reverse phase liquid chromatography, ion-exchange liquid chromatography and 
size-exclusion chromatography. Reverse phase chromatography is the most 
compatible and the mostly commonly used separation mode with mass 
spectrometry. Reverse phase chromatography separates components using a 
polar mobile phase (typically water) and a non-polar stationary phase. Water in 
the mobile phase repels the non-polar regions of a molecule, which facilitates a
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molecule stationary phase interaction through van der Waals forces. Molecules 
that are more polar will interact more with the mobile phase and elute earlier, 
conversely less polar molecules will interact more with the stationary phase and 
elute later. For this reason the vast majority of drug metabolites elute before 
drug by reverse phase chromatography.
1.2.2 HPLC
The mobile phase eluents consist of water and an organic solvent which is 
typically either acetonitrile or methanol for LC-MS applications. Mobile phase 
can be delivered in two ways, firstly isocratically, where the same composition 
of organic and aqueous is maintained across a run and is often used to 
separate a few compounds of similar polarity. Secondly by a gradient, where 
the mobile phase is changed across a run moving from mostly aqueous to more 
organic and is used to separate multiple components with varying polarities. 
Considering the potential for vastly differing polarities of metabolites and parent 
drug, gradient delivery is required for metabolite identification work.
Reverse phase HPLC stationary phases generally consist of a non-polar alkyl 
chain such as C18 bound to silica gel particles which are packed into a metal 
column. Column efficiency is measured in theoretical plates (A/) and height 
equivalent to a theoretical plate (HETP):
HETP = —
N
Equation 1
Where L is column length. The efficiency of chromatographic columns 
increases with the number of theoretical plates and when the HETP is smaller. 
Equilibration rate between mobile and stationary phases is finite; therefore 
analyte band shape and column efficiency depend on the rate of elution, or 
mobile phase flow rate. The Van Deemter equation describes the mechanisms 
of band broadening:
HETP = A+  — + Cv 
v
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Equation 2
A represents Eddy diffusion, which is a measure of the multiple paths of 
different lengths travelled by analytes between particles that is caused by small 
variations in particle size, so is broadly independent of flow rate. B represents 
longitudinal diffusion, since the longer the analyte spends on the column the 
greater its diffusive spreading; therefore it is dependent on flow rate. Cv 
represents the equilibration time between phases and this increases as flow 
rate increases. The band broadening effects due to due A and Cv are reduced 
for smaller particle size columns, so in general smaller particle size columns are 
more efficient. Flow rate for a column is optimal when HETP is at its minimal 
value and is dependent on the particle size (Figure 5).
Figure 5 Van Deemter plot showing the effect of flow rate on column 
efficiency (HETP) for different particle sizes and the optimal flow rate (red 
arrow) increases as the particle size decreases
The smaller the particle size, the higher the optimum flow rate, the better the 
column efficiency; however flow rate is limited due to back pressure (pressures 
above 400 bar are not possible on HPLC systems). Smaller particle size 
columns suffer less diffusion so can accommodate higher flow rates without 
losing column efficiency (Figure 5), where 1.9 pm has the flattest curve.
Introducing a column heater reduces the viscosity of the mobile phase solvents 
to enable higher flow rates and improved column efficiency. Whilst this offers 
some improvement, generally HPLC pressure limitations restrict flow rates 
which are sub optimal for smaller particle size columns, and generally HPLC
Optimal flow  rates
Mobile phase velocity (cm/min)
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particle sizes are typically around 3 to 5 pm. There are significant efficiency 
gains moving to smaller particle size columns if the back pressure limitations 
could be overcome.
1.2.3 UHPLC
UHPLC systems are essentially HPLC systems with pumps, columns and 
fittings that can cope with significantly higher pressures, typically 2x greater. 
The ability to run at higher pressures enables the use of smaller particle size 
columns typically 1.5-3 pm at more optimal flow rates. Using UHPLC systems 
with smaller particle size columns has three main effects; reduced HETP, 
optimal flow rate is higher and the loss in efficiency when flow rates are greatly 
above optimal are significantly reduced. The effects can be used to either 
dramatically speed up analysis times by running at higher flow rates or to 
improve separation on longer runs34'36. Castro-Perez et a l37 demonstrated 
significant gains in chromatographic resolution, speed of analysis and sensitivity 
employing UHPLC for in vitro metabolite identification experiments.
Most modern LC-MS systems for metabolite identification applications have 
replaced HPLC with UHPLC systems; however peak widths are significantly 
smaller than standard HPLC and are often around 3 seconds wide. This would 
limit the number of MS experiments that can be acquired in a single scan.
1.2.4 MS Ionisation Source
Coupling a LC system directly to a mass spectrometer requires an interface to 
convert the liquid flow into gaseous ions prior to introduction into the mass 
spectrometer, which is under a high vacuum. Historically it was not easy to 
couple LC to MS using the conventional ionization methods at the time such as; 
electron ionisation (El), fast atom bombardment or chemical ionisation. It was 
not until the advent of atmospheric pressure ionisation (API) techniques such as 
electrospray (ESI), atmospheric pressure chemical ionisation (APCI) and 
atmospheric pressure photo ionisation (APPI) that LC-MS became popular and 
it is currently amongst the most widely used analytical techniques.
API methods are well suited to LC-MS and essentially involve spraying a 
solution containing analyte at atmospheric pressure into the ion source and
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through a combination of thermal and pneumatic processes, desolvation occurs. 
They are also referred to as ‘soft ionisation techniques’ where very little in­
source dissociation of the analyte is observed and usually a protonated 
molecule ([M+H]+ ion) is formed in positive ion mode and a deprotonated 
molecule ([M-H]' ion) in negative ion mode. Determining the molecular weight 
of an analyte from the [M+H]+ or the [M-H]' ion simply involves adding or 
subtracting the mass of a proton.
For APCI and APPI, ions are formed chemically in the gas phase via gas phase 
reactions precipitated by a corona discharge needle and a krypton discharge 
lamp respectively. For ESI, an electric field is used to generate charged 
droplets and subsequently ions through evaporation. The best ionisation 
efficiency is achieved when analyte ions are already charged in solution and 
therefore ESI is best suited for the analysis of polar and ionic compounds. 
APCI and APPI are complimentary techniques to ESI and are generally applied 
to non-polar analytes which are not detectable or give poor responses by ESI- 
MS. If the parent compound is ionised effectively by ESI then it is highly likely 
all of the metabolites will also be ionised, since most metabolites are more polar 
than the parent compound, therefore ESI is often the first choice ionisation 
technique.
The main disadvantage of API ionisation techniques is ion suppression, where 
background ions may alter the MS response of the analyte of interest38'41. King 
et a/.40 reported that ESI is more susceptible to ion suppression than APCI by 
comparing ion suppression effects from extracted dog plasma. They propose 
that gas phase effects are minimal and the major contributing factor to ion 
suppression is non-volatile material in the spray. Ion suppression is only 
serious concern for metabolite identification studies when attempting to quantify 
metabolite levels by mass spectrometry. Even if ion suppression effects could 
be overcome by sample clean up, differing ionisation efficiencies of the target 
metabolites from the parent compound and other metabolites28,42 make 
quantification impossible without authentic standards. Often other analytical 
techniques are utilised for quantification of metabolites such as NMR, UV or 
radiochemical detection.
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1.2.5 Mass analyzers
Mass analyzers in mass spectrometry are used to separate ions of analytes by 
their mass/charge ratio (m/z) in the gas phase under high vacuum using electric 
and magnetic potentials. The monoisotopic mass can easily be determined by 
multiplying the m/z by the number of charges. Small organic molecule mass 
spectrometry often produces a single charged ion, however double or triply 
charged ions can occasionally be formed. It is easy to identify double or triple 
charged ions, simply by comparing the m/z difference between the 12C and 13C 
isotope peaks in the mass spectrum. For single charge ions it will be 1 Th, for 
doubly charge it will be 0.5 Th and for triply charged -0.33 Th. The ability to 
separate components by mass {m/z) makes mass spectrometry extremely 
useful technique for quantitative and qualitative analysis of molecules in 
biological samples.
Historically metabolite identification studies were conducted on low resolution 
mass analysers such triple quadrupole (QqQ) and ion trap (IT) LC-MS systems. 
These mass spectrometers offered several useful scan functions to find 
metabolites and help elucidate their structure (Section 1.3.1.1 and 1.3.1.2).
More recently, the introduction of hybrid high resolution accurate mass LC-MS 
systems have replaced the low resolution instruments for metabolite 
identification work. The benefits of accurate mass data over nominal mass data 
are very significant for the identification and structural elucidation of metabolites 
and are discussed in Section 1.3.2.1. There are two main types of hybrid mass 
spectrometers; ToF hybrids or orbitrap hybrids, both can be coupled with either 
an IT or a quadrupole mass analyser. The two instruments available for this 
PhD thesis are the quadrupole Time of Flight (Q-ToF) and the IT orbitrap (LTQ- 
Orbitrap XL).
1.2.5.1 Q-ToF
Q-ToF mass spectrometers generally consist of an ion source, a quadrupole 
mass filter, a collision cell and an orthogonal acceleration time of flight (oaToF) 
mass analyser (Figure 6).
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Figure 6 Schematic diagram of a Q-ToF mass spectrometer
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1.2.5.1.1 Quadrupole mass filter
The quadrupole mass filter consists of two pairs of parallel metallic rods 
arranged so the ion beam will be focused axially between them. Each pair of 
rods is connected electrically and a DC voltage is applied to each pair, one at a 
positive potential and the other negative. Variable radio frequency ac potentials 
are also applied to each pair of rods which are 180° out of phase from each 
other. Ions enter the quadrupole and orbit around the central axis of the 
quadrupole, varying the DC/rf electric field can create a suitable path through 
the field for a single m/z. Heavier or lighter ions will not have stable trajectories 
causing them to spin out of the central axis ion path before reaching the 
detector (Figure 7). Thus ions of a selected m/z can be filtered through the 
quadruple by varying the electric field. In the Q-ToF MS Q1 (quadrupole mass 
filter) is used to either filter selected ions into the collision cell for discrete MS2 
experiments or to operate in rf only mode allowing all ions into the collision cell 
for full scan ToF experiments. The collision cell can be used to generate 
collision induced dissociation (CID) with collision gas or allow the ions to pass 
without CID. The Q-ToF scan modes used for metabolite identification work are 
discussed in Section 1.3.2.8.
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Figure 7 Schematic of quadrupole MS filter
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1.2.5.1.2 OaToF Mass analyser
oaToF mass spectrometry determines the m/z of ions by measuring the time it 
takes for them to travel down a flight tube. In oaToF the ion beam from the 
collision cell is focused into the pusher parallel to the flight tube, it then applies 
high voltage push out pulse on a section of the beam, orthogonally accelerating 
a package of ions into the flight tube. Because the m/z of each ion is 
determined by its flight time, the flight tube needs to be under ultra high vacuum 
to avoid any ion collisions with residual background molecules. Any collision 
will alter an ions flight time and therefore the accuracy of its calculated m/z. At 
the opposite end of the flight tube there is a reflectron which is a stack of ring 
electrodes held at increasing voltages at the same polarity as the analyte ion.
As the ions enter the reflectron they are decelerated, stopped and their kinetic 
energy is stored as potential energy, which is released when their direction is 
reversed and they are re-accelerated towards the detector. There are two 
distinct benefits with a reflectron in the flight tube; the length of the flight is 
increased (x2) and a reduction in the arrival time distribution, both improve the 
spectral resolution. Generally there are two detector types for ToF mass
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spectrometry; analogue to digital conversion detectors that measure ion current 
and time to digital conversion detectors that measure individual ion counts.
1.2.5.2 Linear trap guadropole (LTQ) Orbitrap XL
The LTQ orbitrap XL is a linear IT connected to an orbitrap equipped with a 
higher-energy collisional dissociation (HCD) collision cell (Figure 8).
Figure 8  Basic schematic diagram of a LTQ-Orbitrap XL mass 
spectrometer
Ion source LTQ linear ion trap C-Trap
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1.2.5.2.1 Linear IT
The linear IT consists of 4 parallel hyperbolic shaped rods (similar to a 
quadrupole) which are split into 3 sections and rf or DC voltages can be applied 
to each section. The ions are trapped radially by a two dimensional rf electric 
field and axially by a static DC electric field. Mass analysis is done by ejecting 
the ions in the radial direction through a slot in a pair of the central rods. Helium 
is used in the mass analyser to slow down ions, so that the rf field can more 
efficiently trap them. Helium also acts as a collision gas and when an AC 
excitation voltage is applied to the exit rods the ions are driven into the helium 
atoms generating CID. The IT can acquire spectra independently, send ions to 
the orbitrap for mass analysis, or the HCD collision cell for CID.
1.2.5.2.2 Orbitrap mass analyser
The Orbitrap mass analyser consists of two outer electrodes around an interior 
spindle shaped electrode, the electrodes are connected to independent voltage 
supplies. The space between the inner and outer electrodes, where the ions 
are analysed, is at ultra high vacuum (<10"8 torr), Figure 9.
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Figure 9 Schematic of Orbitrap mass analyser
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Applying a voltage between the inner and outer electrodes creates an electric 
field which will bend the path of the ions towards the central spindle electrode, 
while the circular motion of the ions creates an opposing centrifugal force. An 
axial electric field pushes the ions towards the widest part of the central spindle 
electrode creating axial oscillations at the same time as the circular motion 
around the spindle. The outer electrodes measure the ion current in the time 
domain, which is transformed to into frequency domain by Fourier transform 
and then converted into a mass spectrum. The orbitrap is capable of generating 
high resolution and excellent mass accuracy (often <1ppm), which is invaluable 
for metabolite identification work.
1.3 MS scan approaches for metabolite identification studies
It is important to select the most appropriate scan technique for the type of 
analytical work to be undertaken and the MS system employed. All metabolite 
identification scan types are based around similar principles, so it is important to 
understand the advantages and disadvantages for each of them across different 
instrumentation.
1.3.1 Nominal mass approaches to metabolite identification
For metabolite identification studies there are many low resolution nominal 
mass MS scan approaches available on a range of mass spectrometry 
instrumentation, including: QqQ, IT and Quadrupole lontraps. Described below
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are some of the most commonly nominal mass scan modes employed during 
the last 20 years.
1.3.1.1 Triple Quadrupole scan modes in biotransformation studies
Historically low resolution nominal mass scans such as selected reaction 
monitoring (SRM), precursor ion scanning (PIS), neutral loss scanning (NLS) 
and product ion scanning (MS2) were routinely acquired on triple quadrupole 
mass spectrometers (QqQ) for metabolite identification studies43. These 
methods are still used today in biotransformation studies for specific 
applications such as GSH RM trapping assays, which can be done using PIS in 
negative ion for m/z 272 or NLS in positive ion of -129 Da to find any GSH 
conjugates (Section 1.5.1.1). These scan functions form the basic principles for 
all modern metabolite identification mass spectrometry methods and are 
therefore important for any metabolite identification scientist to understand.
Figure 10 Diagram of the 4 scan modes on a triple quadrupole mass 
spectrometer: A Product ion scanning, B Selected reaction monitoring, C 
precursor ion scanning and D constant Neutral loss.
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MS is one of most the most commonly employed scan types on mass 
spectrometers, it is used to generate structural information on an analyte for 
confirmation or elucidation of its structure. The MS2 scan mode for a triple
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quadrupole MS is shown in Figure 10. The m/z of the [M+H]+ ion of the analyte 
is selected in Q1 to allow only ions with this m/z to pass, thus filtering out any 
other ions with different m/z values from reaching to the collision cell. Once it 
is in the collision cell it is broken down by collision induced dissociation (CID), 
also known as collision activated dissociation (CAD), and the ensuing product 
ions are scanned in Q3 prior to hitting the detector. The result is a product ion 
spectrum which will contain structural information about the analyte, see 
example spectrum ibuprofen (Figure 11).
Figure 11 CID Product ion scan (MS2) for ibuprofen
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SRM, precursor ion scanning (PIS) and neutral loss scanning (NLS) are all 
used to identify or/and quantify metabolites/products from complex matrices, so 
require liquid chromatography (LC) to separate components prior to introduction 
to LC-MS analysis. Unlike MS2 no full scan data or structural information is 
acquired and these techniques are purely used to generate a signal when the 
scan criteria are met.
Before conducting an SRM, PIS or NLS experiment, a MS2 is acquired on the 
test compound to identify a product ion m/z for PIS/MRM and a neutral loss 
value for the NLS. Of these three scan modes SRM (Figure 10) is the most 
commonly used with QqQ. Q1 is set to filter a single ion into the collision cell 
which breaks up the ion by CID generating several product ions. Q3 is also set 
filter a single ion and will only allow a selected product ion from the selected 
precursor ion to hit the detector, the m/z from the selected ions can be written 
as: precursor>product ion (e.g.500>250) and is referred to as a mass transition.
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It is possible to monitor multiple mass transitions at the same time; this 
technique is often called multiple reaction monitoring (MRM). SRM and MRM 
modes are very selective/sensitive for analytes of interest on QqQ instruments, 
so are predominately used in quantitative analysis44'46. Though these scan 
modes can be applied to metabolite identification studies to determine the 
presence of or to quantify expected metabolites on QqQ instruments47, they 
have limited applicability in drug discovery. Metabolites are mostly unknown 
prior to analysis, so there would be significant risk of missing unexpected 
metabolites from new novel compounds.
Unlike SRM, PIS and NLS in metabolite identification studies are employed to 
find unknown products or metabolites related to a test compound or drug from a 
complex biological sample extract. These searching scans are required 
because it is very difficult to identify metabolites using full scan total ion 
chromatograms alone, due to the amount of background interference. For 
example Figure 12 shows the total ion chromatograms for a pre-dose and 0-7 
hour post dose rat bile sample, comparing the traces it is not possible to identify 
a peak for the test compound or its metabolites.
Figure 12 Full scan TIC of a pre dose rat bile sample (top) and 0-7 hour 
post dose rat bile sample (bottom).
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For metabolite identification studies the ions arising from molecular species of 
analyte related metabolites/products are unknown, so Q1 is set to scan a mass 
range and all the ions from Q1 are dissociated in the collision cell sequentially in 
both PIS and NLS. In PIS Q3 is set to a specific m/z (a product ion identified 
from test compound) so only ions with this m/z will reach the detector and 
generate a signal. If an ion reaches the detector its precursor ion can be 
identified from the Q1 scan. The NLS is identical to a precursor scan until Q3,
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which is set to scan a mass range rather than a selected ion. Q3 is offset from 
Q1 by a specified m/z (neutral loss identified from test compound), so only 
product ions that have lost the specified m/z offset from the precursor ion 
scanned in Q1 will hit the detector and generate a signal. The result from both 
of these scan experiments is a series of peaks in mass chromatograms, each 
peak corresponding to a precursor ion that met the scan criteria. The peaks 
contain m/z values for the precursor ion responsible for the signal, but no 
structural information.
A second experiment is required to elucidate the structures using the m/z 
values identified from the PIS/NLS run to generate a MS2 of the potential 
metabolites48,49. It is possible with modern software and faster scanning 
instrumentation to automatically trigger further scan modes such as a MS2 scan 
for structural information; this technique is data dependant acquisition (DDA) 
and will be discussed in Section 1.3.1.2.1. While DDA on a QqQ could reduce 
the need to re-run samples for product ion spectra; it can be difficult to achieve 
enough data points across a peak especially if using UHPLC. PIS and NLS 
methodology have been used successfully to detect expected and unexpected 
metabolites for several applications in metabolism50'52. It is also possible to 
acquire PIS and NLS in a single experiment to improve detection, Kasshun et 
a l53 reported a method for the detection of GSH and N-acetylcysteine (NAC) 
conjugates using 129 NLS and 164 PIS respectively.
1.3.1.2 IT scan modes.
Historically ITs were a good alternative to QqQ analysis for metabolite 
identification; however conventional ITs do not have the ability to acquire PIS or 
NLS. ITs acquire full scan data faster and with more sensitivity than QqQ 
instruments and have the ability to carry out MSn experiments. The MSn 
capability of an IT enables the acquisition of CID data on an ion, its resulting 
product ions and their product ions and so on, thus ITs can hypothetically 
generate infinite sequential product ion data.
This data can be very effective in generating detailed dissociation pathways 
aiding the structural elucidation of unknowns. Kolliker et al.54 reported the use 
of MSn (MS3 and MS4) to facilitate the elucidation of 2,4-dinitrophenylhydrazine
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derivatives of carbonyl compounds. Sequential product ion spectra can be a 
powerful tool to help elucidate structures of unknown metabolites and determine 
the sites of biotransformation (Chapter 4). However, there is a major 
drawback with conventional ITs which is the % low mass cut off where any m/z 
below % of the precursor ion selected for MSn will not be detected. This can be 
significant disadvantage for metabolite identification studies, where the 
compound of interest generates low m/z product ions which are key to 
identifying the site of metabolism. Product ion data can acquired by selecting a 
single or multiple m/z for MS2 experiments across an analytical run or by DDA.
1.3.1.2.1 DDA
The DDA mode enables experiments to be automatically created in real-time 
based on results from the previous scan. For metabolite identifications studies 
the DDA experiment is used to generate MS2 data on expected or unexpected 
metabolites based on the ions detected in a survey scan. For expected 
metabolites this is performed in a targeted manner using a predefined list of m/z 
values, which are selected for MS2 if detected in the survey scan. For 
unexpected metabolites, non-targeted m/z selection criteria are employed such 
as most intense ion, least intense ion, highest charge state, highest m/z etc. It 
is also possible to use a targeted list in combination with non-targeted selection 
criteria for both expected and unexpected metabolites. For example if no ions 
are detected from the targeted m/z list, then the most intense ion from the 
previous survey scan will be selected for MS2. DDA is an efficient method for 
acquiring MS2 data on expected metabolites and more importantly unexpected 
metabolites, however scan speed can limit the number of MS2 experiments 
acquired in a run, so potentially metabolites could be missed when analysing 
complex biological samples.
1.3.1.3 Quadrupole linear ITs
More modern IT mass spectrometers such as hybrid quadrupole linear ITs do 
not suffer from the 1/s cut off and can acquire all of the QqQ scan functions with 
any of the IT scan functions. Hopfgartner et a l55 demonstrated rapid screening 
and characterisation of drug metabolites using a quadrupole linear IT, which 
was set to acquire PIS, NLS, targeted product ion and information dependant
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acquisition (another term for DDA) in a single run. Another advantage of this 
hybrid instrumentation is the ability to generate quantitative MRM data and 
qualitative MSn data. Xia et a/.56 described the use of a quadrupole linear IT for 
the identification of metabolites of Gemfibrozil in HLM and the quantification of 
propranolol in rat plasma bioanalysis.
1.3.2 High resolution accurate mass scan approaches
There are two types of high resolution accurate mass analysers used for 
metabolite identification studies; ToF and Orbitrap. However, there are various 
hybrid combinations of these such as Q-ToF, IT time of flight, LTQ-orbitrap Q- 
exactive (quadrupole orbitrap) and Fusion (quadrupole IT orbitrap). The most 
significant advantage of these instruments is the ability to acquire full scan 
accurate mass data, which enables the use of several post acquisition data 
processing techniques.
1.3.2.1 Accurate Mass
Accurate mass data significantly improves quality and confidence of correct 
structural assignments in metabolite identification studies through the use of 
several data processing/stripping techniques that include elemental 
composition, mass defect filtering (MDF), accurate mass chromatograms with
narrow mass window and accurate mass product ion spectra. Accurate mass is
often required to determine the elemental change from a metabolite compared 
to the parent compound: this is impossible with nominal mass data. Mass 
accuracy is often measured in parts per million (ppm) which is the relative error 
between the theoretical and measured accurate mass:
y ii /  7  — f i t  /  Z
Mass accuracy  = ------------------------------------- theoretical x lO 6
m  I  2  theoretical
Equation 3
Mass accuracy is measured in ppm to normalise the error across a mass range, 
i.e. 5 mDa mass error at m/z 100 is 50 ppm, 10x greater than 5 mDa error at 
m/z 1000 (5 ppm).
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1.3.2.2 Elemental composition
Each element has a specific accurate mass which is the sum of its protons 
(1.00728 Da), neutrons (1.00867 Da) and electrons (0.00055 Da) minus its 
mass defect. The mass defect for an element is the loss in mass required to 
create the energy to bind protons and neutrons together in the nucleus 
(E=MC2), thus mass defect is the difference between the measured accurate 
mass of an atom and the sum of its individual particles. For example the mass 
of a nitrogen atom should be (7 x 1.00728) + (7 x 1.00867) + (7 x 0.00055) = 
14.11158, but it is in fact 14.00307 Da due to the mass defect. Every isotope 
has a unique mass defect, so it is possible to determine the elements present in 
a molecule from its measured mono isotopic accurate mass using the 
theoretical exact mass of the most abundant isotopes for each element (Table 
1). In Mass spectrometry the mass defect is often only referred to as the 
difference between the integer mass and the exact mass of a molecule.
Table 1 Exact mass of the most abundant isotopes for common elements 
found in small organic drug-like molecules.
Isotope Exact mass (Da)
1H 1.0078
12C 12.0000
14n 14.0031
16o 15.9949
19f 18.9979
32s 31.9721
35CI 34.9683
79Br 78.9178
Most MS software contains an elemental composition programme, which can 
calculate possible molecular formulae from the measured accurate mass of
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unknowns55,57,58. Modern accurate mass instrumentation can reliably measure 
m/z to <5 ppm of the theoretical value, which significantly reduces the number 
of possible molecular formulae. For example, accurate mass data for 
Propranolol was generated on an LTQ orbitrap and the elemental composition 
calculated at 5 ppm and 20 ppm, there was only 1 molecular formula at 5 ppm 
where as at 20 ppm there were five possible formulae (Figure 13). 
Biotransformation reactions generally only add hydrogen, carbon, nitrogen 
oxygen or sulphur atoms, so it’s possible to restrict the number of potential 
elements, which also reduces the number of potential molecular formulae.
Figure 13 Accurate mass spectrum and elemental composition results for 
Propranolol at 5 ppm and 20 ppm.
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Without accurate mass data there is significant risk of generating incorrect or 
ambiguous structures for metabolites, as it is possible that a nominal mass 
change can represent more than one structure. For example, it may appear 
obvious that addition of 16 Da is simply addition of oxygen, but it could also be 
oxidation of a methyl to the corresponding acid (+2x0 -H2) +30 Da and 
demethylation (-CH2) -14 Da equalling an overall addition of 16 Da. The 
nominal mass addition for both is +16 Da, but the accurate mass addition for +0 
is 15.9949, where as the oxidation to an acid and demethylation metabolite 
would be 15.9585. There are several examples of common biotransformations
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where the nominal mass changes can be ambiguous/misinterpreted without 
accurate mass data, see Table 2 describing several examples.
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Table 2 Biotransformations reactions, where the metabolite formed has 
the same nominal mass but a different structure and accurate mass.
Nominal 
mass change 
(Da)
Elemental
change
Mass
change
(Da)
Biotransformation (fictional molecules) 
includes theoretical mono isotopic 
accurate mass and elemental 
composition
+ 16 Da + 0
+ o 2 —h 2 —c h 2
+ 16
+32 -2 -14
X X ,  —
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C g H n F O  C 9H 11F 0 2
x , —
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- H F  + H 20
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-20 +18
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" X k —  ‘ C O ,
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C io H i 20 2 C 10H 14O 2
A - A
OH
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C io H-|20 2 C 9H 10O 3
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+ 0  - H 2 - c h 2
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+ 16-2-14
- V ,
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It is also possible to incorrectly assign product ion spectra when attempting to 
elucidate metabolite structures by nominal mass, for example loss of -CO and 
C2H4 are both -28 Da, however by accurate mass they are -27.9944 Da and - 
28.0308 respectively, so can easily be distinguished.
1.3.2.3 Mass Defect Filtering
Biological samples contain a large variety of endogenous components that 
complicate mass spectrometry data, so searching for unexpected drug related 
metabolites in a complex biological matrix such as: urine, plasma, bile or faeces 
by LC-MS is very difficult. Drug related metabolites often have similar mass 
defects to the parent drug as most biotransformation reactions do not drastically 
change the molecular formula. Therefore, the mass defect of an analyte could 
be used to remove endogenous component mass spectrum peaks that have 
significantly different molecular formula to the analyte/metabolites of interest. 
This is the principle behind MDF, which is essentially a post acquisition 
technique to help clean spectra/find parent compound and drug related 
metabolites.
Zhang et a l59 developed MDF software to process accurate mass data from 
complex biological matrices for metabolism studies. They demonstrated 
significant simplification of mass spectra data for four compounds in animal bile, 
plasma and human faeces using the MDF software. The method assumes that 
the majority of biotransformation reactions fall within a 50 mDa window of the 
analyte’s mass defect with the exception of GSFI (+68 mDa), hydrolysis 
metabolites or amino acid conjugates.
Since this work there have been many publications on MDF metabolism 
applications and improving the methodology 60'66. MDF is now included in most 
vendors MS software as a routine application. Whilst this technique has proven 
to significantly improve mass spectral data, unexpected/unusual 
biotransformations may fall outside of the selected mass defect window and will 
therefore be removed from the data.
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1.3.2.4 Resolution
High resolution MS scanning is important for accurate mass measurements 
when acquiring data on biological extracts where co-elution of components with 
the same nominal mass or overlapping isotope peaks with the analyte could 
contaminate accurate mass measurements. Acquiring high resolution data 
reduces the potential for peak contamination from components with the same 
nominal mass (Figure 14).
Figure 14 Accurate mass simulated spectra for C 19 H3 2  ON 5 (m/z 347.0934) 
and C 1 6 H 1 6 N3 O 4 S (m/z 347.2680) at 7500 peak resolution (a) and unit 
resolution (b)
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It is possible to separate the lower abundant isotopes using high resolution 
scanning, for example to determine whether sulphur is present in a molecule, 
sulphur has a lower abundant isotope 34S at -4.5%, which makes it very difficult 
to identify it’s isotope pattern in a spectrum due to the contamination with the 2 
x 13C isotope peak or potentially other isotopes such as chlorine (Cl). Fenclozic 
acid contains a sulphur and a Cl so is a good example to demonstrate the 
power of separating lower abundant isotopes. The mass spectra of Fenclozic 
acid has been acquired at unit (low resolution instruments) and 240,000 
resolution (routinely achievable on modern orbitraps) (Figure 15). At unit 
resolution it is impossible to determine if a sulphur is present, but at 240,000 
resolution the 34S, 180 , 37CI and 2x13C are resolved and easily identified.
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Figure 15 Fenclozic acid profile mass spectra at unit and 240,000 
resolution.
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It is possible that the measured accurate mass of the [M+H]+/[M-H]' for a 
glucuronide metabolite could be within 5 ppm of the [M+H]+/[M-H]‘ for a 
cysteineglycine conjugate (Figure 16) making it difficult to identify which was 
formed. A high resolution MS scan can be used to determine the presence of a 
sulphur and therefore differentiate between a potential Cysteineglycine 
conjugate or a glucuronide metabolite, even though both have the same 
nominal mass and very similar mass defects.
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Figure 16 Elemental composition of a metabolite (m/z 864.4105) that is a 
glucuronide (bottom left) or cysteineglycine conjugate (bottom right).
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1.3.2.5 Mass chromatograms with a narrow mass window
Biological samples contain endogenous components that can obscure 
metabolites in nominal mass selected ion chromatograms as interfering peaks 
(Figure 17a). With accurate mass data it is possible to display metabolite peaks 
using a theoretical exact mass and a narrow mass window of 10 ppm (+/-5 ppm 
of the theoretical exact mass), which greatly reduces background and simplifies 
the data (Figure 17b).
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Figure 17 Selected ion mass chromatograms of Fenclozic acid glutamyl 
metabolite in rat bile, (a) 1 Da mass window of the theoretical nominal 
[M+H]+ 382 Da, (b) 10 ppm mass window of the theoretical exact [M+H]+ 
382.06228 Da.
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1.3.2.6 Accurate mass MS-spectra.
With accurate mass product ion spectra it is possible to generate an elemental 
composition for each product quickly which greatly simplifies the structural 
interpretation. Product ion spectra are generated by selecting a precursor ion 
then subjecting it to CID which generate a series of breakdown product ions that 
are measured. If the molecular formula of the precursor ion is known 
(determined by accurate mass), then it is possible to restrict the number and 
type of elements available in the elemental composition software for each 
product ion to the precursor molecular formula. The result of this is a significant 
reduction in possible formula hits for the ions detected in the product ion 
spectra.
1.3.2.7 ToF MS scan modes
The scan modes on a ToF MS are limited and these instruments only acquire 
full scan data, though it is possible to generate some product ion data using in­
source dissociation. Acquiring full scan with in-source dissociation can 
generate some useful product ion information67,68, but the product ion spectra 
are often complicated by background ions. ToF MS has been used to support 
early in vitro turnover assays for quantification and some limited metabolite 
identification69,70. Flowever, ToF MS has limited capability for metabolite
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identification studies as it cannot generate discrete product ion spectra. Hybrid 
ToF instruments such as the QToF mass spectrometers can acquire discrete 
product ion spectra, so are more suited to metabolite identification studies.
1.3.2.8 Q-ToF MS scan modes
Q-ToF instruments offer several scan options for metabolite identification 
studies such as accurate mass full scan, MS2, Mass spectrometry collision 
energy MSE, sequential window acquisition of all theoretical fragment ion 
spectra (SWATH) and DDA MS2 (also known as IDA). The benefit of accurate 
mass full scan and accurate mass MS2 have been discussed previously, whilst 
MSe and SWATH are scans that can only be acquired on hybrid accurate mass 
instruments. DDA experiments on the Q-ToF, consist of MS2 scans triggered 
on predefined precursor list or via information acquired in a ToF survey scan. 
This technique has not been used extensively for metabolite identification 
studies by Q-ToF MS due to the potential to miss precursor ions71.
1.3.2.8.1 MSe
To acquire full scan accurate mass data on a Q-ToF the quadrupole mass 
analyser is set to wide band mode (RF-only), allowing all ions to be transmitted 
into the collision cell, and subsequently the ToF for analysis. In MSE mode two 
full scan data are acquired, the first with no collision energy (low energy scan) 
applied to the collision cell and the second with collision energy applied to the 
collision cell (high energy scan), the result is an all ion precursor survey scan 
and an all ion product ion scan. Bateman et aI.72 first reported this technique to 
study protein phosphorylation, however since then it has been utilised across 
numerous applications.
This technique is very powerful when used in metabolite identification studies 
especially when searching for unexpected metabolites, as no compound or 
metabolite information is required prior to analysis66. Since all precursors and 
their product ions are acquired in MSE, it is possible to perform post acquisition 
data mining such as pseudo neutral loss and common product ion searching as 
well as MDF. These post acquisition techniques are similar to PIS/NLS on a 
QqQ and the fundamental principle is the same. Common product ion
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searching is similar to PIS, product ions from the test compound are identified 
and used to find related products/metabolites. Unlike PIS product ions are found 
by searching the high energy scan data using a selected ion chromatogram at 
the theoretical exact m/z for each product ion and applying a narrow mass 
window. Each peak in the chromatogram is potentially a product ion from a test 
compound related metabolite; however the precursor ion is not automatically 
determined. The precursor ion can be identified in the low energy scan at the 
retention time of the product ion peak detected in the high energy scan.
It is also possible to generate pseudo neutral loss data using the all ion product 
scan, by looking for test compound accurate mass losses in the high energy 
scan. This is similar to common product ion searching where an accurate mass 
neutral loss chromatogram can be generated, highlighting where potential test 
compound related metabolites elute.
Another advantage of the MSE approach, is product ion information on all 
components injected, so it may be possible to interpret numerous metabolites 
without the need for further discrete MS2 experiments. However, endogenous 
co-eluting components can complicate the product ion spectra and if two 
metabolites co-elute then discrete MS2 experiments would be required.
1.3.2.8.2 SWATH
Recently a new scan mode on the Q-ToF has been introduced; SWATH, also 
known as global precursor ion scan mode. In this scan mode the quadrupole is 
set to transmit a small mass range (typically 20 Da) sequentially to the collision 
cell generating product ions which are analysed in the ToF. This scan mode is 
more selective than MSE, as fewer precursor ions pass to the collision cell for 
each mass range, yet it maintains similar precursor coverage owing to the 
acquisition of sequential mass windows across the whole m/z range71. 
Hopfgartner et al.73 and Zhu et al.71 reported the application of SWATH for 
metabolite identification studies, demonstrating cleaner product ion spectra 
compared to those acquired by MSE. Even though a 20 mDa mass range is 
used for SWATH, it is still possible to get contamination from endogenous 
material or co-eluting phase I metabolites, which generally have small 
additions/losses of >20 Da.
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1.3.2.9 Orbitrap scan modes
Orbitrap mass analysers are all hybrid instruments and are either connected to 
an IT (LTQ-Orbitrap), a Quadrupole (Q-Exactive) or both (Fusion orbitrap).
1.3.2.9.1 LTQ-Orbitrap XL
The LTQ-orbitrap XL mass spectrometer consists of an IT, a higher collisional 
dissociation (HCD) cell and the high resolution accurate mass capability of the 
orbitrap mass analyser. The IT is capable of acquiring data independently, 
creating additional scan functionality and some potential for parallel analysis. 
The LTQ-orbitrap offers several scan modes for metabolite such as accurate 
mass full scan, MSn, accurate mass MSn, accurate mass HCD MS2, DDA, DDA 
with accurate mass, all ion fragmentation (AIF) or combinations of these. MSn, 
DDA and full scan accurate mass data have been discussed previously, 
however the LTQ-orbitrap offers some additional functionality for the DDA 
scans.
1.3.2.9.1.1 DDA dynamic exclusion
A problem with DDA is the potential to miss ions in a complex mixture, as there 
is a limit to the number of MS2 scans that can be acquired in a run. To increase 
the number of precursor ions sent for MS2 dynamic exclusion can be activated. 
Dynamic exclusion works by ignoring the precursor ion that has just been sent 
for MS2 for a period of time, (normally the width of an LC-MS peak) then the 
next most intense peak can be selected for MS2. For example if three 
components co-elute only the most intense ion across the peak is selected by 
DDA, however with dynamic exclusion all three would be selected (Figure 18).
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Figure 18 Mass chromatograms of 3 co-eluting components highlighting 
which would be selected by DDA for MS2 (a) Without dynamic exclusion 
(b) with dynamic exclusion.
MS2
c
1.3.2.9.1.2 LTQ-Orbitrap, IT  and HCD Product ion spectra
It is possible to generate product ion spectra through HCD (similar to a collision 
cell) or through IT CID (limited by the cut off). IT CID is softer than HCD CID 
and more likely to generate high m/z product ions, whereas HCD is harsher and 
more likely to generate lower m/z product ions. HCD product ion data is not 
restricted by the % cut off (Figure 19).
Figure 19 MS2 scan of m/z 496.2097 (a) HCD CID and (b) IT CID
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Bushee et al.74 reported a DDA method to generate HCD and IT MS2 data for 
metabolite identification studies on an LTQ orbitrap. This method significantly 
improved spectral information for structural elucidation over DDA with IT MSn 
alone. It is also possible to apply a product ion filter and a neutral loss filter to 
all of the MS2 data from a DDA experiment 75. Product ion and neutral loss 
filters work on the same principles as PIS/NLS, MS2 information on the test 
compound is used to find related metabolites. However complex biological 
matrices, which are likely to have a large number of intense background ions by 
MS, can interfere with DDA experiments. DDA works by sending the most 
intense ion for an MS2 experiment, so if there are many intense background 
ions, it is likely that some metabolites will not be selected for an MS2 
experiment.
Cho et al.76 reported a new method for metabolite identification on a LTQ- 
Orbitrap velos that acquired AIF with DDA, HCD MS2 and IT MSn. AIF on the 
orbitrap generates data similar to the MSE method on a Q-ToF, however it is not 
possible to generate the data in exactly the same way as MSE. In the LTQ- 
Orbitrap, it is done in an MS2 by selecting an m/z in the middle of the m/z range 
of interest and applying an isolation width the size of the required mass range. 
For example if the mass range to be analysed is m/z 200 to m/z 800 then the 
mass selected would be m/z 500 with an isolation width of 600 Da. This is the 
most comprehensive method for metabolite identification discussed so far for 
high resolution accurate mass instruments.
1.3.2.9.2 Q-Exactive
The Q-Exactive mass spectrometer can acquire all the same scan modes as a 
Q-ToF including MSE and SWATH which are referred to as AIF and vDIA 
(variable data independent acquisitions). The Q-Exactive has one major 
advantage over the Q-ToF, its ability to polarity switch and acquire both positive 
and negative ion data in a single analysis. This is very useful for metabolite 
identification studies where the parent may be basic and fly well in positive ion 
mode, but some metabolites could be acidic and only give a good response in 
negative ion mode.
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1.3.2.9.3 Fusion Mass spectrometer
This is a relatively new advance in mass spectrometry and is the world’s first 
tribrid mass spectrometer, containing three mass analysers 
(quadrupole/IT/Orbitrap). This instrument is able to acquire the all scan modes 
discussed previously and additional ones to unique to tribrid instruments.
1.4 Non-MS based analytical techniques for metabolite
identification
There are various MS scanning techniques that have proven to be very efficient 
when applied to metabolite searching as outlined in Section 1.3, however these 
rely on metabolites retaining similar mass spectrometry characteristics as the 
parent compound such as ionisation polarity, product ion formation, isotope 
pattern, or ionisation efficiency. Even simple biotransformation reactions of test 
compounds can dramatically change the MS ionisation, isotope pattern or
dissociation properties potentially leading to important metabolites being
missed. Therefore there are several complimentary analytical techniques for 
the detection, quantification and identification of metabolites including NMR, UV 
spectroscopy and radiochemical detection.
1.4.1 41 NMR
Atomic nuclei with an even number of neutrons and protons have no spin and 
nuclei with odd numbers of both neutrons and protons have integer spins. 
When the number of protons and neutrons in a nucleus add up to an odd 
number they have half-integer spin such as 1H or 13C and 19F. Applying a 
magnetic field to these nuclei will cause the nuclear spin states to be parallel or 
anti-parallel to the magnetic field. The parallel spin state has less energy than 
the anti-parallel state and the lower energy spin state has slightly more nuclei. 
Introducing a rf energy pulse to the nuclei at its Larmor frequency will cause 
some of the low energy spin nuclei to absorb energy and flip spin states. When 
these nuclei revert back to the lower spin state they will release energy at the 
same frequency, which can be measured to generate a proton NMR spectrum. 
Protons in an organic molecule in different environments (non-equivalent
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protons) will experience different magnetic fields and therefore give separate 
signals. Information such as the chemical shift, signal splitting and relative 
intensity of the signal can be used to elucidate structures of organic molecules. 
For metabolite identification work NMR has proven to be very useful to elucidate 
metabolite structures77'79 and in some applications quantify metabolites30,80,81. 
The main difficulties with NMR are its low sensitivity, requiring pg quantities of a 
metabolite to generate useful spectra and its lack of selectivity, as metabolites 
generally require isolation from the matrix prior to analysis. Isolation of a 
metabolite from a matrix is fairly simple by LC and can be collected by time 
slicing or by mass direction (LC-MS).
1.4.2 Ultraviolet Spectroscopy.
Ultraviolet light (UV) absorption spectroscopy is an analytical technique which is 
applied to the quantitative and qualitative determination of molecular species. 
The absorption of UV light in organic molecules usually results from the 
excitation of bonding electrons or unbound outer electrons in atoms such as 
oxygen, halogens, sulphur or nitrogen. All organic molecules are capable of 
absorbing UV light, because they contain valence electrons that can be excited 
and transitioned to higher levels. There are 4 types of electron transitions 
(Figure 20) that involve a bond electrons, tt bond electrons and nonbonding 
electrons (n) to the excited antibonding a* and tt*  orbitals.
Figure 20 Electron transitions of a, t t  and n electrons
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Relative to the other transitions the energy required to induce a to a* transitions 
is large, so single bond electrons will absorb in the ‘vacuum ultraviolet region’
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(<185 nm), where components from the atmosphere strongly absorb. Therefore 
these absorbances are not observed in UV absorbance spectra, which typically 
range from 200-400 nm. The n to a* transition require less energy and gives 
absorbances in the range 150-200 nm, but most are below 200 nm so are 
outside the UV spectral region 200-400 nm. Energies for the n to tt and tt to tt*  
electron transitions are lower and within the spectral region, so most organic 
molecule applications of UV absorbance spectroscopy are based on these 
transitions. Both of these transitions require the presence of tt orbitals, so the 
analyte molecule must contain an unsaturated functional group. For organic 
molecules the term chromophore applies to these absorbing unsaturated 
functional groups. Multiple chromophores in a single molecule are additive 
provided they are separated from each other by more than one single bond, tt 
electrons are further delocalised through conjugation lowering the energy level 
of the tt orbitals giving it less antibonding character, so the absorption maxima 
(Amax) are shifted to higher wavelengths. Drug like structures often contain 
conjugated ring systems and multiple chromophores, so are likely to absorb UV 
at higher wave lengths.
1.4.2.1 UV in metabolite identification
UV absorption spectroscopy is often coupled to LC-MS systems for metabolite 
identification via a photodiode array detector (PDA) that sits between the end of 
the HPLC column and the mass spectrometer (LC-UV-MS). UV detection is a 
non-destructive technique and can be acquired without impacting mass spectral 
data or analysis time so there are no disadvantages acquiring UV scan data
prior to sample introduction into the mass spectrometer. For metabolite
identification studies UV scan data offers two distinct advantages; semi­
quantification and finding test compound related metabolites.
1.4.2.2 UV metabolite semi-quantification
UV is a quantitative technique82'84 and like LC-MS/MS relies on analytical 
standards to determine concentrations accurately, however it does not suffer 
from ion suppression or variable ionisation. Biotransformation reactions rarely 
destroy the conjugation of drug molecules, so the UV absorbance of most 
metabolites will be similar to the parent compound. It is therefore possible to
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semi-quantify metabolites and parent compound without analytical standards 
more accurately than by MS. However, it is important to check the UV 
absorbance spectra for each metabolite to ensure there that there is no 
significant difference from the parent molecule (Figure 21).
Figure 21 Extracted UV chromatogram (330-350nm) of a test compound 
and its metabolites in human plasma (top) and extracted UV absorbances 
for metabolites and drug (bottom).
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If the absorbance spectra are significantly different from the parent drug then it 
is not possible to quantify the metabolite. Another problem with UV 
quantification is the contamination of metabolite UV peaks with endogenous 
components in complex biological matrices that have an overlapping UV 
absorbance. A control sample or predose sample can identify the potential for 
UV peak contamination. However the application of UV quantification is 
generally only applied to relatively clean UV matrices such as plasma or in vitro 
samples.
Improved signal to noise, sensitivity and cleaner chromatograms are achieved 
for compounds that have greater conjugation due to the shift in Amax to higher 
wavelengths. Quantification at higher wavelengths (>300 nm) is more selective
60
due to fewer endogenous biological components generating overlapping 
absorbances. Therefore when compounds contain multiple chromophores it is 
better to use the highest wavelength absorbance rather than the most intense 
absorbance (Figure 22).
Figure 22 UV absorbance of a test compound (top) and extracted UV 
chromatograms of test compound and its metabolites in a rat hepatocyte 
extract (bottom).
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UV semi-quantification of metabolites is more suited to discovery metabolite 
identification studies where turnaround of data needs to be quick and design 
teams are generally only interested in major metabolic liabilities. Whilst UV is a 
good generic technique for the semi-quantification of metabolites, not all 
compounds give a strong UV absorbance, so sensitivity can be issue for certain 
compound types.
1.4.2.3 Finding metabolites by UV
Metabolites often retain similar UV absorbance spectra to the parent compound, 
however when the UV chromophore is altered by metabolic modification the 
metabolite could be missed. Drug like compounds often contain multiple 
chromophores and therefore can generate more than one wavelength 
absorbance. If one chromophore was altered through metabolism it may still be 
possible to find metabolites using a different absorbance wavelength (Figure
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22). UV is not as selective as mass spectrometry, so there is potential for 
endogenous components in biological extracts to have overlapping UV 
absorbances giving rise to background peaks that complicate chromatograms. 
If a compound has a good chromophore and absorbs at a high wavelength, it is 
possible to generate a relatively clean selected UV wavelength absorbance 
chromatogram. This is especially true for plasma or in vitro extract samples 
which are fairly clean matrices, so generally do not suffer from significant 
contaminating peaks (Figure 22). In more complicated matrices such as bile, 
urine or faeces there are considerably more endogenous components that can 
interfere with selected wavelength chromatograms, even at high UV 
absorbances. In this situation it is possible to improve the detection of major 
metabolites using a predose as a control for a chromatogram comparison 
(Figure 23).
Figure 23 Predose rat bile UV extracted chromatogram (280-290nm) (top) 
Test compound dosed 0-8 hour rat bile UV extracted chromatogram  
(bottom).
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1.4.3 Radio chemical detection
Radiolabelled metabolite identification studies are the gold standard for the 
detection and quantification of drug metabolites85. Accurate quantification of 
metabolites by MS and UV require analytical standards as the response can 
change with metabolic modifications of the chemical structure (Section 1.4.2 
and 1.2.4). Whereas measurement of radioactivity is independent of chemical 
structure (provided the analyte contains a radioactive isotope), so no analytical 
standards are required. The most common radioisotopes used in drug 
metabolism studies are 14C or 3H86, which can be incorporated into a drug’s
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chemical structure, producing a radioisotope analogue that is chemically 
identical to the original material. 3H is often used in early drug development as 
it is quicker, cheaper and easier to incorporate into a structure than 14C, and 
can be done by direct iridium catalysed hydrogen exchange of drug or 
modification of a precursor to in include 3H28. The problem with a 3H label is the 
potential for it to chemically or metabolically exchange resulting in unlabelled 
products87 or the 3H isotope label altering the metabolic profile or metabolite 
formation rate 28,86. Therefore 14C is superior to 3H for drug metabolism studies, 
but it is more costly, so is generally only employed in later drug development 
where more accurate data is required. All of the radioisotope work undertaken 
in this PhD will be with 14C labelled Fenclozic acid.
The total radioactivity in a sample can be measured by liquid scintillation 
counting (LSC), solid scintillation counting (SSC) or accelerator mass 
spectrometry. Accelerator mass spectrometry is a very expensive technique 
which involves intensive sample preparation and is beyond the scope of this 
PhD thesis. The principles of scintillation counting are the same regardless of 
the nuclei used or whether the technique is SSC or LSC, which both involve 
mixing the radioactive material with a scintillante. Energy is released as a part 
of the radioactive decay of the isotope and some of this energy is transformed 
into detectable light photons that are measured by photo multiplier tubes in the 
detector.
Scintillation counting is susceptible to quenching, where sample components 
can interfere with the measurement of photons and reduce the number of 
photons detected. For this reason instruments measure counts per minute 
(CPM), rather than decays per minute (DPM), the ratio between these is the 
counting efficiency. There are quenching correction methods available and the 
most common for modern instruments is to use an external source of known 
radioactivity at close proximity to the sample.
Generating a metabolite profile by radio chemical detection requires either a 
flow radiochemical detector for LSC or fractionating the sample, then analysing 
the fractions by SSC. For both methods a flow splitter is often employed to 
divert some of the sample to a MS for metabolite identification and the rest to a
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flow radiochemical detector or a fraction collector and SSC for metabolite 
detection and quantification.
1.4.3.1 Stable label
Compounds containing elements such as Cl or bromine give a distinct isotope 
pattern by mass spectrometry due to their natural isotopic abundance. Cl has 
two abundant isotopes, 35CI and 37CI at a ratio of 3:1 so generates two distinct 
ions 2 Da apart at a ratio of 3:1 see Figure 24. This isotopic ratio is extremely 
useful to help identify parent related metabolites from complex biological 
matrices. It is obviously not possible for every potential drug to incorporate an 
element with multiple abundant isotopes, but it is possible to create a pseudo 
isotope pattern using stable labels.
Figure 24 Partial positive ion mass spectrum of Chlozapine showing the 
[M+H]+ ion and the signals arising from the presence of the 35 and 37 
isotopes of Cl
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The stable labels of drug candidates have been exploited by scientists in drug 
metabolite identification and profiling studies88'90. For example in 1971 Knapp 
et al,89 reported the use of a stable labelled Nortriptyline replacing three 
hydrogens for three deuterium atoms (2H) equating to an overall mass increase 
of +3 Da over unlabelled Nortriptyline. A mixture of 50% labelled and 50% 
unlabelled Nortriptyline would create a very distinct pseudo isotope pattern 
(Figure 25), which could be used to help identify drug/analyte related 
metabolites by mass spectrometry.
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Figure 25 Theoretical mass spectrum for 1:1 mixture of Nortriptyline and 
stable labeled Nortriptyline (3x 2H) showing the two [M+H]+ ions.
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Using this 1:1 mixture in metabolism studies generates parent related 
metabolites or products with two isotope peaks (M and M+3) at ratio of 1:1, 
greatly simplifying the identification of drug related metabolite peaks by mass 
spectrometry in complex biological matrices.
Today there are a host of automated software data stripping techniques which 
can aid metabolite searching and includes programmes such as cluster pattern 
or isotopic pattern recognition that will automate the detection of MS peaks with 
pseudo isotope pattern such as M:M+3 at 1:1. This technique is rarely used for 
optimisation of compound series in drug discovery due to the cost associated 
with the synthesis of multiple stable labelled test compounds.
For development studies where the compound is in the clinic there is often a 
radioisotope labelled analogue available, which is far superior for metabolism 
studies. Therefore these stable labelled metabolite identification studies are not 
conducted routinely, but are often applied ad hoc for specific investigations. A 
review on stable labelled compounds in metabolism by Mutlib91 describes using 
13C labelled DpC96192 in an in vivo study to confirm a GSH adduct was formed 
via oxidation on an alkyne moiety.
Another application for this technique is in the area of detecting GSH adducts 
from RM GSH trapping experiments of test compounds incubated in 
microsomes. Yan et a l93 described the use of stable labelled GSH (2x13C and 
1 x 15N  on the glycine moiety) to improve detection of adducts and reduce false
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positives observed from constant neutral loss scanning of -129 Da (loss of the 
glutamyl). A mixture of 50% labelled and 50% unlabelled GSH was added to 
microsomal incubations of test compounds which resulted in RMs that formed 
two GSH adducts 3 mass units apart. Both the labelled and unlabelled GSH 
adducts could generate the -129 Da neutral loss, therefore each RM trapped 
with GSH would give 2 neutral losses 3 mass units apart, generating a unique 
pattern for an unambiguous result.
1.5 Detecting RMs
RMs are very difficult to detect analytically due to their inherent chemical 
reactivity. There are several in vitro techniques available to help identify 
compounds that form RMs and/or determine potential sites of bioactivation.
1.5.1 RM trapping assays
The pharmaceutical industry standard for identifying RMs in early discovery is 
RM trapping assays or screens94,95, where the reactive intermediate is produced 
under conditions that favour a particular, known endpoint. Test compounds are 
incubated in liver microsomes (usually human), metabolising them by the most 
prevalent phase I metabolic processes occurring in the liver. The microsomal 
incubation of test compound is fortified with an excess of nucleophilic trapping 
agent, to convert any reactive electrophilic species into a stable detectable 
conjugate.
GSH is the most commonly used nucleophilic trapping agent for RM trapping 
screens96'102, and as it is a naturally occurring tripeptide in the body, it is 
favoured over chemically synthetic nucleophiles. GSH is the body’s natural 
defence against toxic/reactive products, forming adducts with them to generate 
inactive stable products, that are easily excreted from the body. GSH will 
efficiently adduct with soft electrophiles such as epoxides, quinonemines 
Michael acceptors etc, but does not react with hard electrophiles such as 
iminium ions. Hard electrophiles (iminium ions) are detected using potassium 
cyanide (KCN) as a nucleophilic trapping agent forming stable detectable -CN 
adducts. In vitro RM screening has become more routine within the
66
pharmaceutical industry with many companies now running primary GSH and 
KCN screens in parallel for maximum coverage103.
1.5.1.1 GSH RM screening assay
GSH adducts with soft electrophiles forming a stable LC-MS detectable product. 
Analysis of the microsomal GSH trapping assays are primarily by LC-MSMS, 
which offers the sensitivity, selectivity and throughput required. A wide range of 
LC-MS methodology can be used to detect GSH adducts, currently the most 
popular are; PIS, NLS, DDA or accurate mass scanning with MDF. Positive ion 
NLS on a QqQ monitoring for -129 Da52 is by far the most well known. The -129 
Da neutral loss corresponds to loss of the glutamyl moiety from GSH, however 
there are additional neutral loss values such as -75, -146, -273 or -275 Da 
(Figure 26A) which can be used independently or in combination with -129 Da. 
Negative PIS monitoring for m/z 272 product ion (Figure 26B) is an alternative 
scan mode on a QqQ, Dieckhaus et a/.101 reported this to be more sensitive and 
less likely to give false negatives over positive ion -129 NLS.
Figure 26 GSH structure showing the positive ion neutral loss fragments 
(A) negative ion precursor ion (B).
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Both PIS and NLS do not require any information about the test compound and 
are simple to set up for relatively high throughput analyses with minimal data 
interpretation. The analytical output is limited and only provides a yes/no 
answer without any information on the site of bioactivation. The methodology is
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amenable to screening high numbers of compounds, which can be used to 
generate some structure activity relationship (SAR)104,105 early in drug discovery 
programs.
Quadrupole linear IT instruments have the capability to acquire data dependent 
scans (DDA) using NLS and/or PIS in combination with full scan data including 
MS2 scans. The DDA experiment for GSH trapping uses information from a 
survey PIS or NLS to trigger MS2 scans to generate structural information. This 
technique removes the need to run a second experiment to acquire MS2 scans 
on all the potential GSH adduct ions detected from PIS/NLS. Wen et a l97 
compared the effectiveness of negative ion PIS and positive ion NLS methods 
to trigger MS2 spectra for GSH adducts, demonstrating negative ion PIS was 
more effective.
More recently Jian efa/.103 reported using both negative ion PIS and positive ion 
NLS to trigger product ion scans in a single experiment for a GSH RM trapping 
screen. This data dependent methodology creates fewer false 
negatives/positives offering greater confidence over triplequadrupole NLS and 
PIS analysis, whilst acquiring additional structural information. High resolution 
accurate mass instrumentation is an alternative to these low resolution nominal 
mass techniques, however they often require more in depth expertise in mass 
spectrometry interpretation. It is not possible to acquire NLS or PIS on a Q-ToF 
mass spectrometer, however Castro-Perez96 presented a method acquiring 
MSe (Section 1.3.2.8.1) looking for a pseudo accurate neutral loss difference of 
129.0426 (+/- 20 mDa mass window) between the high energy and low energy 
scans. This is not technically neutral loss scanning as no neutral loss is 
measured, just an assumed neutral loss when comparing the m/z difference 
between the high and low energy scans. They report an increase in selectivity 
for this methodology over nominal mass NLS, though no comparison is made 
with superior nominal mass GSH detection techniques such as negative ion 
PIS. All of the techniques discussed so far, rely on GSH adducts generating 
expected common neutral losses or product ions for detection; however this is 
not always the case for GSH adducts101. This is a major disadvantage of these 
techniques and is likely to lead to significant number of false negatives.
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Alternative MS methodology utilising accurate mass full scan data and post 
acquisition mass defect filtering rather than GSH fragmentation characteristics 
has been reported in the literature with some success. Zhu et a/.106 have 
compared traditional NLS data with LTQ-Orbitrap high resolution accurate mass 
data processed with MDF. They set the MDF window to +/- 0.04 Da around a 
calculated mass defect for a GSH adduct template ([M+H]+ of drug + GSH -H 2). 
The MDF window was applied over a mass range of +/-50 Da around the 
calculated mass for the GSH adduct. Unlike all of the GSH adduct LC-MS 
screening methods discussed previously, the sensitivity of the MDF approach is 
not dependent on MS2 dissociation efficiency of GSH adducts. The MDF 
approach was reported to be more sensitive and selective over -129 NLS106, 
especially for GSH adducts that do not produce the -129 neutral loss effectively. 
MDF appears to offer significant improvements over traditional approaches, 
however the small mass window (+/- 50 Da) employed by Zhu et a/.106 would 
likely to miss GSH where the bioactivation step involves an increase or 
decreases in its mass by more than 50 Da (e.g. hydrolysis).
1.5.1.1.1 Derivatised GSH trapping studies
Several GSH analogues (Figure 27) have been used to enhance the detection 
and quantification of RMs in microsomal trapping assays, significant 
improvements over GSH trapped adducts have been reported.
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Figure 27 List of GSH analogues for RM trapping experiments: A Dansyl 
GSH, B GSH-ethylester C Quaternary ammonium GSH, D Stable labelled 
GSH and 35S labelled GSH.
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1.5.1.1.2 Dansylated GSH
Gan et a/.107 demonstrated it was possible to attach a fluorescence tag to GSH 
by derivatisation with dansyl chloride. The resulting dansyl-glutathione product 
(Figure 27A) can be analysed by fluorescent detection rather than mass 
spectrometry, offering analytical advantages in sensitivity, selectivity and 
quantification over standard GSH RM trapping experiments.
1.5.1.1.3 GSH ethyl ester
Soglia et a/.108 compared the LC-MS analysis (SRM) of GSH ethylester (GSH- 
EE) (Figure 27B) and GSH microsomal trapping experiments on twelve 
compounds known to form RMs. Of the twelve compounds tested only 4 GSH 
adducts were detectable by mass spectrometry, whereas ten GSH-EE adducts 
were detected. The GSH-EE adducts were shown to give increased MS 
response (up to 80x) over the equivalent GSH adducts.
1.5.1.1.4 Quaternary ammonium ion GSH
An attempt to improve quantification of GSH adducts by incorporation of a fixed 
positive charge into GSH through addition of a quaternary ammonium ion (QA-
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GSH) (Figure 27C) was reported by Soglia et a/.109. The addition of a fixed 
positive charge reduced the variability in ionisation between different QA-GSH- 
adducts. Comparison of MS responses for 3 QA-GSH adducts standards and a 
QA-GSH free thiol, were within about 3 fold of each other, whereas parent 
compound MS responses differed by more than 19 fold. Semi-quantification 
was achieved by the addition of a QA-GSH free thiol internal standard (IS) post 
incubation at a known concentration. Direct comparison of the QA-GSH peak 
area versus the detected GSH adduct enabled semi-quantification.
1.5.1.1.5 Stable labelled GSH
Stable label GSH (15N and 2 x 13C on the glycine, Figure 27D) has been used 
effectively to improve GSH adduct detection and sensitivity in high throughput 
RM screens93’110 (Section 1.4.3.1)
1.5.1.1.6 Radiolabelled GSH
Hartman et a/.111 reported incorporating 35S isotope into intracellular GSH by 
exposing hepatocytes to 35S-labelled methionine, replacing cellular GSH with 
intracellular generated 35S labelled GSH (35S-GSH) (Figure 27E). Incubation of 
acetaminophen (known to form GSH adducts) demonstrated it was possible to 
detect and quantify 35S-GSH adducts by radiochemical detection. This 
approach has significant advantages over all other trapping methods and will 
detect all GSH adduct types while quantifying them accurately. However using 
35S radioisotope in a high throughput setting is extremely difficult, potentially 
time consuming and expensive, so it is not a viable option for early drug 
discovery.
1.5.1.2 Cyanide trapping assays
GSH does not adduct with hard electrophiles such as iminium ions, so trapping 
this type of RM requires an alternative trapping agent. The cyanide anion is a 
hard nucleophile and will adduct with iminium ions efficiently, generating a 
stable detectable product of 25 Da (+C+N -H ) higher than the parent compound 
mass (Figure 28). Cyanide adducts often generate a single diagnostic neutral 
loss (-27 Da) by CID, which greatly simplifies their detection by MS. The 
analysis of the microsomal KCN trapping assays is therefore primarily carried
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out by LC-MS and often run in conjunction with the GSH trapping screen103,112. 
Argoti et al.112 reported using a mixture of stable labelled K13C15N and non 
labelled KCN generating a pseudo isotope pattern by MS to reduce false 
positives. Gorrod et a/.113 used radiolabelled Na14CN to determine the 
formation of an iminium ion intermediate through nicotine metabolism.
Figure 28 Cyanide addition to an iminium ion
KCN trapping offers additional information over GSH trapping experiments, 
however it has the potential for false positive through the formation of cyanide 
adduct artefacts114.
Mitchell et a/.115 and Laine et a/.116 have both described the use of synthetic 
peptides for RM screening. Mitchell reported using an 11 amino acid peptide 
that included Cys and other nucleophilic amino-acid groups to trap electrophilic 
RMs. Analysis was by surface enhanced laser detection/ionisation-ToF MS, 
which is a surface ionisation technique and does not require LC separation to 
introduce the sample into the instrument. Whereas Laine et a/.116 described an 
LC-MS based peptide trapping assay which would be more amenable to 
instrumentation available within drug metabolism groups.
1.5.2 Bespoke trapping experiments
There are a number of trapping experiments employed by biotransformation 
scientists to detect, identify and understand bioactivation of test compounds or 
drugs to RMs. In contrast to RM screening, that often only offers a yes/no 
answer; these studies are targeted at identifying and understanding the reactive 
intermediate. The work is low throughput, and often used to investigate a single 
compound where CVB, toxicity, mechanism based inhibition or a positive RM 
trapping result are observed. GSH and KCN trapping have been discussed
N.
R
Iminium ion
R
Parent
compound
R
-CN adduct
1.5.1.3 Peptide screening assays
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already, but there are a number of other additional trapping agents that have 
been utilized including; semicarbazide, methoxyamine, Cys or NAC.
1.5.2.1 Semicarbazide and Methoxyamine Aldehyde Trapping
KCN and GSH trapping agents form adducts with most electrophilic RMs, 
although reactive aldehyde metabolites are not always trapped. There are two 
commonly used agents to trap reactive aldehyde metabolites; methoxyamine 
(Figure 29A) and semicarbazide (Figure 29B).
Figure 29 Reactive aldehyde trapping by (A) methoxyamine and (B) 
semicarbazide
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There are several excellent examples of methoxyamine and semicarbazide 
confirming the formation of reactive aldehyde metabolites 117'120. Unlike GSH 
and cyanide adducts, there are no straight forward product ions or neutral 
losses consistently generated from semicarbazide adducts. Thus it is not 
possible to use automated scan functions such as PIS/NLS or data processing 
to detect and find these adducts making them less amenable to LC-MS 
screening assays. An additional drawback using methoxyamine as a trapping 
agent in microsomal incubations is the potential for it to interfere with the 
metabolising enzymes, altering the metabolic profile or even inhibiting aldehyde 
formation. Zhang et al,121 described the inhibitory properties of GSH, KCN and 
methoxyamine in liver microsomes. GSH and KCN did not inhibit any P450 
enzyme isoforms at concentrations up to 10mM; however methoxyamine 
inhibited CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5.
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1.5.2.2 Cys and NAC Trapping Agents
Detoxification of RMs by GSH in vivo, can lead to a series of conjugates 
generated from the metabolism/degradation of GSH conjugates (Figure 30).
Figure 30 Metabolism/degradation of GSH adducts in vivo.
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Cys and NAC are two of the breakdown products from GSH and have both 
been used in vitro to trap RMs with some degree of success. Ravindranath et 
al.122 reported that Cys was a better trapping agent than GSH for the RM of 2- 
methyl furan. Whereas Jian et al,123 presented a high throughput method for 
the detection of NAC-adducts using -129 NLS and MRM approaches to 
triggering MS2 experiments for detection and identification in a single LC-MS 
run. They reported the potential for NAC-adducts to generate more product ions 
from cleavages of the test compound/drug providing more information about the 
site of bioactivation.
1.5.2.3 Acyl-glucuronide screening
Acyl-glucuronides are formed by the phase II metabolism of carboxylic acids, so 
it is easy for a chemist to visually inspect the structure of a test compound and 
identify whether it is possible to form an acyl-glucuronide. The detection of an 
acyl-glucuronide metabolite is not confirmation of a RM, as not all acyl- 
glucuronides are reactive. Therefore acyl-glucuronide in vitro screening is to 
determine whether acyl-glucuronide metabolites are likely to be chemically 
reactive rather than focusing on their detection.
Acyl-glucuronides are able to undergo acyl migration and through this process 
generate a chemically reactive intermediate that can covalently bind to proteins. 
This chemical reactivity can be linked to the stability of an acyl-glucuronide124 
and Bolze et al,125, Chen et a/.126, Jinno et al.127 and Zhong et al,128 all describe
74
methods to measure the stability of acyl-glucuronide metabolites. The basic 
principle across all the methods reported, is to first biosynthesize the acyl- 
glucuronide metabolite in vitro, incubating test compound/drug in human 
microsomes activated for glucuronidation. The rate of degradation of the 
resulting acyl glucuronide is then measured by LC-MS in buffer, plasma or 
albumin. The faster this rate the more reactive the acyl-glucuronide and 
therefore the higher the potential for CVB to protein and toxicity.
1.5.3 CVB
The most common way to assess RM risk is to measure the CVB of a 
compound and its metabolites in human microsomes or hepatocytes using 
radiolabelled compound. CVB of xenobiotic metabolites to endogenous macro 
molecules in vivo has been associated with toxicity (Hapten 
hypothesis)10,11,22,124. In theory measuring the CVB of a drug and its 
metabolites could indicate their reactivity and help determine how likely they are 
to generate RM mediated toxicity. Measuring CVB of a drug and its metabolites 
is not a new idea; Gillette et a/.129 reported the merits of investigating CVB for 
drug toxicity in 1974.
CVB is simply a measure of the amount of drug/compound related material 
covalently bound to endogenous macromolecules, after dosing (in vivo CVB) or 
after incubation in a metabolizing system (in vitro CVB). These studies require 
radioisotope labelled test compound or drug and radio chemical detection is 
used to determine the quantity of bound drug. In vitro CVB experiments are 
often used to assess the RM risk of compounds that are close to progression 
into drug development and there are various methods reported in the 
literature130. The data is usually reported in pMol/mg of protein and is used to 
help evaluate whether a compound is safe enough to progress into 
development and studies in humans.
Evans et a/.130 reported that Merck Sharp and Dohme used a threshold of 
50pMol/mg. This was based on the levels of covalent adducts found in the liver 
associated with hepatic necrosis of known hepatotoxins, approximately 1 nmol 
of drug/mg of protein, which was reduced 20 fold for a ‘conservative target’. 
They state that 50 pMol/mg is a target upper limit and not an absolute threshold
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above which compounds cannot progress, since other factors need to be 
considered.
The predicted daily human dose is a very important consideration; drugs given 
at a daily dose of 10mg or less are rarely if ever associated with idiosyncratic 
drug reactions10. Nakayama et a/.131 measured the CVB of 42 marketed drugs 
in vitro and in vivo to determine if CVB predicted the clinical situation. These 
were classified as either safe, or had a warning, black box warning or were 
withdrawn based on their clinical safety profiles. The CVB results on their own 
did not clearly discriminate between the categories, however when the daily 
dose was considered as well, a much better prediction was achieved.
More recent CVB assessments methods, factor in the relative in vitro metabolic 
turnover (Clint) with the predicted daily dose to calculate a predicated daily CVB 
burden132,133. These methods do not accurately predict toxicity for all drugs, so 
the question remains: is toxicity predictable based on a quantity of CVB?
1.6 Aims and Objectives of this Project.
The aims of this project are to apply the methodology discussed in the
introduction to;
• Investigate the metabolism of Fenclozic acid in HRN mice and bile duct 
cannulated rats to identfiy any new reactive/toxic metabolites that could
explain the reported hepatotoxicity observed in the clinic or covalent
binding observed in microsomes (Chapter 2 & 3).
• Identify and determine the mechanism of formation of a novel carbon 
hydrogen addition metabolite formed in vivo in the rat (Chapter 4).
• Investigate the formation of a Homomorpholine GSH rearrangement 
metabolite in human liver microsomes fortified with GSH (Chapter 5).
• Study the formation of isomeric methanol adducts identified from a 
human liver microsomal incubation (Chapter 6).
From the investigation of these RM examples, it is intended to;
• Determine the limitations of current RM trapping screening methodology 
employed within the pharmaceutical industry.
76
• Identify of any unfavourable chemical moieties that should be avoided for 
drug research programmes.
• Discover areas of improvement in the current LC-MS methodology for 
metabolite identification.
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2. THE METABOLIC FATE OF MC-FENCLOZIC ACID IN THE HEPATIC 
REDUCTASE NULL (HRN) MOUSE
Reprinted with permission of Informa UK Ltd. All rights reserved.
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The metabolic fate of [14C]-fenclozic acid in the hepatic reductase null 
(HRN) mouse
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Abstract
1. The distribution, metabolism, excretion and hepatic effects of fendozic acid were 
investigated following a single oral dose of 10 mg/kg to hepatic reductase null (HRN) mice.
2. The majority of the [14C]-fendozic acid was eliminated via the urine/aqueous cage wash, 
(55%) with a smaller portion excreted in the faeces, (5%). The total recovery of radioactivity 
in the excreta over the 72 h period studied was ca. 60%.
3. Metabolism of fendozic acid in the HRN mice was entirely to the carboxylic acid function 
and was dominated by amino acid conjugation to glycine and taurine, with lesser amounts 
of an acyl glucuronide.
4. Whole body autoradiography of mice showed general distribution into all tissues except the 
brain. Radioactivity was still detectable in the kidney and liver of the HRN mice at 72 h post 
dose. Covalent binding studies showed evidence of binding to kidney, liver and plasma 
proteins however, the degree of binding was less than 50pmol equiv/mg protein for all 
tissues.
5. The HRN mouse appears to be a useful in vivo model for the study of the Phase II 
conjugation metabolism of fendozic acid in the absence of hepatic cytochrome P450-related 
oxidative metabolism.
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Introduction
Fendozic acid (2-(4-chlorophenyl)-thiazol-4-ylacetic acid) 
(Myalex) was identified as a potential anti-rheumatic by ICI 
Pharmaceuticals in the 1960’s (Newbould. 1969) and. in early 
clinical trials, (Chalmers et al.. 1969a,b) ascending doses 
(100-400 mg) were found to be well tolerated. The results of 
these, and subsequent, trials suggested that the drug would 
make a suitable alternative to aspirin as a treatment for 
rheumatoid arthritis as it had equal efficacy but higher 
potency with less side effects. However, when large scale 
studies were undertaken, patients at the higher dose of 400 mg 
daily showed adverse effects after 4 weeks of treatment, w ith 
two cases of jaundice out of 12 patients in one centre (Hart 
et al.. 1970). Numerous cases of jaundice and abnormal 
hepatic function emerged at other centres in patients
*Present address: Depatment o f Surgery and Cancer, Imperial College. 
Exhibition Rd, South Kensington. London. UK
Address for correspondence: Kathryn Pickup, Drug Metabolism and 
Pharmacokinetics 1M. Alderley Park, AstraZeneca UK Ltd.. 
Macclesfield, Cheshire S K I0  4TG. UK. Tel: +44-1625-518418. Fax: 
44-1625-230614. E-mail: Kathryn.pickup@astrazeneca.com
administered with the 400 mg dose of fendozic acid for 
over 14 days and consequently trials were stopped (Alcock, 
1971) and the compound was withdrawn from further 
development. Biochemical analysis indicated that the jaun­
dice was cholestatic (suppression of bile flow) and it was 
accompanied by raised alkaline phosphatase, serum glutamic 
oxaloacetic transaminase and serum glutamic pyruvic trans­
aminase levels (Hart et al., 1970). The withdrawal of fendozic 
acid led to a reappraisal of the pre-clinical data, and 
additional work in a wider range of pre-clinical species 
(Alcock. 1971) however, no hepatotoxicity was identified in 
animals. Fendozic acid thus represents an example of a 
compound causing serious and unpredicted non-idiosyncratic 
adverse drug reactions (ADRs) in man despite rigorous 
preclinical testing.
As part of a series of studies to examine whether modern 
methods of safety testing would have detected the hepatotoxic 
potential of fendozic acid, w e recently undertook a range ol 
in vitro investigations (Rodrigues et al., 2013), based on a 
panel of assays, designed to look for effects on the liver 
(Thompson et al., 2012). These studies showed that, in 
microsomal and hepatocyte incubations, fendozic acid 
underwent NADPH-dependant metabolism to reactive species 
that covalently bound to protein. However, incubation of the 
drug together with reactive metabolite-trapping reagents
79
DOI: 10.3109/00498254.2013.866299 The metabolism of [ NC]-fenclozic acid in HRN mice 165
failed to identify any reactive metabolites even when com­
pounds such as glutathione, clearly modified the extent of 
covalent binding. This is interesting because, in the in vivo 
studies undertaken during the development of fendozic acid, 
studies in rat, dog and monkey showed extensive metabolism 
of the drug. In rat and dog, the major metabolites identified 
included 2-(4-chlorophenyl)-4-methyl-thiazole, 2 -(4-hydro- 
xyphenyl)-thiazol-4-ylacetic acid and 2 -(4-hydroxy-3-chlor- 
ophenyl)-thiazol-4-ylacetic acid (Foulkes, 1970). These three 
metabolites, together with fendozic acid itself were also 
converted to acyl glucuronide conjugates. In monkey, the 
fendozic acid acyl glucuronide was the only significant 
metabolite produced. Later studies in the rat, identified 
glucuronide and taurine conjugates in the bile and urine, the 
proportions of which were dose-dependent, with the propor­
tions of the taurine conjugate increasing from 16% to 32% 
of the total in urine when the dose was raised from 2 to 
100 mg/kg fendozic acid, respectively (Bradbury et al., 
1981). The ability of fendozic acid to undergo both Phase I 
oxidative and Phase II metabolic conjugation reactions clearly 
offers the potential for several different types of reactive 
metabolite to be formed in vivo. As such it can be difficult to 
determine whether one, or both types of biotransformation, 
are responsible for the generation of a chemically reactive 
species in vivo. Recently, we have shown (Pickup et al., 2012) 
that using the hepatic reductase null (HRN) mouse model (Le 
& Sauer, 2001), which has no functional hepatic cytochrome 
P450 enzymes, resulted in the production of only conjugated 
diclofenac metabolites. We have therefore undertaken a study 
of [14C]-fenclozic acid in the HRN mouse model to examine 
the disposition, metabolism and covalent binding of fendozic 
acid drug in order to see if this might cast further light on the 
involvement, if any, of Phase II metabolism in the toxicity of 
the drug.
Experimental procedures
Chemicals
Unlabelled fendozic acid [2-(2 -(4-chlorophenyl)thiazol-4- 
yl)acetic acid] was obtained from Compound Management 
(AstraZeneca, Alderley Park, UK, Batch number: 
A Z10002189-024) [,4C]-fenclozic acid [2-(2-(4-
chlorophenyl)[2-,4C]thiazol-4-yl)acetic acid; refer Table 4 
for position of radiolabel] was synthesised and supplied by 
Isotope Chemistry (AstraZeneca, Alderley Park, UK) at 
237 pCi/mg and a radiochemical purity >99%. Ultima Gold 
and Ultima Flo M scintillation cocktails were purchased from 
Packard Instruments (Pangbourne, UK). CarboSorb oxidiser 
absorbent and Permafluor E +  scintillant were obtained from 
PerkinElmer (Beaconsfield, UK) whilst FLUOTHANE'' was 
obtained from the AstraZeneca Group of Companies. Pierce 
BCA protein assay kit was obtained from Perbio Science 
(Cramlington, UK). Acctonitrile, ethanol, formic acid, 
hexane, tctrahydrofuran (THF), trifluoroacetic acid (TFA) 
and xylene were all of analytical grade and supplied by Fisher 
Scientific (Loughborough, UK). Phosphate buffer (pH 7.4) 
was supplied by AZ media (AstraZeneca, Alderley Park, UK). 
All other chemicals or solvents were purchased from 
commercial suppliers and were of analytical grade or the 
best equivalent.
Animals
In total, 12 male Hepatic Reductase Null [HRN; B6.Cg-
Po/m/H"/./Tg(Alb-cre)21Mgn ^7] mjce ag£[j approximately 8
weeks and weighing between 18.5 and 26.0 g were purchased 
from Taconic (Taconic Farms Inc., Germantown, NY). All 
animal procedures and treatments were carried out in 
accordance with approved animal licenses and guidelines 
issued by the British Home Office [Animals (Scientific 
Procedures) Act (1986)].
Methods
Two studies were performed as follows.
Study I :  To determine the route and rate of excretion, and 
metabolic fate of [,4C]-fcnclozic acid (target 1100 pCi/kg) in 
the HRN mouse.
Study 2: To determine the distribution of [14C]-fcnclozic acid 
(target 200 pCi/kg) by semi-quantitative whole body auto­
radiography (WBA) in HRN mice.
Individual mice were identified by tail markings, and 
acclimatised in groups to the environmental conditions for 3 
days prior to dosing. Mice were kept at room temperature and 
exposed to a 12 h dark/12 h artificial light cycle and an R&M  
No. 1 Modified Irradiated diet; potable water was available ad 
libitum. Mice were fasted for 12 h prior to oral administration 
(by gavage) of either [14C]-fenclozic acid (10 mg/kg) or 
phosphate buffer (dosing volume of 5 mL/kg). After dosing, 
the mice designated to the WBA study and the mice dosed 
with vehicle control were housed individually in polycarbon­
ate cages with stainless steel mesh inserts. Mice for the [14C] 
excretion-balance study were housed individually in glass 
metabolism cages.
Two dose solutions were prepared, one for each study. 
[14C]-fenclozic acid, supplied with a specific activity of 
237 pCi/mg, was diluted with unlabelled fendozic acid to 
give material with the target specific activity for each study. 
Unlabelled fendozic was dissolved in phosphate buffer (pH 
7.4) and an appropriate volume of this solution was added to 
the [ l4C]-fenclozic acid to give a solution at the target specific 
activity (110 pCi/mg for the balance study and 20 pCi/mg for 
the WBA study), and a target concentration of 2mg/mL. 
Phosphate buffer (pH 7.4) was used as the vehicle 
control dose.
Sample collection
Study 1: Urine, faeces and aqueous cage wash were collected 
over a 72 h period (urine and cage wash; 0-6 h and 6-12 h 
then daily to 72 h post-dose, faeces; daily post-dose), after 
which animals were sacrificed by FLUOTHANE inhalation. 
Urine and faeces were collected over dry ice to ensure sample 
stability. Following death, the mice were exsanguinated and 
the blood collected into hcparinised blood tubes before being 
spun for 2min, at approximately 7800/,' and ambient 
temperature to produce plasma. The liver (with gall bladder 
removed) and kidneys from each animal were collected and 
a small sample of each liver was taken and fixed for 
histopathology. The remainder of the liver and kidneys were 
snap-frozen in liquid nitrogen and stored at — 80 °C until 
required.
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Study 2: Two HRN mice were sacrificed at 6, 24 and 72 h
TM
post-dose by FLUOTHANE inhalation. Carcasses were 
immediately frozen in a mixture of hexane and dry ice then 
stored at ca. -8 0  C until WBA was performed as described 
below'.
Histopathology
Liver samples were fixed in 10% neutral buffered formalde­
hyde for 5 days before dehydrating in increasing concentra­
tions of industrial methylated spirits (IMS). IMS and xylene 
(70. 80 and 95%) then xylene alone, over a total of 7h. 
Dehydrated samples were embedded in paraffin wax. after 
which sections (3 pm thick) were prepared and stained with 
Haematoxylin and Eosin (H&E). Stained sections were 
observed using a light microscope.
Determ ination of routes and rates of excretion
The radioactive content of liquid samples (dose solutions, 
urine, aqueous cage wash and plasma) was determined by 
liquid scintillation counting (LSC). Weighed aliquots (in 
duplicate) of sample were made up to 1 mL with deionised 
water, after which lOmL scintillation cocktail (Ultima Gold) 
was added and the samples analysed using a Packard TriCarb 
scintillation counter (Pangbourne, UK) for lOmin or until 1 ( /’ 
counts had accumulated. Solid samples, such as faeces, liver 
and kidney, were first homogenised in water (l:3w/v) and 
then combusted using a Packard Oxidiser (model 307). The 
products of combustion were trapped in 9mL of CarboSorb 
and then 12mL Permafluor E +  scintillation cocktail were 
added prior to LSC as described above. The amount of 
radioactivity in the excreta and tissue samples was compared 
with that dosed to the animals in order to calculate the 
percentage recovery from each animal.
W hole body autoradiography
Following the freezing of the animals the hind legs and tail 
were removed. Each carcass was then embedded left side 
uppermost in a block of carboxymethylcellulose {ca. 2% in 
water) then mounted on the stage of a Leica CM3600 
cryomacrotome (Leica Microsystems, Germany) maintained 
at approximately — 20CC. Sagittal sections (30 pm) were 
prepared from each animal based on the work of Ullberg 
(1954) to include as many tissues as possible. Sections were 
then allowed to freeze-dry prior to exposure to FUJI 
phosphor imaging plates (Raytek, Sheffield, UK). Sections 
for imaging w'ere enclosed in a light-tight cassette and were 
exposed for 7 days. After exposure the imaging plates were 
removed from the cassettes under dark room conditions and 
the plates scanned using a FUJI FLA 5000 phosphor imager 
(Raytek) and radioactive content of selected tissues deter­
mined using AIDA image analysis software (Raytest UK. 
Sheffield, UK).
Covalent binding
Individual plasma samples were used untreated whilst liver 
and kidney homogenates from each animal in Study 1 were 
used to assess the extent of covalent binding. The radioactive
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content for each sample was measured by scintillation 
counting. The protein content of the homogenates and 
plasma was determined using a Pierce BCA protein assay 
kit. samples were subsequently diluted to give 2 mg/mL 
protein using 0.1 M phosphate buffer (pH 7.4). Aliquots 
(200 pL in triplicate) were then placed in the wells of a 96- 
well plate and 300 pL of acidified (3% formic acid) acetone 
added, and the samples then agitated for 1 min. A further 
500pL acidified acetone was then added and the samples 
agitated again for 1 min to allow the protein to precipitate. 
The protein pellet was washed with 80% methanol in water 
using a Brandel cell harvester (Gaithersburg, MD). The 
protein concentration and radioactive content of the remain­
ing pellet were determined by scintillation counting, and the 
extent of covalent binding calculated by difference using 
Microsoft Excel. The statistical significance of the difference 
was calculated using the Student’s /-test function in Microsoft 
Excel.
Sample preparation for m etabo lite  identification
Urine and faeces samples were pooled by excreta type to 
include any sample containing greater than 1% of the 
administered dose. For urine the pool w;as 6-72 h whilst for 
the faeces the pool was 24-48 h. The radioactive content of 
each pool w'as determined either by LSC directly (urine) or 
following combustion (faecal homogenates) as described 
previously. Pre-dose urine and faeces samples were also 
prepared in the same way as the post-dose samples.
Pooled urine samples were concentrated to approximately 
400000dpm/mL under a stream of oxygen-free nitrogen and 
analysed directly, whereas faecal homogenates were extracted 
by adding aeetonitrile to each homogenate in the ratio 3:1 
(vol/weight) and the sample mixed on a rotary mixer for 
10 min before centrifuging at 3345 g for 10 min at 20 C. 
The supernatant was removed and the radioactive recovery 
determined by LSC. Two extractions sufficed to give 
complete recovery, and these were combined prior to 
concentration using a Buchi R-I14 rotavapor (BUCHI 
Labortechnik AG. Switzerland) at 30 C followed by further 
concentration to approximately 400 000dpm/mL under a 
stream of oxygen-free nitrogen. The resulting concentrated 
samples were centrifuged at 25 000g for 3 min to remove any 
particulate matter.
Profiling and structural characterisation of 
m etabolites by UPLC-LTQ-Orbitrap and top  count
Accurate mass structural characterisation work was acquired 
on an LTQ Orbitrap XL connected to a Waters Acquity 
Ultra high-Performance Liquid Chromatography (UPLC) 
system. The Waters Acquity system consisted of a binary 
UPLC pump. Column oven, autoinjector equipped and a 
photodiode array detector. Separations were carried out on 
a Waters BF.H C18 (100 x 2.0mm, 1.8 pM). preceded by a 
guard filter in a column oven at 50 C. The mobile phase 
consisted of aqueous formic acid (0.1% in water, eluent A) 
and methanolic formic acid (0.1%, eluent B).
The following elution profile was employed: An initial step 
of 5-20% at 1.00 min. a linear gradient 20% A to 55% A.
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1.01-15.00 min, a fast linear gradient 55% A to 98% A 15.00- 
min, isocratic hold. 2% A 16.00-17.00 min: re-equilibration 
95% A. 17.00-19.00 min. The How rate was 0.45 mL/min and
TM _
was split post-column 5:1 (v/v) using a QuickSplit lixed- 
flow splitter (Analytical Scientific Instruments. Elsobrantc. 
CA) to a HTC-PAL fraction-eollector/autosampler (CTC 
Analytics, Presearch. Baskingstoke, UK) for fraction collect­
ing and an LTQ Orbitrap (Thermo Fisher Scientific. Bremen. 
Germany) for mass spec analysis.
Using an injection volume of 20 pL. fractions were collected 
into 96 deep-well Luma™ plates (Perkin Elmer Inc., 
Cambridge, UK) across the whole run at a rate of 2.4 s per 
well. These plates were then dried and analysed for radioactiv­
ity on a Packard HTS-Topcount-NXT (Pangbourne. UK). The 
data were imported into LAURA software version 4.1.12.89 
(Lablogic systems Ltd., Sheffield, UK) to reconstruct the radio 
chromatograms. The LTQ-Orbitrap XL was equipped with an 
electrospray ionisation (ESI) source (Thermo Fisher Scientific, 
Bremen. Germany) which was operated in positive mode. 
Source settings were: Capillary temperature 300 C. sheath gas 
flow 25. auxiliary gas flow 17, sweep gas flow 5. source 
voltage 3.5 kV, source current lOOpA, capillary voltage 18 V, 
tube lens 75.0 V. Full scan MS data were obtained over the mass 
range of 100-1000 Da at a peak resolution of 7500 FWHM. 
Targeted MSMS experiments were acquired using Higher 
energy Collisional Dissociation (HCD) fragmentation, isola­
tion width 2 Da. normalised collision energy 45. and activation 
time 30 ms. HCD fragment ions were monitored by the 
Orbitrap using 7500 resolution. LTQ and Orbitrap mass 
detectors were calibrated within one day of commencing the 
work using Proteomass LTQ/FT-Hybrid ESI positive mode 
calibration mix (Supelco. Bellefonte, PA).
Data analysis
The assessment of the metabolism of fendozic acid w as made 
by both quantitative and qualitative analyses of the chroma­
tographic profiles obtained via [ l4C]-detection and LC-MS 
respectively. Radio-labelled components were assumed to 
have the same specific activity as parent molecule.
Mass spectrometric data were collected using Xcalibur 
version 2.0.7 (Thermo Fisher Scientific, Waltham. MA). 
Components were identified as being derived from | nC|- 
fenclozic acid if they displayed the retention times corres­
ponding with radio-labelled peaks and demonstrated the 
characteristic, isotopic and fragmentation patterns observed 
with the parent molecule. All accurate mass measurements 
including the MSMS fragmentation and MSMS isolation were 
taken from the fendozic acid [1 ~C] isotope peak. This was 
done due to the interference of the unlabeled fendozic [4 'Cl] 
isotope peak contaminating the | uC]-labelled fendozic acid 
accurate mass. Comparisons with pre-dose control samples 
were conducted to minimise the potential for false positives 
from endogenous compounds.
Results and discussion
Histopathology
Liver sections treated with H&E stains observed under light 
microscopy for HRN mice dosed with l '4C]-fenclozic acid
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Figure 1. Autoradiography images o f hepatic cytochrome P450 reduc­
tase null (H R N ) mice following a single 10mg/kg oral dose o f [ UC]- 
fenclozic acid. Fendozic acid related material is well distributed in all 
tissues with the exception o f the central nervous system, and still remains 
in tissues at 72 h post-dose.
showed no alterations in liver morphology in comparison with 
the corresponding vehicle controls.
W hole body autoradiography
Whole body autoradioagraphy (WBA) of HRN mice showed 
that the radioactivity was widely distributed in to all the 
tissues (with the exception of the CNS where only very low 
levels were detected) (Figure 1). The radioactive content 
determined by imaging analysis software AIDA version 4.22 
(Raytest UK. Sheffield. UK) for selected tissues including 
tissue:blood ratios, illustrating retention of the radioactivity 
compared with circulating drug-related material is presented 
in Table I. The highest concentrations of radioactivity were 
detected in the blood, liver and kidney. The results of the 
WBA study showed retention of the radioactivity in the 
tissues of animals 72 h post-dosing (Figure 1). The amount 
of radioactivity remaining in the liver and kidneys at 72 h was 
quantified as part of the mass balance study and is described 
as follows.
Routes and rates of excretion of radioactivity
Following oral administration of | l4C]-fenclozic acid at 
10 mg/kg to HRN mice, the majority of the recovered 
radioactivity w'as eliminated via the urine (Table 2). 
A significant portion of the dose was also recovered in the 
cage wash, which was attributable to the low volumes of urine 
produced by the mice, resulting in a portion being recovered 
from the wall of the meta-bowls when cage washing was 
undertaken at sample collection. For this reason, the urine and
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Table 1. The mean (/r — 2) radioactive content (dpm/g) of selected tissues in hepatic cytochrome P450 reductase null 
(H R N ) mice, 6, 24 and 7 2 h after a single lOmg/kg oral dose o f [ 14C]-fcnclozic acid.
Tissue
6h 24 h 72 h
dpm/g Tissue:b!ood dpm/g Tissue:bIood dpm/g Tissue:blood
Blood 1 495 895 1.00 324 417 1.00 40 204 1.00
Brain 30 382 0.02 7 803 0.02 439 0.01
Kidney cortex 1 306 595 0.87 684 612 2.11 163 856 4.08
Kidney medulla 692 149 0.46 141 989 0.44 20 772 0.52
Liver 918 417 0.61 306 996 0.95 49 330 1.23
Table 2. The mean (n = 3) percentage of fenclozic acid related material recovered in the excreta of hepatic 
cytochrome P450 reductase null (H RN ) mice over time.
Percentage o f the dose recovered in excreta (%) (M c a n ± S D )
0 -6  h 6-12  h 12-24 h 2 4 -4 8 h 4 8 -7 2 h
Urine 1.45 ± 2 .0 2 2.05 ± 2 .0 8 10.93 ± 1 1 .62 14.87 ± 2 .1 6 5.62 ± 0 .9 2
Cagewash 4.03 ± 0 .7 6 4.17 ±  3.77 5.98 ± 5 .9 9 4.26 ± 2 .5 5 1.17 ± 0 .3 9
Subtotal 5.49 ±  2.48 6.24 ± 5 .0 4 16.91 ± 1 1 .75 19.11 ± 4 .5 4 6.80 ± 0 .8 9
0-24 h 24-48 h 4 8 -7 2 h
Faeces 2.86 ± 2 .2 5 2.08 ±  0.67 0.37 ± 0 .0 6
Subtotal 31.50 ±  10.80 21.18 ± 4 .9 7 7.17 ± 0 .8 4
Total 59.84 ± 6 .3 0
of binding in the liver and plasma (13.43 ±3.35 and 
2.83 ±  1.00 pmol cquiv/mg protein respectively). 
Quantification of the total amount of the dose (i.e. free and 
covalently bound) present in the homogenates of the excised 
livers and kidneys by sample oxidation showed that this 
amounted to 1.01 ±0.06% in the liver and 0.39 ±0.06% 
(mean ±  SD) in the kidneys.
Metabolite profile of [14C]-fendozic acid in urine and 
faecal extracts
Radiochromatograms generated the Topcount data of the 
excreta from HRN mice are shown in Figure 2(A) and (B). 
HRN mice excreted four major radio-labelled components 
via the urine eluting between 10 and 14 min (Figure 2A). 
These were identified by mass spectrometry as unchanged 
fenclozic acid an acyl glucuronide (as a mixture of 
transacylated isomers) and two amino acid conjugates. 
The latter were identified as a glycine conjugate, which 
formed the major metabolite in urine and a taurine 
conjugate (refer Table 4 for structures and proportions of 
the dose).
The faecal extract from HRN mice (Figure 2B) 
showed two major radio-peaks, identified as parent compound 
and the taurine conjugate. In addition, a small peak corres­
ponding to the glycine conjugate was also seen. Full scan and 
fragmentation mass spectra for the glycine, taurine and acyl- 
glucuronide conjugates arc shown in Figure 4.
No loss of radioactivity on the HPLC column was observed 
for any of the samples studied and we therefore assume that 
the profiles obtained represent the contents of the samples.
Structural characterization of drug and metabolites by 
UPLC-MS
To ensure good quality accurate mass measurements all 
structural characterisation was conducted on the unlabeled
Table 3. Covalent binding of fenclozic acid related material in hepatic 
cytochrome P450 reductase null (H RN ) mice, 72 h after a single 
lOmg/kg oral dose of [ l4C]-fenclozic acid.
Animal
pmol cquiv/mg protein
Liver Kidney Plasma
4 9.96 ± 0 .5 4 21.93 ± 0 .3 4 2.37 ± 0 .7 5
5 16.64 ± 0 .3 2 29.82 ± 3 .4 3 2.14 ± 0 .2 4
6 13.69 ±0 .31 27.21 ±  1.18 3.97 ±  1.56
Mean 13.43 ± 3 .3 5 26.32 ± 4 .0 2 2.83 ±  1.00
cage wash values were combined, with cage wash-derived 
radioactivity assumed to result from urinary' excretion. 
Recovery of radioactivity via the urine/cage wash amounted 
to ca. 55 ±  5 % (mean ±  SD) by 72 h post-dose.
A smaller portion of the administered dose was excreted in 
the faeces (Table 2), with ca. 5 ±2%  eliminated via this route 
over 72 h collection period. Therefore, the overall recovery of 
compound-related material in the excreta was approximately 
60 ±6% (mean±SD) over the 72 h period studied. The
reason(s) for the relatively low recovery in the excretion
balance part of the study are not clear. The site of
incorporation of the radiolabel should ensure metabolic
stability so the low recovery more likely reflects either the 
administration of less [l4CJ-fcnclozic acid than expected, or 
difficulties in ensuring the complete recovery of excreted 
radiolabcl from the meta-bowls. As a result of the observation 
of retention of the radiolabcl in certain tissues by WBA at 
72 h post dose, covalent binding studies were performed on 
plasma, liver and kidney samples to determine whether this 
relatively long-retained radioactivity was due to covalent 
binding to cellular macromolcculcs. Covalent binding results 
revealed low levels (<50 pmol equiv/mg protein) of bound 
radioactivity in the plasma, liver and kidneys (Table 3). The 
highest levels of binding were seen in the kidneys 
(26.32 ±  4.02 pmolequiv/mg protein) with much lower levels
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Figure 2. The radiochromatograms generated from the Topcouni data of 
the excreta from hepatic cytochrome P450 reductase null (H R N ) mice 
after a single 10 mg/kg oral dose of [ l4C]-fencIozic acid. ( A ) urine, (B) 
faeces. Labels indicate peaks whose chemical structures were deter­
mined using mass spectrometrie data.
fenclozic acid and metabolite MS peaks. This was due to the 
contamination of the 114C 1-labclled fenclozic acid isotope MS 
peak with the unlabeled C'l|-fenclozic acid isotope. Drugs 
often contain structural motifs similar to those of their 
metabolites; it is therefore common practice to first fully 
characterize the structure of the parent compound with 
accurate mass MS/MS fragmentation. Characteristic fragment 
ions identified from the drug can then be used to elucidate 
metabolite structures.
Structural characterization fenclozic acid
Analysis of fenclozic by LC-MS/MS/MS yielded a prolonated 
molecular ion for unlabeled | 1 “C] with an accurate mass of 
|M + 1I| 254.0035 ( - 1 .0 0 ppm). The proposed fragmenta­
tion pattern and LTQ Orbitrap HCD MS/MS spectrum 
fenclozic acid (Figure 3) revealed three fragment ions m/z 
207.9982 (corresponding to decarboxylation) m/z 138.105 and 
m / z  70.9951 (corresponding to thiazole ring opening 
products).
Structural characterization o f the major metabolites observed 
in the radiochromatogram
The UPLC peak corresponding to M l yielded a prolonated 
molecular ion with an accurate mass of |M + H | 311.0239.
which was consistent with glycine conjugation (+1.81 ppm 
mass error). The accurate mass fragmentation of m/z 311 
(Figure 4) yielded two key fragment ions m/z 265.0197 
resulting from the loss of CO : and m/z 235.9934 for the loss 
of the glycine moiety, which are both indicative of a glycine 
conjugate. It is believed that the ion at m/z 254.0039 is 
an artefact, which has been formed through the addition of 
water to the m/z 235.9931 fragment ion in the MS (+0 .77  ppm 
mass error).
The metabolite M2 yielded a prolonated molecular ion 
with an accurate mass of |M + H |l 430.0381 (—1.61 ppm 
mass error) and this, and the proposed fragmentation pattern 
(Figure 4), were both indicative of direct glucuronidation on 
the acid moiety. A cluster of four MS peaks were detected for 
m/z 430.0381, which is consistent w ith transacylated products 
from an acyl-glucuronide.
The mass spectra data for M3 yielded a protonated 
molecular ion with an accurate mass of [M +  H| 361.0083, 
which was consistent with taurine conjugation (+1.378 ppm 
mass error). The accurate mass fragmentation of m/z 361 
(Figure 4) yielded two key fragment ions, m/z 279.0353 
showing the loss of SO;,H and m/z 235.9934 for the loss of the 
taurine moiety, which are both characteristic of a taurine 
conjugate.
Discussion
As described in the “ Introduction" section, the development 
of fenclozic acid was discontinued due to hepatotoxicity in 
man. This study was undertaken to examine the distribution, 
metabolism, excretion and hepatic effects, if any. of fenclozic 
acid using the HRN mouse, which is deficient in hepatic 
Phase I metabolism (via CYP P450V) but capable of Phase II 
conjugation reactions. Histopathological examination did not 
reveal any evidence of adverse hepatic effects for fenclozic 
acid in these animals after a single dose of 10 mg/kg. From 
the autoradiographic data the radiolabel was well distributed 
into tissues (apart from the brain), particularly into tissues 
such as liver and kidney. The majority of radioactivity (55%) 
was recovered in the urine/aqueous cage wash, w ith a smaller 
amount (5%) in the faeces giving an overall recovery of 
radioactivity in the excreta, over the 72 h period studied, of 
ca. 60%. Whilst the bulk of the radiolabel recovered in the 
urine and faeces was excreted in the first 48 h. appreciable 
amounts were still being excreted at the end of the study, and 
radioactivity was still detectable in tissues such as liver and 
kidney at 72 h post-dose.
The profiles of urine and faecal extracts showed that 
metabolism proceeded largely via conjugation reactions, as 
might be expected from animals where hepatic P450-based 
metabolism had been abolished. The major metabolites in the 
HRN mouse were amino acid conjugates to glycine and 
taurine, w ith quantities of the transacylated ac>l glucuronide.
The detection of transacylated acyl-glucuronide metabol­
ites of fenclozic acid in urine suggests a source of chemically 
reactive metabolites with the potential to form adducts to 
proteins (Stachulski et al., 2006) and indeed such metabolites 
have been designated as toxic in some regulatory guidances 
(FDA Guidance on safety testing of drug metabolites, 2008). 
However, in the in vitro investigations undertaken prior it) this 
study (Rodrigues et al.. 2013), high covalent binding was 
only observed in rat. dog and human microsomal incubations 
in the presence of NADPH (125.8 +  20.1. 70.2+19.8 and 
38.5 ±6 .8  pmol equiv/mg of protein for human, dog and rat 
liver microsomes, respectively). (For comparison when ( 1 'C|- 
diclofenac was used as a positive control covalent binding was
108.6 + 3.6. 145.8 +  20.5 and 126.9+ 18.0 pmol cquiv/mg of 
protein for human, rat and dog, respectively). When the 
ability of the acyl glucuronide to bind to proteins was
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Figure 3. Proposed LTQ Orbitrap HCD  
fragmentation o f fenclozic acid including 
mass error in ppm (top) and accurate mass 
spectrum (bottom).
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examined, in microsomal incubations supplemented with 
UDPGA (where the acyl glucuronide accounted for 4.5. 0.0 
and 4.9% of the total for human, rat and dog respectively) no 
covalent binding was observed. In contrast, when | I4C|- 
diclofenac, as a positive control, was incubated in the 
presence of UDPGA the covalent binding to liver microsomes 
amounted to 155.1 ±17.7, 113±21.4 and 131.4±21.2 pmol 
equiv/mg of protein for human, rat and dog. respectively. This 
suggests that, unlike diclofenac, the propensity for covalent 
binding of the fenclozic acid acyl-glucuronide is low. 
supporting the results obtained in vivo in this study in the 
HRN mouse.
Metabolism to amino acid conjugates provides an alterna­
tive route to reactive metabolite formation as it proceeds via 
an acyl-coenzyme A thioester intermediate. As has been 
shown experimentally, such CoA-thioester metabolites have 
the potential to react with proteins (Boelsterli, 2002; Knights 
et al.. 2007; Skonberg et al.. 2008). In the in vitro hepatocyte 
study the taurine conjugate of [ l4C]-fenclozic acid was 
observed in rat and dog (but not human) hepatocyte 
incubations, and was highest in rat accounting for 9.6% of 
the total radioactivity after ISOmin (Rodrigues el al.. 2013). 
When covalent binding was investigated the greatest amount 
of non-extractable binding in hepatocytes also followed this 
trend with the highest binding seen for rat. then dog and 
finally human hepatocytes, amounting to 539.0±69.6.
269.7 ±143.5 and 74.9 ±  13.6 pmol equiv/mg of protein, 
respectively, and such a result might be taken as support for a 
CoA-thioester-binding mechanism. However, in these in vitro 
hepatocyte studies, interpretation of the covalent binding data 
was complicated since the cells had the ability to perform 
P450 related oxidative metabolism as well as Phase II 
metabolism.
Despite the clear opportunity to covalently bind to proteins 
via either acyl CoA thiocsters or due to acyl-glucuronide 
reactivity, and clear exposure to these metabolites in vivo, the 
determination of the extent of tissue and plasma covalent 
binding detected in the HRN mouse has shown this to be 
modest. Thus, for the tissues examined, covalent binding 
amounted to much less than 50 pmol equiv/mg protein. In 
addition, the highest levels of binding were seen in the kidney, 
at ca. 26 pmolequiv/mg protein, twice that seen for liver 
(ca. 13 pmolequiv/mg protein) whilst that seen for plasma 
(ca. 3 pmol equiv/mg protein) was negligible. In attempting to 
interpret the higher covalent binding of the radiolabel in 
kidney compared to liver it has to be borne in mind that, 
whilst hepatic metabolism can be reasonably considered to 
lack any P450-related contribution the same cannot be 
considered for kidney, which can perform both Phase 1 
oxidative and Phase II conjugation reactions. Whilst based on 
the data obtained in the previous in vitro study (Rodrigues 
et al.. 2013), it may be assumed that the higher levels of 
covalent binding in kidney compared to liver were the result 
of the presence of active P450’s in the former, further studies 
would be required to confirm this.
The results of this study show that it is possible to use the 
HRN to separate the contributions hepatic conjugative and 
P450-related oxidative metabolism from each other for 
fenclozic acid (as indeed it was for diclofenac -  Pickup 
et al., 2012). The results obtained in the HRN mouse suggest 
that the Phase II conjugation of fenclozic acid does not result 
in the production of large amounts of covalent binding, 
supporting the findings of the in vitro studies carried out with 
microsomes (Rodrigues et al., 2013). Further work will 
examine the metabolic fate of the drug in normal mice to 
explore the effects of P450-dependant oxidative metabolism.
86
172 K. Pickup et al. Xenobiotica. 2014; 44(2): 164-173
Figure 4. Proposed LTQ Orbitrap collision 
cell fragmentation of metabolites M l  (gly­
cine conjugate), M 2  (glucuronide) and M 3  
(taurine conjugate) with accurate mass spec­
tra and mass error in ppm.
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ABSTRACT: Fenclozic acid (Myalex) was developed by ICI 
pharmaceuticals in the 1960s for the treatment of rheumatoid 
arthritis and was a promising compound with a good predinical 
safety profile and efficacy. While it did not show adverse hepatic 
effects in predinical animal tests or initial studies in man .
[Chalmers et al. A nn. Rheum. Dis. 1969 , 25, 595 and Chalmers 
et al. Ann. Rheum. Dis. 196 9 , 28, 590], it was later withdrawn 
from clinical development. Hepatotoxicity was observed in i 
humans at daily doses of 400 mg but was not replicated in any < 
of the animal spedes tested. Rodrigues et al. [Arch. Toxicol.
2 0 1 3 , 87, 1569] published a mechanistic investigation using 
modern in vitro  assays/techniques in order to investigate the 
hepatotoxicity; however, only the covalent binding in rat, dog, 
and human microsomes was identified as a potential indicator for hepatoxicity. Metabolites associated with or responsible for 
covalent binding could not be detected, likely due to the low in vitro  metabolic turnover of fendozic acid in microsomes. Foulkes 
[ /. Pharmacol. Exp. Ther. 1970 , 172, 115] investigated the in vivo metabolism of fenclozic acid which included a rat bile duct 
cannulated (BDC) study characterizing the biliary and urinary metabolites; however, no reactive metabolites were identified. This 
study aimed to reinvestigate the in vivo metabolism of fenclozic acid in rat, with a focus on identifying any reactive metabolites 
that could explain the in vitro  covalent binding in microsomes observed across the species. Using modern analytical techniques, 
we were successful in identifying an epoxide reactive metabolite, which upon conjugation with glutathione (GSH), formed up to 
16 GSH-related products including positional and diastereoisomers. Not including the GSH related conjugates, 7 additional 
metabolites were identified compared to these previous metabolism studies.
Cysteine
Tim e (m in)
F enclozic acid ([2-(4-chlorophenyl)-l,3-thiazol-4-yl]acetic acid, Myalex) wras developed by ICI pharmaceuticals in 
the 1960s as a nonsteroidal anti-inflammatory drug for the 
treatment of rheumatoid arthritis and was a promising 
compound with a good predinical efficacy.' While it did not 
show adverse hepatic effects in predinical animal tests or initial 
studies in man,1- it was later withdrawn from clinical 
development. This was due to nonidiosyncratic hepatotoxicity 
at daily doses of 400 mg where several incidences of jaundice and 
abnormal hepatic function were reported.0 The cholestatic 
jaundice was also associated with elevated liver toxicity 
biomarkers such as alkaline phosphatase, serum glutamic 
oxaloacetic transaminase, and serum glutamic pyruvic trans­
aminase. This hepatotoxicity was not observed in any of the 
predinical animal spedes prior to dosing to man or later in 
additional animal studies where a variety of species were used. 
More recently, Rodrigues et al.' published a mechanistic 
investigation using a cascade of modern in vitro  toxicity assays' 
in order to investigate the hepatotoxicity; however, only the 
NADPH dependent covalent binding to protein in rat, dog and 
human microsomes was identified as a potential indicator for the 
hepatoxicity. Additionally, there was a reduction in the covalent
ACS Publications iC 2014 American Chemical Society
binding in microsomes when fendozic acid was incubated in the 
presence of glutathione (GSH) or cysteine. However, they were 
unable to identify any metabolites or adducts from any of the 
incubations including those fortified with nucleophilic trapping 
agents such as GSH, despite the use of radiolabeled fenclozic 
acid.
In contrast, in vivo studies undertaken with fenclozic acid by 
Foulkes4 and by Bradbury et al.9 showed extensive metabolism of 
the drug. A more recent in vivo study conducted in hepatic CYP 
reductase null (HRN) mice10 aimed to further evaluate the 
involvement of any phase II metabolism in the toxicity of the 
drug. The HRN mice lack functional hepatic cytochrome P450 
leading to the formation of direct conjugated metabolites 
exclusively. In both, the in vivo and the hepatocytes incubation 
study, an acylglucuronide was identified which can cause covalent 
binding to protein.11 However, Rodrigues et al. ' showed a higher 
level of covalent binding in microsomes compared to 
hepatocytes or microsomes supplemented with UDPGA
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(uridine 5-diphospho-glucuronosyltransferase), which suggests 
that phase I metabolites were responsible or significantly 
contributing to the covalent binding.
This paper describes the characterization of the biliary and 
urinary metabolites of fenclozic from a bile duct cannulated 
(BDC) study in rats utilizing UPLC (ultra high-performance 
liquid chromatography) and Fourier transform-mass spectrom­
etry. The emphasis is on identifying metabolites that indicate the 
formation of reactive intermediates which may have been missed 
in the previous studies by Foulkes4 and by Bradbury et al.4
■  EXPERIMENTAL SECTION
Chemicals. Fenclozic acid, [2-(4-chlorophenyl)-l,3-thiazol- 
4-yl] acetic acid, was obtained from Compound Management 
(AstraZeneca, Alderley Park, UK, Batch number: AZ 10002189- 
024). Methanol (MeOH), formic acid, and ammonium acetate 
were all of analytical grade and supplied by Fisher Scientific 
(Loughborough, UK). All other chemicals or solvents were 
purchased from commercial suppliers and were of analytical 
grade. No specific safety considerations apply to any of these 
agents, although the agents should be handled with care in a 
fumehood to avoid inhalation or ingestion.
Fenclozic Acid Stock Solution. Fenclozic acid was 
dissolved in MeOH at a concentration of 200 //M.
Animal Dosing and Sample Collection (Bile and Urine) 
of the BDC Rats. Two male Han Wistar rats, aged between 7 
and 12 weeks and weighing between 180 and 250 g at the time of 
dosing, were supplied by AstraZeneca’s rodent breeding unit. 
The animals were surgically fitted with bile duct cannuli under 
full anesthetic.
Each animal received a single i.v. bolus dose of fenclozic acid at 
2 mg/kg at a dose volume of 2 mL/kg in a dose vehicle consisting 
of dimethylamide (DMA)/phosphate buffered saline (PBS, pH 
7.4) (30%/70%, v/v). Urine and bile was collected on ice 
predose and at 0—6 h, 6— 12 h, and 12—24 h postdose and stored 
frozen at —20 °C until analysis. All animal procedures and 
treatments were carried out in accordance with approved animal 
licenses and guidelines issued by the British Home Office 
(Animals (Scientific Procedures) Act (1986)).
Sample Preparation. Urine. 100 //L aliquots were taken 
from each time point for both animals and pooled to produce a 
600 j.iL, 0—24 h postdose sample for metabolite identification. A 
600 //L aliquot of predose urine was spiked with 1.5 //L of the 
fenclozic acid stock solution (2 niM).
Bile. 100 //L aliquots were taken from each time point for both 
animals and pooled to produce a 600 /vL, 0—24 h postdose 
sample for metabolite identification. A 600 //L aliquot of predose 
bile was spiked with 1.5 /tL of the fenclozic acid stock solution (2 
mM).
The spiked predose and pooled 0—24 h postdose urine and 
bile samples were centrifuged at ca. 12 OOOg for 5 min prior to 
analysis. The supernatants were transferred to an equal volume of 
ultrapurified distilled water in Waters HPLC 2 rnL vials for LC- 
MS analyses.
Profiling and Structural Characterization of Metabo­
lites by UPLC-LTQ-Orbitrap Mass Spectrometry. Accurate 
mass structural characterization work was acquired on a LTQ  
Orbitrap XL (Thermo Fisher Scientific, Bremen, Germany) 
connected to a Waters Acquity LJPLC system. The Waters 
Acquity system (Waters, Milford, MA, USA) consisted of a 
binary UPLC Pump, column oven, a sample manager, and a 
photodiode array detector. Separation was carried out on a 
Waters BEH C18 (100 X  2.1 mm, 1.7 //M) (Waters, Milford,
MA, USA), preceded by a guard filter in a column oven at 50 C. 
Two chromatographic methods were used.
Method 1. The mobile phase consisted of formic acid (0.1% in 
water, eluent A) and methanolic formic acid (0.1%, eluent B).
Method 2. The mobile phase consisted of ammonium acetate 
(5 mM, eluent A) and methanolic ammonium acetate (5 mM, 
eluent B). The elution profile for both methods was: An initial 
hold at 95% A and then a step from 95% to 80% A at 1.00 min, a 
linear gradient from 80% to 50% A at 1.01 to 15.00 min, a last 
linear gradient from 50% to 2% A at 15.00 to 16 min, isocratic 
hold, 2% A from 16.00 to 17.00 min; re-equilibration at 95% A 
from 17.00 to 19.00 min. The flow rate was 0.45 mL/min, and the 
eluent was introduced into the mass spectrometer via the LTQ  
divert valve at 1 min. The injection volume was 20 //L, and UV 
spectra were acquired over 190—330 nm. The LTQ-Orbitrap XL 
was equipped with an electrospray ionization (ESI) source which 
was operated in either positive or negative ion mode. Positive ion 
source settings were: Capillary temperature 300 °C, sheath gas 
flow 25, auxiliary gas flow 17, sweep gas flow 5, source voltage 3.5 
kV, source current 100.0 //A, capillary voltage 18 V, and tube lens
75.0 V. Full scan MS data were obtained over the mass range oi 
100 to 1200 Da. Negative ion source settings were capillary 
temperature 300 °C, sheath gas flow 25, auxiliary gas flow 17, 
sweep gas flow 5, source voltage 3.0 kV, source current 100.0 //A, 
capillary voltage — 1 V, and tube lens — 128.3 V. Full scan MS data 
were obtained over the mass range of 100 to 1200 Da. Targeted 
MSMS experiments were acquired in the Orbitrap using higher 
energy collisional dissociation (HCD) fragmentation, isolation 
width 3 Da, normalized collision energy 60 eV, and activation 
time 30 ms. All Ion trap MS” experiments were acquired using 
collision induced dissociation (CID), isolation width 3 Da, 
normalized collision energy 35 eV, and activation time 30 ms. All 
ions acquired in the Orbitrap were monitored at 7500 resolution 
fwhm (full width at half-maximum). LTQ  and Orbitrap mass 
detectors were calibrated within 1 day of commencing the work 
using Proteomass LTQ/FT-Hybrid ESI positive mode calibra­
tion mix (Supelco, Bellefonte, USA).
Data Analysis. Mass spectrometric data were collected using 
Xcalibur version 2.1 (Thermo Fisher Scientific, Bremen, 
Germany). Components were identified as being derived from 
fenclozic acid by common fragments, isotopic pattern (chlorine), 
UV absorbance, and accurate mass. Comparisons with predose 
control samples spiked with fenclozic acid were conducted to 
minimize the potential for false positives from system impurities 
and endogenous components. All accurate mass measurements 
including the MSMS fragmentation were within ±3 ppm ot the 
theoretical accurate mass.
■  RESULTS
Structural Characterization of Fenclozic Acid. It is
common practice to first fully characterize the structure of the 
drug/test compound with accurate mass MSMS fragmentation 
as they often contain structural motifs similar to those of their 
metabolites. Characteristic fragment ions identified from the 
drug can then be used to help elucidate metabolite structures. 
Where required, MSMS fragmentation experiments were 
undertaken in positive and negative ion mode to maximize 
structural elucidation of the metabolites.
In positive ion mode, fenclozic acid yielded a protonated 
molecular ion at [M + H ]+ 254.0037 Da ( — 1.00 ppm mass error) 
and showed a characteristic chlorine pattern. The proposed 
fragmentation pattern and LTQOrbitrap HCD MSMS spectrum 
(Figure la) revealed 3 key fragment ions at m/z 207.9980
dx.doi.org/10.1021/acS02943d I Anal. Chem. 2014, 86, 11281 1128911282
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(corresponding to decarboxylation) and m / z  138.0105 and m / i  
70.9951 (both representative of cleavage of the thiazole ring)
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Figure I .  Accurate mass H C D  M SM S positive ion (a) and negative ion 
(b ) spectra of fenclozic acid and their associated fragmentation patterns 
with theoretical accurate mass shown below each structure.
In negative ion mode, fenclozic acid yielded a deprotonated 
molecular ion at [M  — H ]_ 251.9893 Da (+0.67 ppm mass error) 
and showed a characteristic chlorine pattern. The proposed 
fragmentation pattern and LTQ-Orbitrap H C D  MSMS spectrum 
(Figure lb ) revealed 2 fragment ions m / z  207.9996 (corre­
sponding to decarboxylation) and m / z  70.9964 (corresponding 
to a thiazole ring cleavage product).
Structural Characterization of the Urinary and Biliary 
Metabolites of Fenclozic Acid. Fenclozic acid was found to be
extensively metabolized in the rat. In total, 18 metabolites were 
detected and identified in bile and urine, of which 7 metabolites 
had not been identified previously, not including the multiple 
GSH related adducts (see Table l) .
Metabolite Formation via Direct Conjugation. Acylglu- 
curonide Conjugate. The / i -1 -O-acylglucuronide conjugate of 
fenclozic acid (Table 1, M 10) with [M  + H ]+  4.30.0352 ( — 1.38 
ppm mass error) was detected in both the urine and bile samples 
with evidence of acyl migration products (Figure 2). The 
reactivity of acylglucuronide conjugates and the associated 
idiosyncratic toxicity is well documented in the literature,11’1- 
and as it has been observed previously by Pickup et al., 1 it will 
not be further characterized and discussed here.
Metabolite Formation via Coenzyme A. In this study, 
several conjugates were detected which are known to be formed 
through a coenzyme A intermediate,1' such as the carnitine, 
glutamyl, glycine, and taurine conjugates. The taurine and glycine 
metabolites have been detected and characterized previously by 
Foulkes/ Newbould/ and Pickup et al.10 The glutamyl conugate 
has not been reported for fenclozic acid previously; however, it is 
a fairly common metabolite which is not associated with toxicity. 
In contrast, carnitine conjugation is not a common biotransfor­
mation for xenobiotics. More importantly, carnitine depletion 
has been associated with potential toxicity (i.e., valproic 
acid,141') , so it is characterized here.
Characterization o f  the Carnitine Conjugate. The carnitine 
metabolite (Table 1, M i l )  produced a protonated molecular ion 
with a characteristic chlorine pattern and an accurate mass of [M  
+ H ]+ 397.0979 Da (Figure 3), consistent with carnitine 
conjugation ( —1.09 ppm mass error). Accurate mass H C D  
fragmentation of [M  + H ]+ 397.0979 Da (Figure 3) yielded four 
key fragment ions with m / z  338.0246 (resulting from loss of 
NC,Hg), m / z  254.0033 (loss of carnitine), m / z  207.9981 (loss of 
C 0 2 and carnitine), and m / z  144.1015 (characteristic of the 
carnitine ion).
The zwitterionic nature of the camitine-metabolite was 
demonstrated in a brief experiment with two different mobile 
phase modifiers (formic acid, approximately pH 4.0 (LC method
1), and ammonium acetate, approximately pH 6.5 (LC method
2)). The difference in pH had no effect on the ionization state 
and therefore little effect on the retention time of the carnitine 
conjugate, based on its low pK, (<3), compared to a change in 
the ionization state and retention characteristics of fenclozic acid, 
as shown in Figure 4.
Glutathione (GSH)-Related Conjugates Formed via 
Epoxidation. Several GSH-related conjugates were detected 
consistent with GSH, cysteine—glycine, cysteine, and N- 
acetylcysteine conjugation. For each of these conjugates, up to 
4 isomers were detected (consisting of pairs of positional and 
diasteromeric isomers). These adducts and isomers were formed 
via an epoxide intermediate which was confirmed by accurate 
mass MSMS fragmentation data to be on the chlorobenzene ring. 
The cysteine conjugate, the simplest representative of this class, 
is described here in detail.
C haracterization o f  the Cysteine Conjugate. Multiple 
isomers were detected for the cysteine conjugate ( M l 5, Figure 
5) all of which generated identical fragmentation data. Positive as 
well as negative ion spectra were required to determine the site of 
metabolism, confirming the chlorobenzene ring to be both, the 
site of oxidation (+ 0 )  and cysteine conjugation.
In positive ion mode, a protonated molecular ion with a 
chlorine pattern and an accurate mass of [M  + H ] 1 391.0192 Da 
was observed, which was consistent with cysteine conjugation
11283
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Table 1. Metabolites of Fenclozic Acid Identified in Rat Bile and Urine"
Metabolite M atrix
detected
Observed |M + I I |4 
IM -H I
Structure/description New Key fragment ions observed (positive ion)
Fenclo/ic acid Rile /IJrine 254.0037251.9892
70.9950
138.0105
207.9982
M l Bile/Urinc
269.9986
267.9841 G '- O 'i? y ^ ° H 
-------[+0]
Oxidation (+0)
Yes
86.9905 
114.9848 
138.0105 
154.9722 
195.9982 
223.9928
M 2 Bile/Urine
269.9986
267.9841
1*0)
Oxidation (+0)
223.9931
154.0053
70.9950
M 3 Bile/ Urine
269.9986
267.9841
[+0] 
Oxidation (+0)
223.9930
154.0051
70.9949
M 4 Urine
269.9986
267.9841 o O - i j T ^
l+O)
Oxidation (+0)
223.9931
154.0056
70.9950
MS Urine
269.9986
267.9841
....... l+O]
Oxidation (+ 0 )
223.9932
154.0054
70.9950
M 6 Bile/Urinc 272.0128ND “ - O
I+h  2o)
Hydrolysis (+11.-0)
Yes
195.9982
154.9717
138.0105
89.0054
M 7 Bile/Urine 272.0128ND
|+H20]'
Hydrolysis (+H.-0)
Yes
195.9981
154.9717
138.0108
89.0055
M 8 Bile/Urine 239.9877ND
x ^ °
Oxidative decarboxylation
Yes
221.9774
193.9824
150.0103
M 9 Bile 297.0095
i / °
X ^
Oxidative decarboxylation + Glycine 
conjugation
Yes
239.9883
221.9776
193.9828
150.0105
*M 1 0 Bile/Urinc 430.0352ND
.9 H°  OH
Glucuronidation
207.9987
70.9947
M i l Bile/Urine 397.0979ND j
\
Carnitine conjugation
Yes
338.0246
254.0033
297.9981
144.1015
1 1284  dx.doi.org/10.1021/ac502943d I Anal. Chem. 2014, 86,11281 -11289
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Table 1. continued
Metabolite
M a trix
detected
Observed |M + H |*  
|M -H | Structure/description New Key fragment ions observed (positive ion)
M 12 Bile 382.0621
N D
> ~ N
O
Glutamyl conjugation
Yes
235.9931
207.9882
130.0499
84.0444
70.9950
M 13 Bile/Urinc 361.0077N D
J O 4
1 aurine conjugation
279.0353
235.9939
126.0219
M 14 Bile 311.0252
N D
Glycine conjugation
265.0195
235.9932
207.998
* M ! 5 Bile/Urine
391.0192
389.0035
\  '?s ' ' s ' ^ y ^ o h  
|+0) H n h 2 
Oxidation ( K )) • Cysteine conjugation
Yes
70.9951
154.0056
194.0094
207.9985
222.0045
223.9937
283.9603
*M 1 6 Bile
448.0398
446.0254
O
° H
/  ^  J l  ^  O H
1+° 1  H n h 2 0
Oxidation (+ O l + Cysteineglycine conjugation
Yes
283.9601
223.9935
194.0094
154.0044
70.9950
* M I7 Bile
433.0294
431.0144
CI' W ^ / T  0H
H HN o
Y
Oxidation (+ 0 )  + N-Acctylcystcine conjugation
Yes
415.0190
223.9935
154.0054
70.9950
*M 1 8 Bile
577.0830
575.0679
l+°> H h A rj O
X
J .  OH 
0
Oxidation (+01  +  Glutathione conjugation
Yes
448.0404
373.0083
354.9978
283.9603
177.0335
154.0042
130.0506
“Note: M 6  and M 7  are potentially diastereoisomers. *  denotes the presence o f positional and diasteroisomers. N ew  -  not previously identified in 
published data.
(2.13 ppm mass error). The accurate mass HCD fragmentation 
of [M + H ]‘ 391.0192 Da (Figure 5a) yielded several diagnostic 
ions with one key fragment at m/z 154.0056 (equivalent to the 
m/z 138.0105 +0 product of fenclozic acid) which confirmed 
oxidation on the chlorobenzene ring.
In negative ion mode, a molecular ion of [M — H] ” 389.0037 
Da (Figure 5b) was observed, which was consistent with cysteine 
conjugation (0 ppm mass error). The accurate mass HCD 
fragmentation of [M — H] 389.0037 Da (Figure 5b) yielded 3 
key fragment ions at m/z 283.9610, a characteristic fragment of 
GSH-related conjugates, corresponding to cleavage of the
cysteine leaving the thiol attached to chlorobenzene ring. The 
fragment ions at m/z 239.9710 and at m/z 167.9678 are 
representative of decarboxylation and thiazole ring cleavage, 
respectively, while preserving the thiol-chlorobenzene ring.
Characterization of the GSH-Related Metabolites, 
Epoxide, and Isomer Formation. The key fragments at m/z 
167 (in negative ion) and m/z 154 (in positive ion) were present 
in all the GSH-related conjugates. This suggests that they were all 
formed through bioactivation via oxidation of the chlorobenzene 
ring forming an epoxide intermediate, followed by GSH addition
dx.doi.org/10.1021/ac502943d! A na l Chem. 2014, 86,11281 -1 128911285
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Figure 2. LCM S selected ion ( m /z  430.0352) mass chromatogram 
showing partially resolved transacylated products o f fenclozic acid 
acylglucuronide.
and subsequent metabolism/degradation to the cysteine— 
glycine, cysteine, and finally acetylation to the N-acetylcysteine.
Up to four LCMS peaks were detected for each of the GSH- 
related conjugates with literally identical accurate masses (within 
±2 ppm mass error). In each case, the chlorobenzene ring was 
identified as the site of conjugation based on the accurate mass 
MSMS data, confinning that the cysteine, cysteine—glycine, and 
N-acetylcysteine were derived from the same GSH adduct.
As an example, the cysteine conjugate, the simplest 
representative of the GSH family, showed three distinct 
chromatographic peaks and a very minor fourth peak for which 
MSMS fragmentation was not possible, although the accurate 
mass was within ±5 ppm. Following epoxidation of the 
chlorobenzene ring and subsequent conjugation with GSH, a
Ammonium
Acetate Fenclozic
acid
Carnitine
metabolite
6.75
Formic
Acid
Fenclozic 
acid
Carnitine 
metabolite
4.80
i I i i r  i | i i i i | —t  r t~t~ | ~r
3 4 5 6
Time (min)
i"i ■ i l i i
Figure 4. Selected ion mass chromatograms for fenclozic acid and the 
carnitine metabolite ( M i l )  with LC method 2 at pH  6.5 (top) and LC  
method 1 at pH  4  (bottom).
pair of diastereoismers and two positional isomers are formed 
which can be separated chromatographically (Figure 6). Overall, 
up to 16 GSH-related products were formed from the single 
epoxide reactive intermediate, with four GSH-related conjugates 
(GSH, cysteine—glycine, cysteine, and N-acetylcysteine) and up 
to four isomers for each (consisting of positional isomers and 
diasteroisomers).
cij0 ^ s
m /z [M+HJ* =397.0983  
E rror = -1 .09ppm
m /z= 144.1019  
E rror = -2 .82ppm
m /z=  207.9982  
E rror = -0.12ppm
m /z=254.0037  
E rror = -0 .12ppm
m /z= 338 .0248  
E rror = -0 .69ppm
207 9981
100 m
o 60 —
^  40
254 0033
144.1015 338.0246
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Figure 3. Accurate mass H C D  M SM S spectrum of the carnitine metabolite ( M i l )  in positive ion mode and its associated fragmentation pattern with 
theoretical accurate mass shown below each structure.
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Figure S. Accurate mass H C D  M SM S spectra and fragmentation patterns with theoretical accurate mass shown below each structure for the cysteine 
metabolite (M 1 5 ) o f fenclozic acid, acquired in positive ion mode (a) and negative ion mode (b ). Note: The exact positions o f the O H - and cysteine- 
substituents on the benzyl-ring o f the fragment ions are not confirmed.
■  DISCUSSION
This study has demonstrated that fenclozic acid is extensively 
metabolized in the BDC rat, with a total of 18 metabolites 
detected and identified, exclusive of the multiple GSH-related 
conjugate isomers. Several previously unreported metabolites 
were identified including a carnitine conjugate as well as a series 
of GSH-related adducts formed through bioactivation of the 
chlorobenzene ring via epoxidation.
The in vivo metabolite identification studies conducted in the 
rat by Foulkes1 and by Bradbury9 showed fairly extensive 
metabolism of fenclozic acid. Foulkes reported 7 metabolites, 
including 4 oxidation products on the chlorobenzene ring 
(including an oxidative dechlorination product), an acylglucur- 
onide, a taurine, and a reductive decarboxylation product. 
Bradbury' reported an increase in taurine conjugation when the 
dose was increased from 2 to 100 mg/kg. There is a significant
dx.doi.org/10.1021/ac502943d I Anal. Chem 2014. 86, 11281-1128911287
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Figure 6. Cysteine conjugate with the structures of the four isomers 
(consisting ot positional and diastereoisomers) formed upon con­
jugation. The MS selected chromatogram (a) shows 3 major peaks/ 
isomers, with the 4th isomer present at trace level1'. Accurate mass HCD 
MSMS spectra of the 3 main cysteine conjugate isomer MS peaks are 
shown (b). Note: the cysteine serves as a representative of the GSH 
family (GSH, cysteine—glycine, cysteine, and N-acetylcysteine).
difference in the number and type of metabolites identified 
between these studies and those reported in this paper. A simple 
explanation for the differences observed could be the harsh 
extraction and chromatographic conditions employed by both 
groups. Foulkes 4 extracted metabolites from urine samples with 
chloroform or a mixture of methylene chloride/chloroform at 
pH 4.5 initially and then adjusted the aqueous phase (the residual 
urine) to pH 2 and re-extracted with the same solvents. The bile 
was either diluted with water and applied directly to TLC plates 
or extracted as described for urine. Bradbury et al.9 used freeze- 
drying then extraction with MeOH before concentrating the 
sample using rotary evaporation. All extracts were applied to 
TLC plates and subjected to a variety of solvents including 
isopropanol, water/ammonia, butan-l-ol, chloroform, and acetic 
acid. These extraction and chromatographic conditions are far 
harsher than those used in this study, as the bile and urine 
samples were simply diluted with water and injected on to a 
reverse phase column with mobile phase systems consisting of 
MeOH buffered with either formic acid (0.1%, v/v) or 
ammonium acetate (5 mM, w/v).
Foulkes4 reported a reductive decarboxylation metabolite but 
also described photochemical degradation of fenclozic acid to the 
reductive decarboxylation product when extracted into dilute 
chloroform. As no reductive decarboxylation product was
detected in this study, it is likely that this metabolite was an 
analytical artifact.
Foulkes and Bradbury did not detect any GSH-related adducts 
in their in vivo studies in the rat (or in any animal species), while 
our in vivo study in the rat did confirm their presence. This would 
suggest that the analytical methodology applied during the 
development of fenclozic acid was unsuitable for the detection of 
GSH adducts.
It is plausible that under the harsh conditions applied in the 
previous analyses the GSH-related conjugates could have 
degraded to the oxidative dechlorination product, which was 
not detected in this study. Apart from the differences in sample 
preparation procedures, the vastly improved chromatography 
and sensitivity of modern Fourier transform-mass spectrometers 
undoubtedly aided the detection of the larger number of 
metabolites described here in this study. Only one in vivo study 
has been conducted on fenclozic acid in recent years10 with 
hepatic CYP reductase null (HRN) mice which lack functional 
hepatic cytochrome P450, leading to the formation of conjugated 
metabolites only. The team did not uncover any additional phase 
ll/conjugated metabolites to those reported by Foulkes and 
Bradbury.9
Here, in this study, 7 additional metabolites (not including the 
multiple GSH-related adducts) were identified that had not been 
reported in any of the previous studies, which include a carnitine 
conjugate, additional oxidation products, and additional amino 
acid conjugates (see Table l). The amino acid, taurine, and 
carnitine conjugates imply the formation of a coenzyme A 
intermediate. This potentially reactive intermediate has been 
associated with the toxicity of carboxylic acid-containing 
xenobiotics and could explain the observed toxicity of fenclozic 
acid in the clinic. However, as the coenzyme A thioester is not 
formed in rat, human, and dog microsomal incubations, it cannot 
be responsible for the covalent protein binding observed by 
Rodrigues et al.' Likewise, the detection of an acylglucuronide 
metabolite, which showed evidence of acyl migration in both rat 
urine and bile samples, is a potential contributor to the toxicity 
observed in humans. The reactivity' of acyl glucuronides and the 
associated protein binding (Hapten hypothesis) and idiosyn­
cratic toxicity is well documented in the literature.'However, 
as with the potential coenzyme A intermediate, it could not be 
formed in the microsomal incubations (due to a lack of active 
UGT) and, hence, cannot contribute to the covalent binding 
observed in the microsomal incubations.
In contrast, the observed bioactivation via expoxidation on the 
chlorobenzene ring is likely to be responsible for the NADPH 
dependent covalent binding in microsomes. Yet, the covalent 
binding studies conducted by Rodrigues et al.,' which included 
GSH and cysteine microsomes trapping experiments, contradict 
this theory. If the epoxide reactive intermediate was the cause of 
covalent binding, then a GSH adduct should have been detected. 
However, fenclozic acid was shown to have very little metabolic 
turnover in the microsomal experiments as no metabolites were 
detected by radiochemical detection following the 2 h incubation 
period, supported by measurements of the intrinsic clearance of 
fenclozic acid in HLMs (measured CIm, < 3 (//L/mL/mg), 
unpublished data). It is therefore possible that epoxide 
intermediate formation was low, which in combination with 
the formation of 4 isomers (consisting of positional and 
diastereoisomers) upon GSH conjugation suggests that the 
GSH-derived metabolites were likely not present at sufficiently 
high concentrations to be detected even by top-end mass 
spectrometers.
11288 dx.doi.org/10.1021/ac502943d 1 Anal. Chem. 2014, 86, 11281-11289
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This is one of the problems facing current reactive metabolite 
screening strategies which are often focused on eliminating 
potential problematic compounds with medium to high in vitro 
metabolic turnover. While improvements have been made in 
analytical technology which enables better detection of 
metabolites, the current in vitro techniques to aid reactive 
metabolite detection such as GSH trapping in human liver 
microsomes still require refining especially for compounds with 
very low in vitro metabolic clearance.
■  CONCLUSION
After careful consideration of the data generated in this study, in 
comparison to all the data trom previous literature, we propose 
the reactive epoxide intermediate/metabolite to be the agent 
responsible for the observed covalent binding in rat microsomes 
and likely the cause of covalent binding in human microsomes. 
While the intact GSH adducts were not detected previously in 
human or any other species in vivo/ the identification of 
oxidation metabolites on the chloro-benzene ring, identified here 
and by Foulkes,4 is consistent with the formation of an epoxide 
intermediate. It is also important to note that the analytical 
approach by Foulkes was not suitable for the detection of GSH or 
the GSH-related adducts. This is in contrast to the recent in vitro 
microsomal GSH trapping work by Rodrigues et al.,3 where the 
lack of detection of the GSH adducts could be attributed to the 
very slow in vitro metabolic turnover of fenclozic acid.
The observed covalent binding in human and rat microsomes 
could also not be attributed to the formation of the 
acylglucuronide or thioester, as these metabolites are not 
generated in microsomes (which produce exclusively phase I 
metabolites). It is plausible that they contributed to or caused the 
observed toxicity in the clinic; however, the acylglucuronide and 
amino acid conjugates (indicating the formation of a coenzyme A 
thioester) were also detected in rat and dog where no significant 
toxicity was observed.
Hepatotoxicity wras not prevalent in any of the predinical 
species. It is therefore possible that the biotransformation to the 
epoxide intermediate is a minor metabolic pathway in the rat or 
that it is more efficiently detoxified by GSH than in humans.
Hence, we propose that the observed covalent binding in rat 
and human microsomes together with the GSH metabolites 
detected in the rat (predominantly in the bile samples) are an 
indicator for the cause of the observed hepatotoxicity in the 
clinic. Unfortunately, without dosing humans and collecting 
excreta tor metabolite identification studies, direct comparisons 
cannot be made.
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ABSTRACT:
Drug reactivity and bioactivation are of m ajor concern to the de­
velopm ent of potential drug candidates in the pharm aceutical in­
dustry (Chem  Res To x ico l 17:3-16, 2004; C hem  Res To x ico l 19:889- 
893, 2006). Identifying potentially problem atic compounds as soon 
as possible in the discovery process is of great im portance, so 
often early in vitro screening is used to speed up attrition. Identi­
fication of reactive m oieties is relatively straightforward with ap­
propriate in vitro trapping experiments; however, on occasion un­
expected reactive interm ediates can be found later during more  
detailed in vivo studies. Here, we present one such exam ple in­
volving a series of com pounds from  an early drug discovery cam ­
paign. These compounds were found to react with endogenous  
form aldehyde from  a rat in vivo study, resulting in the form ation of 
novel +  13-Da bridged hom opiperazine products (equivalent to  the  
addition of one carbon and one hydrogen atom ), which w ere de­
tected in urine and blood. The identification of these +  13-Da prod­
ucts and their origin and m echanism  of form ation are described in 
detail through analyses of a representative hom opiperazine com ­
pound [/V -(3-(3-fluorophenyl)-1,2,4-thiadiazol-5-yl)-4-(4-isopropyl- 
1,4-diaze-pane-2-carbonyl)piperazine-1-carboxam ide (AZX)] by 
liquid chrom atography-UV-m ass spectrom etry, 1H N M R, and 
chemical tests.
Introduction
Understanding the metabolic fate of putative drug candidates both 
in vitro and in vivo is a key component of drug discovery. Rapid 
production of early information describing the rate of clearance and 
site of metabolism is essential for directing iterative synthetic chem­
istry make-test cycles toward promising structural templates with the 
requisite properties for an effective daig.
Reactive drug metabolites are of great concern in the pharmaceu­
tical industry (Evans et al„ 2004: Baillie 2006. 2009). Although their 
identification is relatively straightforward with appropriate in vitro 
trapping experiments, sometimes additional reactive compounds are 
found unexpectedly. In general, early metabolism studies involve 
incubation in hepatocytes or mierosomes to mimic the most prevalent 
metabolic processes occurring in the liver. Incubate samples at / = 0 
min and at a terminal time point (usually 30-60 tnin) are then 
compared by LC-UV-MS/MS. These studies can be both challenging 
and time-consuming even w hen only a small number of metabolites 
are identified. Simply mining the raw data to find the metabolites in 
the terminal sample often requires the use of a variety of techniques, 
ranging from simple UV comparison to complex common fragment 
searching (commonly referred to as broad band or MSC) or the use of
Article, publication date, and citation information can be found at 
http://dm d.aspetjournals.org.
http://dx.doi.O rg/10.1124 /d m d . 112.044917.
sophisticated MS subtraction routines such as mass defect filtering. 
Experiments are therefore normally performed using state-of-the-art 
instruments offering a variety of options to aid detection and structure 
identification. The information is then used to direct and modify the 
chemistry toward compounds with favorable metabolic properties.
Improved understanding of bioactivation mechanisms, reactive in­
termediate formation (so-called reactive metabolites), and adverse 
toxicity has led to the front loading of biotransformation studies. In 
response, most pharmaceutical companies now employ reactive me­
tabolite trapping screens using liver mierosomes (usually human) 
fortified with nucleophiles such as GSH. cysteine, KCN. and me- 
thoxylamine (Prakash et al.. 2008). The nucleophiles trap reactive 
electrophilic species at sufficient concentration to favor the formation 
of a stable product identified by their unique MS/MS spectral char­
acteristics. Both early site of metabolism and reactive metabolite 
trapping studies rely on in vitro systems to generate the metabolites. 
However, metabolites can also be formed in complete biological 
systems, which could be missed if the metabolic pathways are un­
known and/or the endogenous reagents are not represented in these in 
vitro systems. Hence, in our laboratories potential drug candidates 
undergo nonradiolabeled in vivo metabolite identification studies. 
These generally involve either a bile duct-cannuiated study in rats, 
with collection of urine and bile over a 24-h period or collection of 
blood and urine from a high-dose rat pharmacokinetic study. The 
studies aid the identification of the excreted metabolites and ensure
ABBREVIATIONS: LC, liquid chromatography; MS/MS, tandem mass spectrometry; MS, mass spectrometry; AZX, A/-(3-(3-fluorophenyl)-1,2,4- 
thiadiazol-5-yl)-4-(4-isopropyl-1,4-diaze-pane-2-carbonyl)piperazine-1-carboxamide; ACN, acetomtrile: MeOH. methanol; UPLC, ultra high-per­
formance liquid chromatography; ESI, electrospray ionization; HCD, higher energy collisional dissociation; COSY, correlation spectroscopy: 
ROESY, rotating frame Overhauser effect spectroscopy; 4 ESI, positive ion electrospray ionization; RT, retention time.
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identification of any unexpected reactive metabolites not generated or 
detected in the preliminary in vitro systems.
During recent rat in vivo metabolite identification studies with a 
series of lead compounds, cyclized GSH adducts were detected, 
similar to those reported by Doss et al. (2005). highlighting a potential 
reactive metabolite alert. This alert was not raised in the conventional 
GSH trapping screen, because of the type of the GSH rearrangement 
(data not shown). The reactophore in these lead compounds consisted 
of a terminal piperazine, which was responsible for this bioactivation. 
To preserve the potency of the compounds and remove the reactive 
metabolite risk, the chemistry was changed to a homopiperazine 
series.
Hence, several promising homopiperazine compounds from this 
series were dosed to rats to assess whether these GSH adducts were 
also formed. Instead, the analyses led to the observ ation of unusual, 
novel products with a molecular weight gain of 13 Da (while showing 
an apparent increase of +12 Da by mass spectrometry) as the major 
parent-related material in the urine and blood samples, which were not 
detected in the preliminary in vitro studies. The formation of these 
products, referred to as /V-(3-(3-fluorophenyl)-1.2.4-thiadiazol-5-yl)-4- 
(4-isopropyl - 1,4-diaze-pane-2*carbonyl)piperazine-l -carboxamide 
(AZX) + 13 throughout, is subject to further investigation in this 
article, with compound AZX (Fig. 1) as a representative structure for 
the “homopiperazine series.”
Materials and Methods
Chemicals and Suppliers. Compound AZX was synthesized and devel­
oped ai AstraZeneca UK l.td. (Macclesfield, UK). Acetonitrile (ACN). meth­
anol (MeOH). ammonium acetate (analytical reagent grade), and formic acid 
were acquired from Thermo Fisher Scientific (Loughborough. UK ). Potassium 
cyanide, formaldehyde (379; in 11,0). and the dcuterated NMR solvents were 
sourced from Sigma-Aldrich (Poole. UK).
Standard/Stock Solutions. AZX stock solution. AZX was dissolved in 
MeOH at a concentration of 200 gM.
ATX lest solution. AZX was dissolved in MeOH/water (30:709; , v/v) to a 
concentration of 10 gM, The test solution was prepared from the stock 
solution. (Equivalent stock and test solutions were prepared in ACN to assess 
whether MeOH was a contributing factor in AZX +  13 formation.)
Formaldehyde. Formaldehyde (379; in H ,0 )  was used undiluted in all 
spiking experiments.
KCN. KCN was prepared in water to a concentration of 50 mM.
Animal Dosing and Sample Collection (Urine and Blood). Dosing solu­
tion. AZX was prepared in a formulation of dimethylamine-water (40:60. v/v) 
at a concentration of 1 mg/ml.
Rats. Male Han Wistar rats in  — 4) were divided into two groups (/? = 
2/group), each reeeiv ing a single dose of AZX at 2 mg/kg i . \ . at a dose volume 
of 2 ml/kg. Urine was collected predose and at 0 to 6. 6 to 12. and 12 to 24 h 
from group I, whereas group 2 provided blood via (he toil vein predose and at 
20 min. 1.5 h. 6 h (at a volume of 0.3 ml), and finally 24 h (at a volume of 1.3 
ml). Rat urine and blood were stored frozen at - 2 0  C until further analysis. 
Additional predose/control rat urine samples were provided on request, 
throughout the study.
Sample Preparation. Urine. Urine samples (0 -24  It postdose) were pooled 
using a set volume (100-p.l aliquots) from each time point before analysis. 
Predose urine (190- and 90-/xl aliquots) was spiked with 10 /al of the AZX 
stock solution (2(X) jxM) to give a final concentration of 10 and 20 /xM. 
respectively. Both the predose and 0 to 24 h urine samples were centrifuged at 
approximately I2,000g for 5 min before analysis. The supernalant was then
F
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transferred to Agilent high-performance liquid chromatography 2-nil \ials with 
200-/uI inserts for LC-MS analysis.
Blood. Blood samples (0 -24  h postdose) were pooled using a set volume 
(50-/xl aliquots) front each lime point. Blank/predose rat hlood w as spiked w ith 
10 /aI of the AZX stock solution (200 pM ). Both the predose/blank and 0 to 
24 h blood were diluted 1:1 with 114) and quenched w ith chilled (4 Ct ACN 
(1:3. v/v) followed by centrifugation at l2.(X)(h> for 5 min. and the supernatant 
was transferred to Agilent high-performance liquid chromatography 2-ntl vials 
for LC-MS analysis.
Formaldehyde Addition. The formaldehyde-spiked AZX test solution was 
prepared by adding It) pi of formaldehyde (3791 in water) to 5(H) /aI of the 
AZX test solution (It) pM . Me()H/H>0. 30:70. v/v) and analv/ed by LC-MS 
immediately.
Potassium Trapping Experiments. Ten-microliter aliquots of the KCN 
solution (50 mM KCN/water) w ere added to a) 90 p.I of the 0 to 24 h rat urine 
pool, b) 90 pi of predose rat urine, which was spiked w ith 10 pi of AZX (200 
pM . i.e.. the stock solution) to give a final concentration of 20 pM , and c) 90 
pi of the formaldehyde-spiked AZX test solution (detailed above). Both the 
urine samples and the formaldehyde-spiked A ZX test solution were left at 
room temperature for 24 h before injection onto the LC-MS system.
Preparation of N M R  Samples. Here, a more concentrated solution of AZX  
was prepared, at a concentration of 1 mM in ACN. For NMR spectroscopy, 
three solutions were prepared: a) 2 ml of AZX/ACN ( I mM): b) solution a with 
100 pI of formaldehyde (37'4 in H.O): and c) I ml o f solution b with 100 pi 
of KCN (50 mM). Each of the solutions was stored for 24 h (to allow complete 
formation of the products) before evaporation of the solvents. The solvents 
w'ere e\ aporated under nitrogen: each sample w as freeze-dried and reconsti­
tuted in 200 pi of MeOH-d4 for ‘H NM R spectroscopic analysis.
Identification and Structural Characterization of A ZX  +  13 by 
U P LC -LTQ  O rbitrap. Accurate mass structural characterization was ac­
quired on a LTQ Orbitrap XL connected to a Waters Acquity HPLC system. 
The Waters Acquity system consisted of a binary UPLC PUMP, a column oven, 
an autoinjector, and a photodiode array detector. Separations were performed out 
on a Kinetix CIS column (100 x  2.0 mm. 2.6 /am: Phenomenex. Macclesfield. 
UK) preceded by a guard filter in an column oven at 50 C. The mobile phase 
consisted of different solvent systems to assess the contribution of solvent/ 
buffer/acidifier to the AZX + 13 formation: I ) ammonium acetate (5 mM. 
eluent A) and methanolic ammonium acetate (5 mM, eluent Bi and 2) 
formic acid (0.1%, eluent A) and formic aeid/ACN (0.1%, eluent B).
The AZX slock and test solution were found to be stable in both mobile 
phase systems. For the in vivo samples, the AZX + 13 product was detected 
at approximately the same concentrations in either solvent system used. Hence, 
solvent system I was subsequently used routinely.
The elution profile was linear gradient 90% A to 10% A. 0.(X) to 8.00 min; 
isocratic hold, 10% A 8.00 to 10.00 min; and reequilibration 90% A. 10.01 to
13.00 min. The flow rate was 0.6 ml/min. and the eluent was introduced into 
the mass spectrometer via the LTQ divert valve at I min. The injection volume 
was 20 ju.1. and UV spectra were acquired over 190 to 330 nm. The LTQ 
Orbitrap XL was equipped with an electrospray ionization (ESI) source 
(Thermo Fisher Scientific. Bremen. Germany), which was operated in positive 
mode. Source settings were as follows: capillary temperature. 350 C: sheath 
gas How. 25: auxiliary gas How. 17: sweep gas flow. 5: source voltage. 3.5 kV: 
source current, 100.0 p.A; capillary- voltage, 18 V: and tube lens. 75.0 V. 
Full-scan MS data were obtained over the mass range of 100 to 1000 Da at a 
peak resolution of 7500. Targeted MS/MS experiments were acquired using 
higher energy collisional dissociation (HCD) fragmentation, isolation width 2 
Da. normalized collision energy 45. and activation time 30 ms. HCD fragment 
ions were monitored by the Orbitrap using 7500 resolution. LTQ and Orbitrap 
mass detectors were calibrated within I day of commencing the work using 
ProteoMass LTQ/FT-Hybrid ESI positive mode calibration mix (Supelco. 
Bellefonte, PA).
'H  N M R  Spectroscopy for Structure Verification. 'H NM R analyses 
were performed to confirm and structurally characterize AZX +  13 and the 
AZX + 13 + CN adduct. H NMR data were acquired on a Bruker A VANCE  
600 MHz spectrometer, operating at 600.13 MHz 'H resonance frequency. The 
NMR spectrometer was equipped with a 2.5-mm SF.I 1 H/'*'F probe.
One-dimensional 'H NMR spectra of substrate and product were acquired 
without solvent suppression into 65K data points over a spectral width of
12,376 Hz. resulting in an acquisition time of 2.64 s. A relaxation delay of 2.4 s 
was used to ensure T l relaxation between successive scans and. depending on 
concentration, approximately 64 to 512 scans were acquired per sample.
Two-dimensional 'H -‘H COSY (gradient enhanced; Bruker Biospin Ltd.. 
Coventry. UK) experiments were used on the samples to determine signal 
connectivities. Here, spectra were acquired into 4K data points in F2. and 128 
increments in F I. The spectral width was set to 8012 Hz. resulting in an 
acquisition time of 0.26 s. A relaxation delay of 1.5 s was used between 
successive scans: 128 increments were acquired in F I. consisting of four scans 
each. Before Fourier transformation, the data were apodized with a sine bell 
window function, linearly predicted to 512 data points and zerofiiled in FI to 
1024 data points. Selective excitation experiments were performed to confirm 
the structure of the AZX + 1 3  +  CN adduct.
A one-dimensional selective ROF.SY experiment (selrogp: Bruker Biospin 
Ltd.) was performed. The data were collected into 65K data points, over a 
spectral width of 12.019 Hz. resulting in an acquisition time of 2.77 s. A 
relaxation delay of 2.4 s was used and a spin lock time of 100 ms.
Results
Structural Characterization of Compound AZX. Test com­
pounds often contain structural motifs similar to those of their me­
tabolites: it is therefore common practice to first fully characterize the 
structure of the test/parent compound with accurate mass MS/MS 
fragmentation. Characteristic fragment ions identified from the test 
compound MS/MS can then be used to find and elucidate metabolite 
structures.
Analysis of AZX by LC-UV-MS-MS/MS yielded a protonated 
molecular ion with an accurate mass of [ M  + H ]' 476.2243 (+0.9 
ppm). The proposed fragmentation pattern and LTQ Orbitrap HCD 
MS/MS spectrum of compound AZX (Fig. I) revealed two intense 
key fragments, m/z 255.2175 (corresponding to the loss of the fluo- 
rophc q' ' ’ group of AZX) and m/z 141.1385 (corresponding
to the homopiperazine isopropyl moiety).
Detection of the Novel Metabolite with m/z 488 (AZX + 13) in 
the In Vivo Samples. Typically, in early in vivo metabolite identifi­
cation studies, temporal blood and urine samples are typically com­
bined to obtain a single pooled sample for each matrix. The sample is 
then analyzed on a LC-UV-MS/MS system in conjunction with a 
predose sample spiked with analyte to obtain a final concentration of 
10 pM (a concentration shown to produce a discernible UV response 
in the biological matrix).
Spiking of the predose serves two purposes: it helps to rule out 
synthetic impurities that could be misinterpreted as metabolites and to 
discount endogenous material visually or by automated data subtraction.
In this study, only low levels of compound AZX were detected 
upon analysis by UPLC-UV-MS/MS in both the 0 to 24 h rat urine- 
pooled sample and the AZX-spiked predose urine sample. However, 
an unexpected major parent-related peak was detected with a molec­
ular ion of m/z 488. This observation was confirmed by respiking of 
parent compound into samples of fresh predose/control urine (repre­
senting final AZX concentrations of 10 and 20 pM), which, once 
again, resulted in the spontaneous formation of the m/z 488 product as 
the major parent-related component, at an average ratio of approxi­
mately 95:5 (m/z 488: AZX parent) (data not shown).
It was initially assumed that either the wrong compound was dosed 
or (hat the parent had either degraded/formed chemical adducts, 
because the molecular ion, i.e.. the mass addition, could not be 
explained. Therefore, to verify the identity and stability of the parent, 
the solvent standards (i.e.. the 200 pM AZX stock solution and the 10 
pM AZX test solution) and the actual dose solution (diluted to 10 pM 
in 30:70. methanol/water, v/v) were analyzed in conjunction with 
repeat predose and 0 to 24 h rat urine samples. A comparison of the 
UV chromatograms (extracted at A = 240-245 nm) for the AZX-
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spiked predose urine samples (at 10 and 20 juM final concentrations) 
and the AZX solvent standards showed that in urine the UV peak for 
AZX (RT ~ approximately 5.32 min) was depleted, whereas the m/z 
488 product (RT -  approximately 4.45 min) was abundant (Fig. 2). 
However, the AZX solvent standards and the dose solution resulted in 
the observation of the correct molecular ion of [M + HI* 476. 
confirming that the compound had not degraded in solution ov er time.
Similar observations w'ere made with the 0 to 24 h rat blood, in 
which the m/z 488 product was also observed, although at a reduced 
amount (at an approximate ratio of 40:60, m/z 488: AZX) as assessed 
by UV (data not shown). Furthermore, the spiking experiments with 
predose blood, as conducted with the urine samples, again confirmed 
the formation of the m/z 488 product. From these data it was surmised 
that AZX was reacting with a component present in the urine and 
blood, which is the subject of this investigation.
A thorough review of the 0 to 24 h sample data (urine and blood) 
confirmed that this m/z 488 metabolite/product (RT = approximately
4.45 min). represented the majority of the AZX-related material in 
urine as determined by UV and mass spectrometry. The mass of the 
m/z 488 product was equivalent to an increase of 12 Da from parent 
(AZX, |M + H] ‘ 476). although it represented an actual increase of 
13 Da when molecular weights were compared (as detailed in the 
following section).
Structural Characterization of the Novel Metabolite/Product, 
m/z 488 (AZX + 13) by UPLC-MS/MS. From accurate mass mea­
surement this apparent metabolite was determined to have a mono­
isotopic mass of 488.2242. almost exactly an increase of 12.(XWH) Da 
over the parent [M + H] 476.2243. suggesting addition of one 
carbon atom. This was further substantiated after an elemental com­
position analysis in which no rational alternative molecular formula 
could be identified.
The proposed fragmentation pattern and LTQ Orbitrap HCD 
MS/MS spectrum of this metabolite/product (R T  = approximately
4.45 min) (Fig. 3) contained diagnostic fragment ions m/z 267.2184 
and m/z 153.1386. These ions corresponded to the addition of 12 Da 
to the key fragments m/z 255 and m/z. 141 in the MS/MS spectrum of 
A Z X . The observation of the fragment ions m/z 267.2184 and m/z
153.1386 with accurate mass ( ±2 ppm) and elemental composition 
analysis appeared to confirm the addition of a single carbon atom to 
the homopiperazine ring. The exact position of the carbon addition 
could not be determined by MS: however, it w'as possible to postulate 
the structure as a bridged homopiperazine (as shown in Fig. 3).
Difference between Theoretical Molecular Weight and Mea­
sured Molecular Ion of the Proposed bridged Homopiperazine. 
The proposed bridged structure equates to the addition of one carbon 
and one hydrogen atom. i.e.. a gain of 13 Da. which is inconsistent 
with the 12-Da increase as determined by the mass spectrometry data. 
However, because the bridged product has a fixed permanent positive 
charge (M '). it cannot produce a protonated molecular ion |M + Hj 
by positive ion electrospray (+ES1). Hence, whereas the calculated 
nominal mass of the parent (A ZX ) is 475 and the mass measured by +ESI 
mass spectrometry ([M + H| ‘ ) is 476 (Fig. 1). the calculated nominal mass 
and the mass measured by -I-ESI MS of the bridged ion tire both 488. 
Therefore, a comparison of the theoretical molecular weights of A Z X  and 
A Z X  + 13 results in a mass difference of 13 Da. compared w ith the 12-Da 
difference in the measured molecular' ions by mass spectrometry. To high­
light the + 13 Da addition of this structurally unique product compared with 
the +12 carbon addition products reported in the literature (see Discussion). 
the product is referred to as A Z X  + 13.
KCN Addition as a Chemical Test to Confirm the Presence of 
a Quaternary Nitrogen. Cyanide chemically forms adducts with 
iminium ions and is used widely in reactive metabolism trapping
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sluciics in biological samples across the pharmaceutical industry 
(Argoti et at., 2005). To confirm the presence of a quaternary 
nitrogen (i.e.. the bridged homopiperazine moiety as shown in Fig.
3). KCN was added to the AZX-spiked predose and the pooled 0 to 
24 h urine sample. On addition of KCN. the AZX + 13 product 
peak (m/z 4X8, RT = approximately 4.45 min) reduced in size 
(based on its UV response), whereas an additional peak [M + H| 
515 (RT = approximately 5.85) was detected in each of the 
samples (Fig. 4). Further investigation by MS/MS fragmentation 
determined the addition of 27 Da (CN) on the homopiperazine ring.
by the presence of the key fragment ions m/z 294.2289 and m/z 
180.1497, corresponding to +27 Da on m/z 267.2179 and m/z 
153.1386, respectively. Confirmation of the presence of the qua­
ternary nitrogen on the homopiperazine led to the investigation of 
the mechanism of formation of AZX + 13.
Investigation of the Formation of AZX + 13. On the basis of the 
MS results and the KCN trapping experiment (confirming the quater­
nary nitrogen), it appeared that AZX was reacting with a component 
in the urine to produce a one carbon and one hydrogen atom addition 
bridged homopiperazine.
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The same product was observed w ith pooled blood, albeit to a lesser 
extent. Formaldehyde, reported to occur naturally in living systems 
(Heck and Casanova. 2004), was suggested as a likely candidate to 
generate AZX + 13, via a quaternary Schiff base intermediate (imi- 
nium ion), which is then intramolecularly stabilized by forming the 
bridged homopiperazine (as shown in Fig. 5).
To test this hypothesis, formaldehyde (10 pi. 37c/i in H ,0) was spiked 
into the AZX test solution (10 pM. 500 pi), which was analyzed 
immediately on the UPLC-MS system. A prtxluct was formed at nearly 
l(X)'/r yield within the time taken to inject the sample, confirming that 
formaldehyde reacts rapidly w ith AZX at room temperature. This chem­
ical product was verified as the AZX + 13 product, which was 
identical to that detected in the biological samples (urine and blood), 
as assessed by chromatographic retention time. UV. accurate mass, 
and MS/MS fragmentation. This now provided an efficient means to 
generate AZX + 13 at a sufficient scale for full structural confirma­
tion by 'H NMR spectroscopy, as detailed under Methods and Mate­
rials. Not only was the confirmation of the bridged homopiperazine 
structure of importance, but the resultant structure of the AZX + 13 
CN adduct was also of interest to confirm the exact position of the CN 
addition, in view of several possible isomeric products.
Confirmation of AZX + 13 and the AZX + 13 + CN Adduct by 
‘H NMR Spectroscopy. After identification by MS, the structures of 
the parent (AZX). the AZX + 13 product, and the AZX + 13 + CN 
adduct were verified by 'H NMR spectroscopy (Fig. 6. A. B. and C. 
respectively). After the addition of formaldehyde, no changes in the 
spectra were observed in the aromatic regions of AZX and AZX + 13 
spectra, indicating that the site of modification is remote (data not 
shown).
However, the aliphatic region highlighted several chemical shift 
changes supporting the proposed formation of the bridged ho­
mopiperazine (Fig. 6. A and B). These mainly comprised changes in 
the chemical shifts of the protons on the homopiperazine moiety, such 
as the isopropyl methyl doublets, which have shifted from 0.94 and 
0.98 to 1.34 and 1.38 ppm. respectively. Likewise, all the residual
homopiperazine protons experienced a shift to higher frequency. In 
addition to the chemical shift changes, two doublets (labeled Ha and 
Hb). not initially present in the parent spectrum, were observed at 4.08 
and 3.91 ppm. with a coupling constant of V = 9.82 Hz and an 
integral value of one proton per doublet, which showed a clear 
connectivity in the two-dimensional COSY spectrum (data not 
show n). The suggested structure is consistent with the proposed one 
carbon bridge across the homopiperazine.
Figure 6C shows the 'H NMR spectrum of the AZX + 13 + CN 
adduct. The -CN addition was shown to have largely reversed the 
chemical shift changes induced by the addition of formaldehyde (the 
formation of the bridged homopiperazine), yet an additional set of 
doublets (an AB system, labeled He and Hd) w as noted ai 3.7 and 3.5 
ppm. which showed a strong connectivity in the two-dimensional 
COSY spectrum (data not shown). On the basis of this evidence, two 
isomeric possibilities could be suggested (Fig. 7. isomers I and 2). 
Selective irradiation experiments were used to determine the correct 
structure of the AZX + 13 + CN adduct.
The selective ROESY experiment, irradiating the isopropyl methyl 
signals (labeled 8.8’). showed clear through-spaee interactions to the 
isopropyl proton (labeled 9 in the structure), as well as the ho­
mopiperazine protons 2 and 3 (Fig. 7). There was no enhancement of 
the bridged protons (labeled a and b). indicative of the six-membered 
ring (isomer 2). hence providing evidence that this was not the 
preferred structure. Instead, the spectral data supported the presence 
of the NCH-.CN side chain (isomer I ). after addition of KCN.
Discussion
This study demonstrated that compound AZX and various analogs 
containing a homopiperazine moiety reacted rapidly with formalde­
hyde in biological matrices to form a carbon and hydrogen addition 
bridged homopiperazine (+ 13-Da products). However, the origin/ 
source of formaldehyde was still unclear, because it could have been 
endogenous, as reported by Heck and Casanova (2004) or. indeed, 
derived from the solvent system (methanol or formic acid), although 
it was shown to form irrespective of the mobile phase combination or 
spiking solvent used. A series of publications have described the 
formation of a + 12-Da product from a reaction with formaldehyde, 
which was suggested to have derived from methanol, as discussed 
below.
It has to be pointed out that in these articles the reaction with 
formaldehyde resulted in + 12-Da heterocyclic products (having 
gained one carbon atom over their respective parent compounds), 
whereas our example, through a different mechanism, yielded a novel 
bridged homopiperazine with a quaternary nitrogen (after addition of 
one carbon and one hydrogen). Hence. Yin et al. (2001) described the 
addition of + 12 Da to the parent compound identified in/dcrived from 
in vitro experiments, in which S9 fractions/hepatic incubations were 
spiked with an analyte in methanol. However, it was concluded that 
the MeOH was first metabolized to formaldehyde (Teschke et al., 
1974), which then reacted with a basic group on the incubated 
compound. Each of the compounds tested, containing either 1,2- 
amino hydroxyl or 1,2-diamino reacted with the metabolic formalde-
Schiff base 
intermediate
F ig . 5. The proposed structure and formation  
o f the bridged homopiperazine (A Z X  +  13) 
through a quaternary S chiff base intermediate.
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hyde to generate ring-closed heterocyclic or + 12-Da products. Cun­
ningham et al. (1990) reported a similar problem with diaminotoluene 
reacting with formaldehyde generated from the use of methanol as a 
spiking solvent for in vitro incubations. The product was formed 
through cross-linking of two molecules of 2.4-diaminotoluene with 
formaldehyde to give bis(2,4diamino-5-tolyl)methane.
Koppel et al. (1991) described the formation of +12-Da products 
from the gas chromatographic analyses of several drugs by addition of 
formaldehyde and subsequent loss of water. It was suggested that the 
formaldehyde was formed by thermal degradation of MeOH in the gas 
chromatographic source.
These reported cases describe an analytical or in vitro artifact 
from the use of MeOH us a diluent or solvent, which is then 
believed to be oxidized chemically or metabolically to formalde­
hyde. In this study AZX + 13 (the formaldehyde addition product) 
was derived directly from an in vivo investigation, suggesting a 
potentially different (i.e.. natural) source of formaldehyde for the 
reaction. AZX + 13 was not detected in any preliminary in vitro 
experiments because test compounds are typically spiked into 
incubations using ACN and not MeOH. However, we have also 
demonstrated that the MeOH used as mobile phase constituent 
and/or indeed as the AZX diluent (used in the stock and test 
solutions) did not cause the formation of AZX + 13.
Further investigations were performed to rule out MeOH as the 
source of the formaldehyde or indeed as the reagent itself. The 
experiments are not described in detail here: however, a brief sum­
mary is provided.
On spiking of compound AZX/MeOH into "freshly collected" 
predose/control rat urine, using the MeOH/H20  gradient. AZX + 13 
was produced spontaneously with 90 to 100% yield (based on the UV 
response) and remained constant over I month (with the urine stored 
at 4 C). However, on spiking of AZX/MeOH into "old" predose/ 
control rat urine, there was very little evidence of the formation of the 
AZX + 13 product. Here, the urine was stored cold (at 4 C) tor 
approximately 2 months before spiking, allowing degradation/evapo­
ration of the formaldehyde, on the basis of the half-life of formalde­
hyde (Organization for Economic Cooperation and Development 
Screening Information Data Set. Formaldehyde. 2002. http:// 
www.inchem.org/documents/sids/sids/FORMALDEHYDE.pdf). Af­
ter the 2-month aging period, upon spiking of AZX. only approxi­
mately 5 to 10% of the product was formed, the ratio remaining 
constant over a further month.
Additional evidence on the formation of the in vivo AZX + 13 was 
provided by spiking fresh rat urine samples with AZX. as conducted 
in the experiments detailed above, using ACN as the spiking 
solvent. The UPLC-UV-MS/MS analysis was also performed in the
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absence of MeOH. using ACN (containing 0.1% formic acid) as 
the mobile phase, revealing that AZX + 13 was still formed as the 
major product (between 90 and 100%), as assessed by UV quan­
tification and MS analysis (data not shown). However, the AZX 
standards (the stock and test solutions, prepared in ACN) did not 
produce the product when subjected to UPLC-UV-MS/MS analy­
sis. ruling out ACN and formate as possible reagents.
These simple experiments suggested not only that the formaldehyde 
in the urine was naturally present but also that it was depleted over 
time. In addition, they proved that AZX + 13 was not likely to be an 
analytical artifact from the MeOH. ACN. or formate used in the 
analyses.
The findings from our research appear to support the evidence in 
(he literature, namely that the formaldehyde occurs naturally in all 
mammalian tissues, cells, and bodily fluids and that it is present in rat 
blood at approximately. 0.1 mM concentration (Heck and Casanova, 
2004). Formaldehyde and its oxidation product formate are reported to 
be key intermediates in the "one-carbon poof (Neuberger, 1981). 
Certain xenobiotics such as MeOH. N-. 0-. or S-Me compounds, and 
methylene chloride apparently can also contribute to this pool. The 
one-carbon pool is used for the biosynthesis of purines, thymidine, 
and certain amino acids, which are incorporated into the DNA. RNA, 
and proteins during macromolecular synthesis. It is therefore sug­
gested that compound AZX scavenges endogenous formaldehyde in 
vivo, similar to aminoguanidine. which was reported by Kazachkov et 
al. (2007).
Formaldehyde is known to be responsible for cross-linking proteins 
(e.g.. Met/ et al., 2004; Toews et al.. 2008) and some xenobiotics 
(Cunningham et al.. 1990) through a Schiff base intermediate. Con­
sidering that basic amine groups are ubiquitous on many xenobiotics 
and proteins, it is worth noting the potential for formaldehyde to cause 
cross-linking between xenobiotics and proteins in vivo. Hence, sus­
ceptibility to formaldehyde addition via a direct or metabolic route 
could lead to the formation of covalently bound protein adducts. 
How ever, the reaction in vitro relies on the presence of MeOH. e.g.. 
used as spiking solvent, as a source of the formaldehyde (as outlined 
by Yin et al. (2001) and Cunningham et al. (1990)]. Therefore, the 
potential for some basic xenobiotics to covalently bind to protein may 
not be flagged by reactive metabolite screening or radiolabeled in 
vitro covalent binding studies.
Here, the Schiff base reactive intermediate, trapped because of the 
proximity of the two nitrogens (as in a twisted boat conformation), 
formed a very' stable bridged homopiperazine detectable by LC-UV- 
MS. However, in most other basic xenobiotics the Schiff base inter­
mediate would not be intramolecularly trapped to form a stable 
product detectable by subsequent analyses. Hence, there is potential 
for this reactive intermediate to be missed in in vivo/in vitro metab­
olite identification studies, even when formaldehyde is present.
Because the initial terminal piperazine series w as found to generate 
electrophilic, reactive intermediates metabolically. the homopipera­
zine series w as thought to provide a safer suitable alternative. There­
fore. the formation of a bridged homopiperazine through a reactive 
quaternary Schiff base intermediate was an unexpected observation. 
The homopipera/ine ring is neither planar nor symmetrical, so the 
conformation adopted clearly proved favorable for the formation of a 
one-carbon bridge.
Various other homopipera/ine analogs of compound AZX have 
also been investigated for + 13-Da product formation and as demon­
strated in this study with compound AZX. these products have been 
formed rapidly in vivo, as well as being confirmed in spiking exper­
iments with formaldehyde (data not shown). These studies have 
highlighted the fact that the homopipera/ine moiety appears to be a 
highly reactive group, and the observations made in this study support 
the decision to change the chemistry of these compounds.
In conclusion, this study has demonstrated that compound AZX and 
various analogs containing the homopipera/ine moiety reacted rapidly 
with formaldehyde present in biological fluids, as a constituent of the 
one-carbon pool, suggesting that it is a metabolite, as well as a 
chemical product. The homopipera/ine moiety was initially included 
in the lead compounds as an inerl/unreactive alternative to the termi­
nal piperazine, which was shown to be prone to bioactivation and 
subsequent covalent binding with GSH. Hence, the addition of the 
terminal homopipera/ine group was believed to retain the potency of 
the compounds while decreasing their reactivity. However, as we have 
shown in this study, this group is itself highly reactive w ith endoge­
nous formaldehyde, forming bridged homopiperazines.
The findings in this article suggests that compound AZX and its 
homopipera/ine analogs scavenge endogenous formaldehyde in vivo 
similar to aminoguanidine, which was reported by Kazachkov et al.
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(2007). What appears to he a desired effect with aminoguanidine 
proved to be a toxicity alert with the AZX-derived compounds.
Apart from the reactivity aspect itself, quantitation of parent drug in 
blood and urine would be greatly compromised, creating problems for 
lead optimization and pharmacokinetic assessments. In addition, the 
formation of this adduct could artificially distort metabolite profiles in 
human metabolism studies, affecting (metabolites in safety testing) 
investigations (U.S. Food and Drug Administration guidance on Safety 
Testing of Drug Metabolites, 2008, http://www.fda.gov/dow nloads/Dmgs/ 
GuidanceComplianceRegulatoiy Infoiination/Guidances/ucm()79266.pdt).
However, overall the study demonstrated that the bridged ho­
mopiperazine was readily formed in vivo, producing a stable product/ 
metabolite, which did not degrade in urine for at least I month. This 
finding has provided a suitable method and an easy and highly 
efficient means (>95% yield) for the generation of a bridged ho­
mopiperazine synthetically by a simple reaction with formaldehyde.
Authorship Contributions
Participated in research design: Martin. Len/. Tentesi. Wild, and Clench. 
Conducted experiments: Martin and Lenz.
Contributed new reagents o r analytic tools: Martin and Lenz.
Performed data analysis: Martin and Lenz.
Wrote o r contributed to the writing o f the manuscript: Martin. Lenz. 
Tentesi. Wild, and Clench.
References
Argoti D. Liang L. Conteh A. Chen L. Bcrshas D. Yu CP. Vouros P. and Yang F, (20(15) Cyanide 
trapping of iminium ion reactive intermediates followed by detection and structure identifi­
cation using liquid chromatography-tandem mass spectrometry (LC'-MS/MSl. Chem Re* 
Toxicol 18:1537 1544
Baillie TA i2006> Future of toxicology-metabolic activation and drug design challenges and 
opportunities in chemical toxicology . Chem Res Toxicol 19:889-894
B.iillic TA (20001 Approaches to the assessment of stable and chemically reactive drug metab­
olites in early clinical trials Chem Rc\ Toxicol 22:263-266.
Cunningham ML. Matthews I IB. and Burka LT (1990) Activation of methanol by hepatic 
postmilochondrial supernatant: formation of a condensation product w ith 2.4-diaminotoluene. 
Chem Res Toxicol 3:157-161.
Doss GA. Miller RR. Zhang Z, Teffcru 3 Nargund RP. Palucki B. Park MK. Tang VS. f vans 
IX '. Baillie TA. et al. (20051 Metabolic activation of a 1.3-disuhstituted piperazine derivative: 
ev idence for a novel ring contraction to an imidazoline Chem Res Toxicol 18:271-276
Evans DC. Watt AP. Nicoll-Griffith DA. and Baillie TA 12004) Drug-protein adducts an 
industry perspective on minimizing the potential for drug bioactivation in drug discovery and 
development. Chem Res Toxicol 17:3-16.
Heck H and Casanova VI (2004) The implausibility of leukemia induction by formaldehyde: a 
critical review of the biological evidence on distant-site toxicity. Regul Toxicol Pharmacol 
40:92-106.
Kazachkov M. Chen K. Babiy S. and Yu PH (2007) Evidence for in vivo scavenging by 
aminoguanidine of formaldehyde produced via semicarbazide-sensitive amine oxidase- 
mediated deamination. 7 Pharmacol Exp Ther 322:1201-1207.
Kiippel C. Tenczer J. and Peixoto-Menezes KM (1991) Formation of formaldehyde adducts from 
various drugs by use of methanol in a loxicological screening procedure with gas chromatog­
raphy-mass spectrometry. 7 Chromatogr 563:73-81.
Metz B. Kerxten GF, Hoogcrhout P. Brugghc HF. Timmermans HA. dc Jong A. Meiring H, ten 
Hove J. Hennink WE. Crommelin DJ. et al (2004) Identification of formaldehyde-induced 
modifications in proteins: reactions with mixlel peptides. ./ Biol Chem 279:6235-6243.
Neuberger A (19X11 The metabolism of glycine and serine, in Comprehensive Biochemistry, vol. 
I9A (Neuberger A and van Deenen LLM edxl pp. 257-303. Elsevier. Amsterdam
Prakash C. Sharma R. Gleave M. and Nedderman A (2008) In vitro screening techniques for 
reactive metabolites for minimizing bioactivation potential in drug discovers Cun Drug 
Metals 9:952-964
Teschke R. Hasumura Y. and l.ieber CS (19741 NADPH-dependent oxidation of methanol, 
ethanol, propanol and butanol In hepatic mierosomes Biochem Bioplns Rev Commun 60: 
851-857.
Toevvx J. Rogalski JC. Clark IJ. and Kast .1 I200X) Mass spectrometric identification ot 
formaldehyde-induced peptide modifications under in vivo protein cross-linking conditions. 
Anal Chim Ada 618:168-183.
Yin H. Tran P. Greenberg GE. and Fischer V (2001) Methanol solvent may cause increased 
apparent metabolic instability in in vitro assays Drug Metuh Dispos 29:185-193
Address correspondence to: Scott Martin, D M PK  Departm ent, Alderley Park, 
AstraZeneca UK Ltd.. Macclesfield. Cheshire SK10 4TG. UK. E-mail: 
scott.m artin2@ astrazeneca.com
108
5. REACTIVE METABOLITE TRAPPING SCREENS AND POTENTIAL 
PITFALLS: BIOACTIVATION OF A HOMOMORPHOLINE AND
FORMATION OF AN UNSTABLE THIAZOLIDINE ADDUCT
Reproduced with permission from Chem. Res. Toxicol. (2014) 27:968-980. 
Copyright 2014 American Chemical Society.
109
Chemical 
Research in 
Toxicology
Article
pubs.acs.org/crt
Reactive Metabolite Trapping Screens and Potential Pitfalls: 
Bioactivation of a Homomorpholine and Formation of an Unstable 
Thiazolidine Adduct
Eva. M. Lenz,*’’ Scott Martin/ Ralf Schm idt/’* Pierre-Emmanuel Morin/ Robin Smith/
Daniel J. W eston/ and Malken Bayrakdarian
DMPK Department, Alderley Park, AstraZeneca UK Ltd., Macclesfield, Cheshire SK10 4TG, United Kingdom 
DMPK and Medicinal Chemistry Department, AstraZeneca R&D Montreal, St. Laurent, QC Canada H4S 1Z9
©  Supporting Information
ABSTRACT: Successful early attrition of potential problematic 
compounds is of great importance in the pharmaceutical industry.
The lead compound in a recent project targeting neuropathic pain 
was susceptible to metabolic bioactivation, which produced reactive 
metabolites and showed covalent binding to protein. Therefore, as a 
part of the backup series for this compound several structural 
modifications were explored to mediate the reactive metabolite and 
covalent binding risk. A homomorpholine containing series of 
compounds was identified without compromising potency. However, 
when these compounds were incubated with human liver micro- 
somes in the presence of GSH, Cys-Gly adducts wrere identified, 
instead of intact GSH conjugates. This article examines the formation 
of the Cys-Gly adduct with AZX ([M +H ]+ 486) as a representative 
compound for this series. The AZX-Cys-Gly-adduct ([M +H ]4 662) 
showed evidence of ring contraction by formation of a thiazolidine-glycine and was additionally shown to be unstable. During its 
isolation for structural characterization by *H NMR spectroscopy, it was found to have decomposed to a product with [M +H]+ 
446. The characterization and identification of this labile GSH-derived adduct using LC-MS/MS and ‘H NMR are described, 
along with observations around stability. In addition, various structurally related trapping reagents were employed in an attempt 
to further investigate the reaction mechanism along with a methoxylamine trapping experiment to confirm the structure of the 
postulated reactive intermediate.
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■  INTRODUCTION
Reactive metabolites are of great concern in the pharmaceutical 
industry’.1 4 Hence, great emphasis is placed on the early 
identification of potentially reactive metabolites, which has led 
to the front loading of biotransformation studies. Reactive 
metabolite trapping screens with liver mierosomes (usually 
human) fortified with nucleophiles such as GSH, cysteine, 
potassium cyanide, and methoxylamine4 are routinely em­
ployed to trap reactive electrophilic species at sufficient 
concentration to form stable, recognizable products/adducts 
which can be identified by their expected MS changes. 
However, unexpected or structurally unusual products from 
nonstandard biotransformations such as structural rearrange­
ments' 11 could escape detection during the MSMS inves­
tigations due to changes in molecular structure, molecular 
weight, and the lack of expected fragmentation patterns. Of 
particular concern are cyclized GSH adducts' 10 which can 
produce a false negative result in conventional LC-MSMS GSH 
trapping screens, as GSH adducts are generally identified by 
their expected target mass, a neutral loss of 129 Da in positive
ion mode, or/and a m/z of 273 in a precursor ion scan in 
negative ion mode.
A recent in vitro reactive metabolite investigation of a series 
of potential lead compounds using human liver microsomal 
incubations fortified with GSH revealed the formation of 
unexpected Cys-Gly adducts instead of intact GSH-adducts. 
However, only those compounds containing a homomorpho­
line moiety produced the Cys-Gly adduct, implying the 
homomorpholine was the site of bioactivation. Compound 
AZX (Figure 1, with [M+H]+ 486), the lead compound for this 
series, however, was shown to produce the Cys-Gly adduct ( [M 
+H]+ 662) exclusively in human liver mierosomes, indicating 
the potential to produce a human specific reactive metabolite. 
While the [M+H]+ 662 adduct was clearly detected, the intact 
GSH adduct was not observed in the AZX-human liver 
microsomal incubations. From the accurate mass fragmentation 
pattern of the [M+H] + 662 adduct, it was possible to propose a 
GSH rearrangement product through the loss of the glutamate
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Figure 1. Total ion chromatogram (T IC )  ot the scaled-up bacterial cytochrome enzyme ( t = 16 h ) incubation with selected ion chromatograms of 
the metabolites characterized. Data generated on the U P LC -Q ;TO F . Key: [+ X ] = GSH-derived moiety.
and intramolecular cyclization of the Cys-Gly moiety. However, 
the [M+H]+ 662 adduct was shown to degrade to [M+H]+ 446 
during its isolation for subsequent structural identification by 
’H NMR spectroscopy.
The human liver microsome incubations also showed a 
minor signal for a compound with [M+H]+ 446, suggesting it 
was both a metabolite and a decomposition product of [M+H]' 
662. The formation of the [M+H]+ 662 adduct and its stability 
are subject to further investigation in this article.
■  EXPERIMENTAL PROCEDURES
Chem icals and Reagents. Compound A ZX  (4-[[4-(3-m ethox- 
ycyclobutyl)-l,4-oxazepan-2-yl] m e th y l]-N -[6 -m eth y l-5 -( trill uoro- 
methyl)-2-pyridyl]piperazine-l -carboxamide) was synthesized at Astra 
Zeneca R & D  Montreal, Canada. The structure of A ZX  is novel; 
however, its synthesis was based on the described procedure o f similar 
analogues (A Z  patent W 0200606740  and, for the homomorpholine 
subunit, W 0 2 0 0 6 105262).
Ammonium formate, dithiothreitol (D T T ) , and /7-nicotinamide 
adenine dinucleotide sulfate reduced tetrasodium salt (N A D P H ) were 
purchased from Sigma-Aldrich (Oakville, Canada) and acetonitrile 
(C H ,C N ) , methanol (M e O H ), ammonium acetate, and formic acid 
from Fisher-Scientific (Loughborough, U K ). Methoxylamine, potas­
sium cyanide (K C N ), and the deuterated N M R  solvents were sourced 
from Sigma-Aldrich (Poole, U K ).
In cu bation  o f P aren t (AZX) and  T ra p p in g  C ond itions . A Z X
was incubated at a concentration o f 10 / /M  with human and rat liver 
mierosomes ( l  m g/m L o f protein, respectively) (BD-Gentest) in 0.1 
M  potassium phosphate buffer at pH  7.4 in the presence o f 2 m M  of 
the respective trapping reagent and 1 m M  N A D P H  at 37 °C  for 30 
min. After precipitation with 2 equiv (v /v ) o f C H ;C N  and cooling for 
20 min at 4 °C , the samples were centrifuged at SOOOg for 30 min. In 
the trapping experiment with dansyl-yGlu-Cys-Lys (dE C K ), precip­
itation was executed with 2 volumes (v /v )  o f M e O H  containing 5 m M  
D T T . The supernatant diluted with water (1:1, v /v )  was analyzed by 
LC -M SM S. Clozapine was used in the trapping experiments (see 
Table l )  as the positive control.
The incubations were carried out with a range o f diff erent trapping 
agents that were o f commercial origin (Sigma-Aldrich, Oakville, 
Canada), such as yGlu-Cys-Gly (G S H ), yGlu-Cys-Gly-[l'N ,1 'C 2], N - 
Ac-Cys, Cys-Gly, Cys, yGlu-Cys, and yG lu -C ys-G ly -O E t, or 
synthesized in-house, such as yGlu-Cys-Lys (E C K ), dansyl-ECK 
(d E C K ),ls Glu-Cys-Gly, and //Asp-Cys-Gly, using the conditions of 
the standard G SH  fortified trapping human liver microsomal 
incubation, as detailed above.
Scale-Up Incubations w ith  B acterial C yto ch ro m e  Enzym e  
Variants. A 1 m M  solution of A ZX  in incubation buffer was prepared 
by die addition of M e O H  not exceeding 0.2% (v /v )  organic solvent in 
a 24-well M icroCyp plate (Codexis, Redwood City, CA, USA)
dx.doi.org/10.1021/tx50004091 Chem Res. Toxicol 2014, 27, 9 6 8 -9809 69
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Table 1. Human Liver Microsome Incubations of AZX with Different Trapping Reagents"
HLM
NAD PH  
trapping 
agent X [+X]
Trapping characteristics Adduct Adductstructure
m/z formedreagent
GSH 662yGlu-Cys-Gly yes
labelled Gly-[ N. 665 yes
Glu-Cys-Glv 662uGlu-Cys-Gly yes
(no iso-peptide bond)
662pAsp-Cys-Gly yes
F.CK 733yGlu-Cys-Lys yes’
dF.CK 733Dansyl-yGlu-C ys- Lys no
(blocked yGlu N-lerminus)
blocked N-terminusN-Ac-Cys 647 no
no Gly 605 no
no yGluCys-Gly 662 yes
Cys no yGlu, no Gly 605 no
GSH-OEt yGlu-Cys-Gly-OFt 690 yes’
(GSEF) (Gly ethyl ester)
"The observation o f adduct peaks was performed by LC -M S (U P L C -Q jT o f). Analyses were conducted in duplicate, with some incubations ( * )  
repeated twice. The GSH-adduct was detected in the control incubation with clozapine (data not shown), providing evidence that intact GSH was 
available for reaction. However, no GSH-adducts were observed with any o f the trapping agents (data not shown).
containing variants of a bacterial cytochrome enzyme. GSH was added 
to obtain a trapping reagent concentration o f 10 m M  and the 
incubation mixture was shaken for 16 h at 30 °C . Following 
precipitation with 2 equiv (v /v ) o f ice-cold C H .C N , the plate was 
centrifuged at 8000g at 4 C  for 30 min before the supernatants were 
collected and analyzed by LC-MS. The content of vials with similar 
metabolite profile w^ ere pooled to produce 5 distinct samples, then 
lyophilized before shipping to the U K  for further structural 
characterization o f the [M + H ]+ 662 adduct. At time = 0 h, C H ,C N  
was added to one reaction vial without GSH, thus containing
exclusively the parent compound, which served as both a control 
incubation and a structural control.
The Codexis M icroCyp screening plates contain engineered 
cytochrome P450 (C Y P ) variants o f CYP102A1 from Bacillus 
mcgatcrium, which do not contain y-glutamyl transferase (G G T ).
Analysis o f th e  H um an  Liver M icrosom e and  Bacterial 
C ytochrom e Enzym e Sam ples by LC-MS (U ltrah ig h -P erfo rm - 
ance LC (UPLC)-Q-TOF). The incubate samples were initially 
analyzed (at AstraZeneca R &D , Montreal) on an Acquity U P LC -Q ; 
T O F  Premier system (Waters, USA). The mobile phase consisted o f 
aqueous 10 m M  ammonium formate (w /v )  containing 5% C H ,C N
dx.doi.org/10.1021 Ax50004091 Chem. Res. Toxicol. 2014. 27, 968 -9 8 0
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(v /v , eluent A ) and C H .C N  (eluent B). A  linear gradient from 0% to 
80% B over 7 min at 60 °C  at a flow rate o f 0.5 m L/m in  was employed 
and separation achieved on a HSS T 3  column (1.8 //m , 2.1 X 100 m m ) 
connected to the mass spectrometer operating in positive electrospray 
ionization without flow split. Data was acquired on a Q -T O F  Premier 
in positive ion full scan mode, and fragmentation data were obtained 
by collision energy ramping using M S H. MetaboLynx 4.1 (Waters, 
USA) was used to analyze the Q -T O F  M S f data, and the structure o f 
trapped adducts was characterized in M SM S experiments. Total ion 
chromatograms were produced generating a metabolic profile for each 
of the bacterial cytochrome enzyme-GSH-incubate samples (data not 
shown).
Sam ple  P rep aratio n  o f th e  Bacterial C yto ch ro m e Enzym e  
Sam ples fo r S tructural C haracterization  o f [M + H ]+ 6 62 . Upon 
arrival in the U K , the protein precipitated scaled-up bacterial 
cytochrome enzyme incubate samples were relyophilized, extracted 
into 5 m L of M e O H , and centrifuged at SOOOg. The supernatant was 
transferred and the M e O H  evaporated under a stream of nitrogen. The 
dried methanolic extracts were stored at 4 °C  until subsequent 
analyses.
Each of the scaled-up bacterial cytochrome enzyme incubate 
samples was used for a different purpose: samples 1 and 2 were utilized 
for LC -M S (U P L C -D A D -L T Q -O rb itrap ) method developments, 
sample 3 was used for the semiprep LC-separation, and sample 4 
was used to assess the stability o f the GSH-derived metabolite. Sample 
5, when finally analyzed, was found to contain no residual [M + H ] + 
662. For the LC-M S analyses ( U P LC -D A D -M S , L T Q O rb itra p ), the 
bacterial cytochrome enzyme samples were reconstituted in 0.5 m L o f 
xVleOH, to which 1 mL o f deionized water was added. For 'H  N M R  
analysis, sample 6, serving as a source o f the parent compound (A ZX ), 
and the isolated fractions from sample 3, were reconstituted in 0.5 mL 
of M eO H -d4.
Id en tifica tio n  and S tructural C haracterization  o f [M + H ]+ 662  
by LC-MS (U P LC -D A D -LTQ -O rb itrap ). Accurate mass structural 
characterization work was acquired (at AstraZeneca R & D , Alderley 
Park) on a L T Q , Orbitrap X L  connected to a Waters Acquit)' UPLC  
system, which consisted of a binary U PLC  PUM P, column oven, 
autoinjector, and a photodiode array detector (D A D ).
The eluent was introduced into the mass spectrometer via the LT Q . 
divert valve at 1 min, and U V  spectra were acquired over 190—330 nm. 
The LTQ,-Orbit rap XL was equipped with an electrospray ionization 
(ESI) source (Therm o Fisher Scientific, Bremen, Germany), which 
was operated in positive mode. Source settings were as follows: 
capillary temperature, 350 °C; sheath gas flow, 25; auxiliary gas flow, 
17; sweep gas flow, 5; source voltage, 3.5 kV; source current, 100.0 //A; 
capillary voltage, 18 V; and tube lens, 75.0 V. Full scan M S data were 
obtained over the mass range o f 100 to 1000 Da at a peak resolution of 
7500. Targeted M SM S experiments were acquired using higher energy 
collisional dissociation (H C D ) fragmentation, with an isolation width 
of 3 Da, a normalized collision energy o f 45 eV, and an activation time 
30 ms. H C D  and ion trap MS" fragment ions were monitored by the 
Orbitrap using 7500 resolution. L T Q  and Orbitrap mass detectors 
were calibrated within 1 day of commencing the work using 
Proteomass L T Q /F T -H yb rid  ESI positive mode calibration mix 
(Supelco Bellefonte USA).
Method 1: Initial method development was carried out with 
bacterial cytochrome enzyme sample 1 on an analytical column 
(Acquity BEH C l 8, 1.7 um, 100 X 2.1 mm, Waters, USA) at a flow 
rate of 0.45 m L/m in , with a column temperature of 50 °C. The  
separation was monitored at 280 nm.
The mobile phase consisted o f aqueous 5 m M  ammonium acetate 
(w /v , eluent A ) and M e O H , buffered with 5 m M  ammonium acetate 
(w /v , eluent B). The elution profile was a linear gradient of 90% to 
20% A, from 0.00 to 8.00 min; followed by a column wash o f 5% A  for 
3 min (8.01 to 11 m in) and re-equilibration with 90% A, 11.01 to
15.00 min. The maximum column loading capacity was assessed as 20 
//L.
The adduct eluted at ca. fR = 6 .1  min and produced a molecular ion 
of [M + H ] ' 662 and an in-source fragment ion of m /z  446.
Isolation o f [M + H ]+ 662  by S em iprep  LC Linked to  a HTC- 
Fraction C ollector. M ethod 2: The separation method and sample 
loading capacity were assessed with BCE sample 2 (on the U PLC - 
D A D -L T Q O rb itra p ), on a semiprep A Q C U IT Y  HSS T 3  150 X 3 mm 
UPLC (Waters, USA) column. The same mobile phase eluents as 
those in Method 1 w'ere used. The elution profile was modified to a 
sharp linear gradient o f 90% to 40% A, from 0.00 to 0.1 min; held 
isocratically at 40% A from 0.1 to 8.00 min; follow't'd by a linear 
gradient of 40% to 5% A  from 8.01 to 1 LOO min; and re-equilibration 
at 90% A, 11.01 to 19.00 min. The flow rate was 0.45 m L/m in , and the 
sample loading w m s  assessed as 40 //L . The U V  detector was set to 280 
nm. Here, the [M + H ]+ 662 adduct eluted at ca. fR = 5.1 min with a 
peak-width o f approximately 12 s.
The isolation o f [M + H ]+ 662 was carried out with bacterial 
cytochrome enzyme sample 3 and captured on a H T C  PAL fraction- 
collector/autosampler (C T C  Analytics, Presearch U K ) collecting at 
approximately 2.6 s intervals (ca. 18 //L /fra c tio n ) under full 
automation (using Cycle Composer (C T C  Analytics, Presearch 
U K )) overnight (35 sequential injections representing ca. 1.4 m L o f 
sample) into 4x 96 well plates. The well contents were evaporated to 
diyness and freeze-dried prior to analysis by 'H  N M R  spectroscopy.
’ H NM R Spectroscopic S tructure  V erifica tio n . 'H  N M R  
structural characterization o f the parent (extracted from bacterial 
cytochrome enzyme sample 6) and o f the isolated [ M + H ] ! 662 GSH- 
derived adduct was performed on a Bruker A V A N C E  600 M H z  
spectrometer (Bruker Biospin Ltd., Coventry, U K ), operating at 
600.13 M H z  *H resonance frequency. The N M R  spectrometer was 
equipped with a 5 mm SEI 'H  probe. The ID  'H  N M R  spectra of 
A ZX and the isolated fractions were acquired without solvent 
suppression into 65k data points over a spectral width o f 9615 Hz, 
resulting in an acquisition time o f 3.4 s. A relaxation delay o f 2.6 s was 
employed to ensure T1 relaxation between successive scans, and 
depending on concentration, approximately 64—1024 scans were 
acquired per sample. All spectra were referenced to M eO H -cf, at S' H  
3.32.
2D 'H — 'H  COSY (Correlation SpectroscopY, gradient enhanced) 
and 2D  'H —*H TO C S Y  (TO ta l Correlation SpectroscopY) (Bruker 
Biospin Ltd., Coventry, U K ) experiments were acquired into 4k data 
points in F2 and 256 increments in F I, consisting o f 8 scans each. The  
spectral widths were set to 8012 Hz, resulting in an acquisition time of 
0.26 s. A relaxation delay of 2 s was employed between successive 
scans. In  the TO C S Y  experiment, a spin lock o f 2.5 ms and a mixing 
time o f 70 ms were used. Prior to Fourier Transformation, the data 
were apodized with a sine bell window function, linearly predicted to 
512 data points, and zerofilled in F I to 1024 data points.
Selective ID  TOCSY' experiments (Bruker Biospin Ltd., Coventry, 
U K ) were collected into 65k data points, over a spectral width o f 8389 
Hz, resulting in an acquisition time o f 3.9 s. A  relaxation delay o f 2 s 
was employed with a spin lock o f 2.5 ms and a mixing time o f 70 ms. 
Selective spectra were acquired with approximately 64 scans (for the 
parent) and up to 2k scans (tor the isolated metabolite).
In cu ba tion  o f th e  Parent (AZX) w ith  Potassium  C yan ide  
(KCN) and M e th o x y la m in e . This experiment w'as carried out in 
duplicate to confirm the presence o f the iminium ion or aldehyde 
intermediate as postulated in the mechanism of formation o f [M + H ]+ 
662. A ZX  was incubated at 10 / /M  with human liver mierosomes (2  
mg protein,inL, BD-Gentest 150 donor ultrapool) in 0.1 M  potassium 
phosphate buffer at pH  7.4 in the presence o f either 10 m M  K C N  or 
methoxylamine trapping reagent and 2.5 m M  N A D P H  at 37 °C . After 
60 min of incubation, an aliquot was removed and the reaction 
stopped by the addition of ice cold C H ,C N  (1:3, v /v ). An incubation 
containing no A ZX  was performed as described above with A ZX  
added after the reaction was stopped with C H ^C N . This was used to 
obtain a background sample. Both samples were centrifuged at SOOOg 
for 15 min, and the supernatants were removed and combined with 
water (1:1, v /v ) before LC -M SM S analysis.
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Figure 2. (A ) Aliphatic regions o f the 'H  N M R  spectrum of the parent (A Z X ) (top ) and o f the selective ID  'H  N M R  T O C S Y  spectra o f the 
individual ring moieties (below, in descending order: the piperazine ring, the individual chain-moieties o f homomorpholine (i.e., the 1,3-diamino- 
propan-2-ol and the 3-amino-propanol), and the 3-amino-cyclobutanol moiety). Key: X indicates “coexcitation” (spectral contamination with the 3- 
amino-cydobutanol) moiety. M eOH-d., = deuterated M eO H , the N M R  solvent used. (B ) Diagnostic MS-fragments (top) from the mass spectrum 
(bottom) of the parent (A Z X ). Note: mass errors are within ± 3  ppm.
■  RESULTS
Identification of the Metabolites and Adducts of AZX 
in the Human Liver Micosome and Scaled-Up Bacterial
Cytochrome Enzyme Incubations with GSH. Several 
metabolites and adducts of AZX were detected and tentatively 
characterized in the incubate samples during the initial LC-MS 
(UPLC-Q_-TOF) analyses. The main metabolites and adducts
972 dx.doi ,org/10.1021 /tx50004091 Chem. Re s. Toxicol. 2014, 27. 968 -9 8 0
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Figure 3. Aliphatic regions o f the 'H  N M R  spectrum of the isolated GSH-derived metabolite [M + H ]'1' 662 (top) and o f the selective ID  H  N M R  
TO CSY spectra of the individual ring moieties (below, in descending order: the piperazine ring, the l,3-diamino-propan-2-ol o f the 
homomorpholine, and the 3-aminocyclo-butanol). Key: X  indicates “coexcitation" (spectral contamination) with an impurity. M eO H -rf, =  
deuterated M eO H , the N M R  solvent used. Note: the 3-amino-propanol moiety of the homomorpholine ring could not be detected.
in both the human liver microsome ( t = 30 min) and the 
scaled-up bacterial cytochrome enzyme ( f  = 16 h) incubations 
were found to be identical, albeit present at different ratios 
(data not shown).
The total ion chromatogram of the scaled-up bacterial 
cytochrome enzyme-incubate (together with the selective ion 
chromatograms) are shown in Figure 1. The parent (AZX), 
eluting at 6.21 min, produced a molecular ion at [M+H] + 486. 
A minimum of six structurally different metabolites were 
identified. These included several oxidation products, such as a 
ring opened product (+18) with [M+H]+ = 504 (fR = 5.57 
min), and a number of + 16 oxidation products with [M+H]+ = 
502 (fR = 5.08, 5.28, 5.42, 5.72, and 6.06 min). Additionally, an
O-demethylated metabolite was observed with [M+H]+ = 472 
(fR = 5.26 min); an O-des-methyl homomorpholine hydrolysis 
product with [M +H]+ = 490 (fR = 5.00 min), as well as a 
dealkylated metabolite with [M+H]+ = 446 (fR = 5.08 min) 
together with its O-demethylated analogue with [M+H]" = 432 
(fR = 4.56 min) were also observed. How'ever, the peak ol 
interest was the GSH-derived adduct with [M+H]* = 662, 
eluting at tK = 5.34 min.
The intact GSH-conjugate was not observed in the human 
liver microsome or bacterial cytochrome enzyme incubations.
Structural Characterization of the Parent (AZX) by ’H 
NMR Spectroscopy and LC-MS. While the aromatic protons 
of the pyridine ring (2 doublets at d'H 7.90 and d 'H 7.76, 
spectral region not shown) and both the aromatic (d 'H 2.57) 
and the methoxy (d 'H 3.27) methyls could be easily assigned, 
the aliphatic region of the spectrum was very complex due to
excessive signal overlap. The application of 2D NMR  
experiments (such as 'H—'H COSY and 'H —‘H TOCSY) 
helped greatly in the assignments of the signals (data not 
shown), with the 'H—'H COSY experiment showing 2- and 3- 
bond connectivities between neighboring protons, and the 
'H—‘H TOCSY experiment creating correlations between all 
protons within a given spin system. In order to resolve and 
deconvolute the individual aliphatic ring-moieties and to 
preserve the signal multiplicities, ID  selective TOCSY 
experiments produced the most conclusive data (Figure 2A).
The aliphatic region of the spectrum was comprised of 
numerous multiplets from the piperazine ring protons (d'H 
3.57 and d'H 2.56), from the l,3-diamino-propan-2ol (d'H 
3.88, d'H 2.58 (an AM system) and d'H 2.41 (an AB system)), 
and the 3-amino-propanol (d'H 3.83 (AB), d'H 2.79, d'H 2.41, 
and d'H 1.89 (AB)) moieties of the homomorpholine ring, and 
from the 3-amino-cyelobutanol (d'H 3.64, d'H 2.62, d'H 2.51, 
and d'H 1.73).
The LC-MS data (UPLC-DAD-LTQ;Orbitrap) of AZX 
highlighted a molecular ion of [M +H]+ = 486.2689, with 
fragment ions of m/z = 203.0424, m/z = 284.2329, m/z = 
128.1067, m/z = 198.1488, m/z = 140.1067, m/z = 85.0646, 
and m/z = 99.0915. The mass spectrum and fragment ions 
(including mass errors in ppm) of AZX are shown in Figure 2B.
Isolation of the [M+H]f 662 Adduct by LC-DAD-MS 
Fraction Collection. The [M +H]+ 662 adduct contained in 
the bacterial cytochrome enzyme samples (analyzed on the 
UFLC-DAD-LTQjOrbitrap) showed a protonated molecular
dx.doi.org/TO. 1021 /txS0004091 Chem. Res. Toxicol. 2014, 27, 968 -9 8 0973
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Figure 4. LC -M S data o f the scaled-up bacterial cytochrome enzyme-GSH incubate sample 1 showing the U V  chromatogram (at X = 280 nm ) and 
the selective ion chromatograms for [M + H ]*  446 and [M + H ]*  662. Data were generated on the U P LC -D A D -LTQ O rb itrap  (M ethod l ) .  Key: The  
arrow indicates the small [M + H ]*  446 in-source contribution from the [M + H ]*  662 component (fR = 6.1 m in), highlighting that [M + H ] ' 446 is 
also formed in the gas-phase from [M + H ]+ 662. Note the small delay between the U V  and MS detection.
ion with an accurate mass of [M+H]+ 662.2953 and also 
revealed an in-source fragment at m/z 446.2380.
The isolation of [M+H]+ 662 was conducted with bacterial 
cytochrome enzyme sample 3 (Method 2) collected into 96- 
well plates. On the basis of the MS-data and UV-response, the 
wells of interest were identified as wells 5—8 in row B, which 
were paired (wells B5—6 and B7—8) and subjected to 'H NMR 
analysis, together with those (B9—10, B11 —12, and B l—2, B3—
4) representing the fronting and tailing edges of the peak, 
respectively.
Structural Characterization of the Isolated [Mt H]+ 
662 Adduct by ’H NMR Spectroscopy. The 'H NMR
spectra of the fractions confirmed that the majority of the AZX- 
related material was contained in fractions B5—6 and B7—8 and 
that these were found to be identical.
The ‘H NMR spectra showed that there were no changes in 
the chemical shifts of the aromatic protons (doublets at r)!H 
7.90 and ri'H 7.76) or of the aromatic methyl signal (d'H 
2.57); however, changes in the aliphatic region of the spectrum 
were evident. Selective ID TOCSY experiments (Figure 3) 
confirmed the presence of the piperazine ring (multiplets at 
<5'H 3.58 and <5‘H 2.57) and 3-amino-cydobutanol (multiplets 
at <5‘H 3.74, <5‘H 3.21, <5'H 2.71, and /)'H 1.92). Selective 
irradiation of either multiplets (at <5'H 2.45 or rS1 H 3.94)
resolved the same signals, consistent with 1,3-diamino-propan- 
2-ol (<5lH 3.94, o'H 2.81 (an AB system), and <5'H 2.45 (an AB 
system)). However, the 3-amino-propanol moiety of the 
homomorpholine ring could not be detected. Signals 
representing the GSH-moiety were not detected either, 
implying that the metabolite in question was consistent with 
a dealkylated metabolite (with a theoretical mass of 446), as 
shown in Figure 3.
Structural Recharacterization of the Isolated [Mt H]+ 
662-Adduct by LC-MS. The LC-MS (UFLC-DAD-LTQ_ 
Orbitrap) analyses of the ’H NMR samples confirmed that the 
contents were consistent with [M+H]+ 446. Analysis of all the 
wells in row B (Bl —12) highlighted that [M+H]* 662 was 
undetectable, indicating that it had degraded to [M+H]+ 446 
during fraction collection. Although baseline separation 
between the two UV-peaks was not fully achieved in the 
semiprep separation (fR = 5.00 min for [M +H]+ 446 and 5.09 
min for [M+H]* 662, i.e., approximately 5.4 s between peaks, 
with a peak width of 12 s), the high speed HTC collection was 
considered adequate for their initial separation. However, the 
LC-DAD data showed that soon after the initial injections the 
peaks started to merge, mirroring the conversion of [M+H]* 
662 to [M+H]* 446. The observation of m/z 446 as an in-
dx.doi.org/10.1021 /tx50004091 Chem. Res. Toxicol. 2014. 27, 9 68 -980
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Figure 5. U\7 chromatogram (A = 280 nm) assessing the stability of the GSH-derived metabolite [M+H]* 662 of a bacterial cytochrome enzyme 
extract (sample 4) comparing t = 0 h with t = 12 h. The peak identity was derived from the MS data. Key: RT = room temperature.
source fragment (as shown in Figure 4) additionally masked the 
degradation process.
Stability of [M +H ]+ 662 Investigated by LC-MS. The
bacterial cytochrome enzyme sample 4 was analyzed immedi­
ately after reconstitution on the UPLC-DAL) - LTQ_ Orbitrap 
with analytical LC Method 1 to ensure separation of the two 
components. Comparison of the UV-peak intensities at t = 0 
and 12 h showed that the [M+H]+ 662 peak decreased, while 
[M+H ]f 446 increased (Figure 5). The stability of the [M+H]+ 
662 metabolite was also examined in acidic and basic 
conditions, which confirmed that under non-neutral conditions 
the degradation was accelerated (acid > base > neutral) (data 
not shown).
The [M+H J + 662 adduct was also shown to degrade upon 
storage. Reanalysis of the residual bacterial cytochrome 
enzyme-incubate samples (samples 1 and 2, used for method 
development, and sample 5, stored at 4 °C until the end of the 
investigations) showed that [M+H]+ 662 was depleted while 
[M+H]+ 446 was abundant. Reanalysis of residual aliquots
(stored at 4 °C for approximately 1 month) of the original 
incubate samples also confirmed that [M +H]+ 662 had 
degraded (data not shown). This finding helped to address 
the question whether [M+H]+ 446 was a metabolite or 
degradation product. The LC-MS data collected (on the 
UPLC-Q.-Tof) during the original incubations showed [M+H]+ 
662 in vast excess in the human liver microsome-(30 min)- 
incubations compared to the scale-up bacterial cytochrome 
enzyme-(l6 h)-incubations where [M+H]+ 446 was abundant 
(data not shown), suggesting that [M +H]+ 662 was converted 
to [M+H]* 446 either metabolically during the extended 
incubation time or, more likely, chemically.
Structural Characterization o f the [M +H ]+ 662-A dduct 
by LC-MSMS. The MSMS fragmentation data (generated on 
the UPLC-DAD-LTQjOrbitrap) of the [M +H]+ 662.2953 
adduct (Figure 6) provided evidence of Cys-Gly cyclization and 
formation of a thiazolidine moiety. The mass spectrum showed 
the in-source fragment of [M+H]+ 446.2380 (with a mass error 
of +1.45 ppm), as well as 2 further diagnostic fragments at m/z
dx.doi.org/10.1021/txS0004091 Chem. Res. Toxicol. 2014, 27, 9 68 -980
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Figure 6 . Diagnostic MS-ffagments (top) from the mass spectrum (bottom ) o f the GSH-derived metabolite [M + H ] + 662. Note: the mass errors are 
within ± 3  ppm.
217.0643 and m/z 114.0371, representing the thiazolidine— 
glycine moieties. A clear change in the homomorpholine ring 
fragmentation from the parent (AZX) was also observed 
(lacking fragments at m/z 198.1488 and m/z 140.1067), while 
the presence of the m/z 158.1175 and m/z 143.1178 fragments 
were indicative of major structural differences in the 
homomorpholine region of the molecule. The m/z 203.0427 
fragment indicated that the aromatic region of the molecule was 
unchanged.
Incubation of AZX with KCN and Methoxylamine. The
incubation of AZX with methoxylamine produced an adduct 
with [M+H]+ 531.2886 with a characteristic fragment of m/z 
329.2544 (Figure 7), producing (MS3) fragments at m/z 
282.2175 and m/z 244.2019, indicative of the bioactivation to 
an carbinolamine, ring-opening of the homomorpholine, and 
the formation of the aldehyde functional group. However, 
incubating AZX in human liver mierosomes in the presence of 
KCN did not produce a detectable quantity of the expected CN 
adduct for an iminium ion intermediate (mass ion [M+H]+ 
511), suggesting the equilibrium favored the carbinolamine/
i j  i j  f z —14aldehyde.
Proposed Mechanism of Formation of [M+H]+ 662.
The proposed mechanism of formation of [M+H]* 662 
involves initial oxidation ot the homomorpholine moiety via 
cytochrome P450-mediated bioactivation to a carbinolamine 
intermediate, followed by ring-opening to a reactive aldehyde 
intermediate12,13 (Figure 8, Step l) and conjugation with either
the a m i n o 1 or thioP group of the cysteine moiety (Figure 8, 
Step 2, A and B, respectively). The resulting Schiff base1' 1 
(A) or substituted mercaptomethanolVcarbosulfonium (B) 
intermediates then ring-contract to a thiazolidine (Figure 8, 
Step 3) with cleavage of the iso-peptide bond (liberating the 
glutamic acid) prior to (A) or after the intermolecular 
conjugation (B).
The failure to detect the intact GSH-conjugate in the human 
liver microsome or bacterial cytochrome enzyme incubations 
suggests either facile hydrolysis of the glutamate or a preference 
of route A. The subsequent loss of the thiazolidine—glycine 
moiety then results in the observed formation of the [M+H] + 
446 degradation product.
Incubation of AZX in Human Liver Mierosomes with 
Different Trapping Agents. Further experiments were 
conducted with structurally modified trapping reagents (Table 
l) using clozapine as the positive control (individual data not 
shown) to further investigate the mechanism. Incubations of 
AZX with agents 3 and 4, characterized by variations in the 
peptide bonds and modifications in the N-terminus, produced 
adducts with the same molecular weight, retention time, and 
fragment ions (data not shown) as the GSH-derived adduct 1, 
indicating the loss of the Glu (y or <x) or //-Asp residue. Reagent 
5 (C-terminal substitution of Gly with Lys) produced an adduct 
(with [M +H]+ 733) also characterized by the expulsion of Glu. 
No adduct was observed with 6 (dansylation of yGluls) 
suggesting either the necessity of a free N-terminal amino
dx.doi.org/10.l021/tx50004091 Chem. Res. Toxicol. 2014, 27, 968 -9 8 0
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group on Glu or prevention of cleavage of the Glu-Cys bond, or 
simply steric hindrance. The GSH-derivative 8 (containing the 
yGlu but lacking the C-terminal Gly) did not produce any 
trapped adduct, whereas 9 (retaining the Gly but lacking the N- 
terminal yGlu) produced the [M+H] + 662 adduct with the 
same structural properties as those in 1. Contrary to the 
piperazines forming adducts with Cys (10) or N-Ac-Cys (7),10 
no adduct was observed with AZX with either of these agents. 
The [M+H] + 662 adduct was also observed with GSEE (11, 
ethyl-esterification of Gly). The MS-data (i.e., relative 
quantification by MS, CTTof) showed a [M+H] + 690/662 
ratio of 1:5 (data not shown). The assumption that commercial 
GSEE had partially hydrolyzed to GSH (either metabolically or 
chemically) was disproved by incubation with clozapine, as the 
corresponding hydrolysis product for the clozapine GSEE 
adduct (with an expected [M+H]+ 632) was not detected 
under the same conditions (data not shown). Similarly, the 
presence of clozapine-GSH adducts in the control incubations 
proved that intact GSH was available for reaction.
■  DISCUSSION
This study demonstrated that the bioactivated homomorpho­
line moiety of compound AZX reacted rapidly with GSH and 
various other trapping agents, of which most of them contained 
the Cys-Gly-moiety (as shown in Table 1).
Unexpectedly, the Cys-Gly adduct [M+H]+ 662 of AZX 
proved to be unstable, degrading readily during its isolation to 
the desalkyl product with [M+H]+ 446, which was observed as 
an in-source fragment in the LC-MS analyses but also as a 
metabolite in the human liver microsome and bacterial 
cytochrome enzyme incubations. The presence ol m/z 446 as 
in-source fragment, however, initially obscured the detection of
the [M+H]+ 662 decomposition process. The very failure in 
successfully characterizing the isolated [M +H]+ 662 adduct by 
'H NMR spectroscopy prompted the reinterrogation of the 
LC-MS data, as the 'H NMR spectrum show'ed the structure to 
be exclusively consistent with the dealkylated metabolite [M 
+ H] + 446, lacking the 3-aminopropanol moiety of the 
homomorpholine ring. The LC-DAD-MS data, acquired on 
the LTQ;Orbitrap after the isolation, confirmed the degrada­
tion of [M +H]+ 662 to [M +H]+ 446. In addition, the LC-MS 
data (generated on the tTTof) of the original human liver 
microsome (30 min) and scaled-up bacterial cytochrome 
enzyme (16 h) incubations highlighted that the [M +H]+ 446 
metabolite featured more prominently in the bacterial 
cytochrome enzyme incubates, due to enzymatic trans­
formation during the extended incubation time or chemical 
degradation, or a mix of both. Reanalysis of the stored samples, 
how'ever, supported the facile chemical degradation of [M+H] + 
662.
Although the proposed Cys-Gly-thiazolidine adduct could 
not be structurally verified by 'H NMR spectroscopy, the 
successful structural characterization of [M +H]+ 662 (by LC- 
MSMS) and its [M +H]1 446 degradation product (by LC-MS 
and 'H NMR spectroscopy), as well as the MS" fragmentation 
data of the methoxylamine adduct allowed us to propose the 
mechanism of its formation. This involved initial enzymatic 
oxidation of AZX to a carbinolamine and the formation of the 
aldehyde1" 1' followed by adduct formation with Cys-Gly or 
GSH (via route A or B) and rearrangement to the thiazolidine. 
The proposal of both routes derived from the data in Table 1, 
as the free thiol group, present in every trapping agent, did not 
ensure adduct formation. Likewise, the presence of the 
glutamate («- or y-) or aspartate moieties provided no
dx.doi.org/10.1021 /tx50004091 Chem. Res. Toxicol. 2014, 27, 968 -9 8 0
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Figure 8 . Proposed mechanism of formation of [M + H ]+ 662 and its subsequent decomposition to [M + H ]+ 446. Step 1: bioactivation to the 
aldehyde. Step 2: (A ) nucleophilic addition o f the free Cys-Gly amine group or (B ) nudeophilic addition of GSH via the thiol group followed by loss 
ot the glutamate moiety. Step 3: cyciization to form the thiazolidine, followed by the elimination of the ethylene—thiazolidine—glycine moiety.
indication of preference, as these moieties were expelled in 
either route producing the [M+H]+ 662 adduct.
Both routes have literature precedents, with route A1' 1 
describing nucleophilic addition of the primary amino group of 
Cys (forming a carbinolamine), followed by elimination of 
water forming an imine (a reactive Schiff base) intermediate. 
Nucleophilic attack of the Cys-thiol function on the imine 
carbon produces thiazolidine—glycine. The mechanism has 
been previously detailed for the detoxification of the ethanol 
metabolite acetaldehyde.16
Route B5 describes the nucleophilic addition of the Cys-thiol 
group to the aldehydic carbon generating the substituted 
mercaptomethanol intermediate and subsequently, following 
elimination of water, a carbosulfonium intermediate.5 Here, 
ring contraction occurs via nucleophilic attack of the Cys-amino 
group on the carbosulfonium intermediate to form the 
thiazolidine—glycine-adduct.515-1
While recent literature data highlighted examples of desired 
reversible binding, such as saxagliptin (Onglyza) where 
prolonged binding via the cyanide functional group19 to the 
target peptidase inhibitor balanced maximizing pharmacody­
namic effects with minimizing drug levels,"0'"1 the formation of 
the reactive aldehyde intermediate as described in this article 
was an entirely unexpected and undesired effect.
The mechanism of the chemical degradation of the [M+H]+ 
662 adduct to the observed [M+H]" 446 product was initially 
unclear with two possible routes to the final alcohol, hydrolysis, 
or elimination. However, an experiment with water, labeled 
with oxygen-18, showed no oxygen-18 incorporation, thereby
disproving the hydrolysis route (experimental details and 
results are in the Supporting Information). Hence, elimination 
assisted by either an intramolecular hydrogen bond between 
one of the amines on the core of the molecule and the ether 
oxygen or by protonation of the oxygen by acid present in the 
solution could weaken the oxygen—carbon bond. A base either 
from the molecule or from solution could then deprotonate the 
2-position of the ethyl chain thereby leading to elimination of 
the alkene to afford the alcohol.
The observations made in the human liver microsome 
incubation experiments (Table l) allowed us to come to the 
following conclusions. First, the data suggest that the hydrolysis 
of the GSH y-glutamyl-cysteine isopeptide bond is not reliant 
on the presence of GGT,9 based on the observation that 
modifications of the X-Cys peptide bond, represented by r/Glu 
and /^ Asp, did not have any negative impact on [M+H] * 662 
formation (Table l). In fact, as the [M +H]+ 662 adduct was 
formed with GSH, aGSH, and /iAsp-Cys-Gly, as well as Cys- 
Gly alone, the release of any residue blocking the cysteine 
amino group appeared to be a requirement for successful 
adduct formation. Although a GSH-adduct was produced in the 
control incubations with clozapine (data not shown), no intact 
GSH adducts were detected for any of the trapping agents with 
AZX (data not shown). This suggested that hydrolysis of the 
glutamate (or //Asp) moiety must have occurred readily ' or 
that the aldehyde intermediate of AZX had a preference for the 
amino-group of hydrolyzed GSH (and its derivatives) (route 
A). This observation is mirrored in the literature. A study on 
acetaldehyde1 showed that there was only limited adduct
978 dx.doi.org/10.l021/tx5000409l Chem. Res Toxicol. 2014, 27, 968 -980
120
Chemical Research in Toxicology Article
formation with intact GSH (nucelophilic attack of the thiol), 
while rapid equimolar adduct formation was reported with Cys- 
Gly, following the addition of yGTP.
Second, adduct formation not only requires either the 
unsubstituted/free amino group (A) or the thiol function of 
cysteine (B) but also a C-terminal amino acid, as neither Cys or 
yGlu-Cys produced an adduct with AZX. Successful adduct 
formation appeared to rely on the presence of a terminal 
glycine or lysine group. However, the importance of these 
groups in either the intramolecular rearrangement or the initial 
addition of Cys-Gly to the aldehydic carbon would require 
further investigation.
In summary, we were able to determine the structure of the 
Cys-Gly adduct and confirm the presence of the aldehyde 
intermediate responsible for its formation. However, as the 
Cys-Gly [M+H]+ 662 adduct was observed with GSH as well as 
with several other trapping agents (as outlined in Table l), the 
possibility of additional alternative mechanisms of formations 
cannot be ruled out.
■  ASSOCIATED CONTENT 
Q  Supporting Information
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ALDEHYDE METABOLITE OF CPAQOP IN HUMAN LIVER MICROSOMES BY 
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Methanol adducts leading to the identification of a reactive 
aldehyde metabolite of CPAQOP in human liver microsomes by 
ultra-high-performance liquid chromatography/mass spectrometry
Scott Martin1*, Eva M. Lenz1, Robin Smith2, David G. Temesi2 +, Alexandra L. Orton1 and 
Malcolm R. Clench3
'Oncology iMED, Hodgkin Building, Chesterford Science Park, AstraZeneca UK Ltd., Saffron Walden, Essex CB10 1XL, UK 
‘ Oncology iMED, Alderley Park, AstraZeneca UK Ltd.. Macclesfield, Cheshire SK10 4TG, UK 
JBiomedical Research Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, UK
RATIONALE: The incubation of CPAQOP (l-[(2R)-2-[[4-[3-chloro-4-(2-pyridyloxy)anilino]quinazolin-5-yl]oxymethyl]-
l-piperidyl]-2-hydroxy) with human liver microsomes generated several metabolites that highlighted the 
hydroxyacetamide side chain was a major site of metabolism for the molecule. The metabolites were derived 
predominantly from oxidative biotransformations; however, two unexpected products were detected by liquid 
chromatography/ultraviolet/mass spectrometry (LC/UV/MS) and identified as methanol adducts. This observation 
prompted further LC/MS investigations into their formation.
METHODS: Three separate incubations of CPAQOP were conducted in human liver microsomes; Naive, fortified with 
methoxyamineand fortified with glutathione. Separation was achieved via ultra-high-performance liquid chromatography 
with either methanol or acetonitrilegradients containing formic acid. MS analysis was conducted by electrospray ionisation 
LTQ Orbitrap mass spectrometry acquiring accurate mass full scan, data-dependent MS2 and all ion fragmentation. 
RESULTS: No methanol adducts were detected by MS when acetonitrile was used in the mobile phase instead of methanol, 
verifying that a metabolite was reacting with methanol on column. Although this reactive metabolite could not be isolated 
or structurally characterised by LC/MS directly, product ion spectra of the methanol adducts confirmed addition of 
methanol on the hydroxyacetamide side chain. Additional experiments using methoxyamine showed the disappearance 
of the two methanol adducts and appearance of a methoxyamine adduct, confirming the presence of an aldhyde. Product 
ion spectra of the methoxyamine adduct confirmed addition of methoxyamine to the hydroxyacetamide side chain. 
CONCLUSIONS: The proposed bioactivation of CPAQOP occurred via the reactive aldehyde intermediate, which readily 
reacted with methanol in the mobile phase to form a pair of isomeric hemiacetal methanol adducts. In acidified methanol 
the equilibrium favoured the methanol adduct and in acidified acetonitrile it favoured the hydrate; therefore, the reactive 
aldehyde metabolite was not detected and could not be structurally characterised directly. Copyright © 2016 John 
Wiley & Sons, Ltd.
Metabolite identification studies within drug discovery are 
generally used to identify; metabolically labile sites on 
chemical structures, human metabolites which may not be 
represented in the toxicological species, active metabolites or 
potential reactive/toxic metabolites, which are of concern for 
the pharmaceutical industry.11 11 These discovery studies are 
conducted in  v itro  and generally involve incubation of a test 
compound in hepatocytes or microsomes, which mimic the 
most prevalent metabolic processes occurring in the liver. 
Typically, samples are taken from the test compound incubates, 
then added to acetonitrile to quench the reaction at t = 0 min
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Present address: (DGT) Recipharm, Vale of Bardsley, 
Ashton-under-Lyne, Lancashire OL7 9RR, LJK
Rapid Commun. Mass Spectrom. 2017, 37, 145-151
(control) and at a terminal time point (usually 30-60 min). 
Subsequently, samples are analysed on high-resolution accurate 
mass ultra-high-performance liquid chromatography/tandem 
mass spectrometry (UHPLC/MS/MS) systems and 
comparison of the 7 = 0 min vs the t = 60 min samples enables 
easier identification of metabolites from endogenous 
components. The analyses can be both challenging and time 
consuming even when identifying only a small number of 
metabolites. Often the data has to be generated and reported 
quickly to impact the chemistry design and unusual unexpected 
metabolites/products are not fully investigated due to time 
constraints. Such products can occasionally be formed through 
reactive or toxic metabolites.
Here we present an unusual finding from an in  v itro  
metabolite identification study of CPAQOP (l-[(2R)-2-[[4-[3- 
chloro-4-(2-pyridyloxy)anilino]quinazolin-5-yl]oxymethyl|-l- 
piperidyl]-2-hydroxy), a representative compound from a 
structurally related chemical series, in human liver 
microsomes (HLM). CPAQOP (Fig. 1) generated several
Copyright ©  2016 John Wiley & Sons, Ltd.
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Figure 1. Accurate mass HCD-MS positive product ion mass 
spectrum of CPAQOP (bottom) and proposed product ions 
with theoretical exact mass and mass error in ppm (top).
metabolites in HLM that were predominantly oxidative 
biotransformation products, which highlighted the 
hydroxyacetamide side chain as a major site of metabolism 
for the molecule. However, two unexpected methanol adduct 
products were also detected with different retention times yet 
identical mass. Methanol adducts are fairly common in mass 
spectrometry and are normally identified as analytical 
artefacts of the parent drug, generated during the positive 
ion electrospray ionisation process. Pozo et a/.141 reported the 
analysis of steroids using electrosprav-generated adducts such 
as [M + methanol) or [M + Na + methanol). In this case, 
CPAQOP reacted with methanol in the mobile phase prior 
to the MS ionisation process. The methanol adducts not only 
eluted at a different retention time to the parent drug, but 
two chromatographically separate methanol adduct peaks 
were observed, indicating the presence of isomers. These 
adducts were not detected in the control sample or in 
the analysis where acetonitrile replaced methanol as the 
mobile phase. This inferred a metabolic transformation to 
a reactive metabolite formed in the t = 60 sample, which 
subsequently generated the methanol adducts on injection 
onto the UHPLC column. The formation of these methanol 
adducts is subject to further investigation in this paper.
EXPERIMENTAL
Chemicals
CPAQOP was synthesised at AstraZeneca R&D (Alderley 
Park, Macclesfield, UK).
Methanol, acetonitrile and formic acid were all of analytical 
grade and supplied by Fisher Scientific (Loughborough, UK). 
Methoxyamine hydrochloride was sourced from Sigma- 
Aldrich (Poole, UK). All other chemicals or solvents were 
purchased from commercial suppliers and were of analytical 
grade. No specific safety considerations apply to any of these 
agents, although the agents should be handled with care in a 
fume hood to avoid inhalation or ingestion.
CPAQOP stock solution
Solid CPAQOP was dissolved in dimethyl sulfoxide (DMSO) 
to a concentration of 10 mM. The purity of CPAQOP was 
determined to be >98% by LC/MS and LC/UV.
In vitro incubation spiking solution
CPAQOP DMSO stock was diluted with 0.1 M potassium 
phosphate buffer (pH 7.4) to a concentration of 2 mM. This 
solution was then spiked into the in vitro incubation at 1:100 
(v/v) to give a final concentration in the incubation of 20 pM.
In vitro incubation experimental methods
Three separate incubations were performed with the parent 
compound (CPAQOP): (A) CPAQOP was incubated at 
20 pM with HLM (2 mg protein/mL, Corning 150 donor 
ultrapool) in 0.1 M potassium phosphate buffer at pH 7.4 
and 2.5 mM nicotinamide adenine dinucleotide phosphate 
(NADPH) at 37°C. An aliquot was removed after 0 min 
(control) and 60 min and the reaction stopped by the addition 
of ice cold acetonitrile (1:1, v/v). (B) CPAQOP was incubated 
as described in (A), but with 10 mM methoxyamine trapping 
agent added. An aliquot was removed after 60 min and the 
reaction stopped by the addition of ice-cold acetonitrile 
(1:1, v/v). (C) CPAQOP was incubated as described in (A). 
An aliquot was removed after 60 min and the reaction 
stopped by the addition of ice-cold acetonitrile (1:1, v/v) 
containing 10 mM methoxyamine. The extract was then 
incubated for a further 10 min at 37°C. (D) CPAQOP was 
incubated as described in (A), but with 10 mM glutathione 
(GSH) trapping agent added. An aliquot was removed after 
60 min and the reaction stopped by7 the addition of ice-cold 
acetonitrile (1:1, v/v).
Sample preparation
Quenched incubates were centrifuged at ca. 3000 g for 15 min, 
and the supernatant retained. An aliquot of the supernatant 
was transferred to a 2 mL HPLC vial (Waters, Milford, MA, 
USA) and diluted 1:3 (v/v) with ultra-purified distilled water 
prior to the LC/MS analyses.
Profiling and structural characterisation of metabolites by 
UPLC/LTQ-Orbitrap mass spectrometry
Accurate mass structural characterisation work was 
performed on a LTQ-Orbitrap XL instrument (Thermo Fisher 
Scientific, Bremen, Germany) connected to an Acquitv UPLC 
system (Waters). The Acquitv system consisted of a binary 
UPLC pump, column oven, a sample manager and a 
photodiode array detector. Separation was carried out on a 
BEH C18 column (100 x 2.1 mm, 1.7 pM; Waters) preceded 
by a guard filter in a column oven at 50°C.
Two chromatographic methods were used. Method 1: 
The mobile phase consisted of formic acid (0.1% in water, 
eluent A) and methanolic formic acid (0.1%, eluent B). 
Method 2: The mobile phase consisted of formic acid (0.1% 
in water, eluent A) and acetonitrile containing formic acid 
(0.1%, eluent B). The elution profile for both methods was: 
Initial conditions 95% A, then a linear gradient to 20% A from
1.01 to 9.00 min, isocratic hold at 2% A from 9.01 to 11.00 min 
and re-equilibration 95% A from 11.00 to 14.00 min. The flow
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rate was 0.45 mL/min and the eluent was introduced into the 
mass spectrometer via the LTQ divert valve at 1 min. The 
injection volume was 20 pL and UV spectra were acquired 
over 200-350 nm. The LTQ-Orbitrap XL was equipped with 
an electrospray ionisation (ESI) source which was operated 
in positive ion mode. Positive ion source settings were: 
capillary temperature 300°C, sheath gas flow 25, auxiliary 
gas flow 17, sweep gas flow 5, source voltage 3.5 kV, source 
current 100.0 pA, capillar)' voltage 18 V, and tube lens 
75.0 V. Full scan MS data were obtained over the mass range 
100-1200 Da. Targeted MS/MS experiments were acquired 
in the Orbitrap using Higher Energy Collisional 
Dissociation (HCD) fragmentation, isolation width 3 Da, 
normalised collision energy 60 eV, and activation time 
30 ms. All ions acquired in the Orbitrap were monitored 
at 7500 resolution full w'idth at half maximum. LTQ and 
Orbitrap mass detectors were calibrated within one day 
of commencing the work using Proteomass LTQ/FT- 
Hybrid electrospray positive mode calibration mix 
(Supelco, Bellefonte, USA).
Data analysis
Mass spectrometric data were collected using Xcalibur version
2.1 (Thermo Fisher Scientific, Bremen, Germany). Components 
were identified as being derived from CPAQOP by common 
fragments, isotopic pattern (Chlorine), UV absorbance and 
accurate mass. Comparisons with t = 0 incubations were 
conducted to minimise the potential for false positives from 
system impurities and endogenous components.
RESULTS
The initial full characterisation of a test compound with 
accurate mass MS/MS data often allows structural motifs 
and characteristic product ions to be identified, which assist 
the elucidation of the metabolite structures. MS/MS product 
ion experiments were undertaken in positive ion mode for 
the structural characterisation of metabolites or chemical 
addition products. All accurate mass measurements including 
the MS/MS product ions were within ±3 ppm of the 
theoretical exact mass.
Structural characterisation of CPAQOP by LC/MS/MS
In positive ion mode CPAQOP yielded a protonated molecule 
[M + H]+ = 520.1749 Da (+0.56 ppm mass error) and showed a 
characteristic chlorine pattern. The proposed dissociation 
pattern and LTQ Orbitrap HCD-MS product ion spectrum 
(Fig. 1) revealed three key product ions at m/z 365.0797 
(corresponding to loss of the methylpiperidylethanone), 
156.1018 (methylpiperidylethanone) and 98.0964 
(methy lpiperazine).
Structural characterisation of the acid metabolite (+0 -H2) 
by LC/MS/MS
In positive ion mode the acid metabolite yielded a protonated 
molecule displaying the characteristic chlorine pattern with a 
measured accurate mass of [M + H]+ = 534.1539 Da (0.0 ppm 
mass error), which is consistent with addition of one oxygen 
and loss of two hydrogen atoms. The proposed fragmentation
pattern and LTQ Orbitrap HCD-MS product ion spectrum 
(Fig. 2) revealed diagnostic product ions; m/z 365.0789, 
170.0808, 126.0911 and 98.0963. The product ion at m/z 
170.0808 corresponded to the addition of 14 Da (+O, H?) to
m/z 156.1018 observed in CPAQOP. Detection of the 
methylpiperazine product ion (m/z 98.0963, also observed in 
CPAQOP) confirmed the piperazine ring was unchanged 
and the biotransformation had occurred on the 
hydroxyacetamide side chain. The product ion m/z 126.0911 
represents loss of CO? from the hydroxyacetyl side 
chain, which is consistent with an acid on the terminal 
side chain carbon.
Structural characterisation of the hydrate product (+0) by 
LC/MS/MS
The hydrate metabolite was only detected at trace levels when 
methanol was used in the mobile phase, but it was the 
predominant species when methanol was substituted by 
acetonitrile. Therefore, the MS/MS spectra (shown in Fig. 3) 
for the hydrate have been taken from the LC/MS analysis 
where acetonitrile mobile phase eluent was employed. In 
positive ion mode the hydrate product yielded a protonated 
molecule displaying a characteristic chlorine pattern with a 
measured accurate mass of [M + H]+ = 536.1691 Da 
(-0.04 ppm mass error), which is consistent with addition of 
one oxygen atom. The proposed dissociation pattern and 
LTQ Orbitrap HCD-MS product ion spectrum (Fig. 3) revealed 
diagnostic product ions; m/z 172.0964, 126.0911 and 98.0963. 
The m/z 172.0964 product ion corresponded to the addition 
of 16 Da to the m/z 156.1018 product ion observed in CPAQOP 
and the accurate mass confirmed addition of one oxygen atom 
to the methylpiperidylethanone group. Detection of the 
methylpiperazine product ion (m/z 98.0963, also observed in 
CPAQOP) confirmed the piperazine ring was unchanged
o c >
[M + H]*= 534.1539 
I Error = -O.Oppm
O
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Error = -0.88ppm Error = -1.75ppm Error = -1.9ppm Error = -3.0ppm
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Figure 2. Accurate mass HCD-MS positive product ion mass 
spectrum of the acid metabolite (bottom) and proposed 
product ions with theoretical exact mass and mass error in 
ppm (top).
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Figure 3. Accurate mass H C D -M S  positive product ion mass 
spectrum of the hydrate (bottom) and proposed product ions 
w ith  theoretical exact mass and mass error in ppm  (top).
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and the oxygen atom addition had occurred on the 
hydroxyacetamide side chain. The m/z 126.0911 product ion 
represents loss of C H 20 2 from this side chain, w h ich is 
consistent for a hydrate on the terminal carbon.
Figure 4. Accurate mass H C D -M S  positive product ion mass 
spectra o f the hemiacetal methanol adducts (bottom) and 
proposed product ions w ith  theoretical exact mass and mass 
error in ppm  (top).
Structural characterisation of the methanol addition product 
(a hemiacetal) by LC/MS/MS
T w o  distinct L C /U V /M S  peaks were detected in the 
chrom atogram  for this product. In  positive ion mode the 
methanol addition products yielded protonated molecules 
displaying characteristic chlorine patterns w ith  measured 
accurate masses of [M  + H ]+ = 550.1854 Da (+0.41 ppm mass 
error) and [M  + H ] '  = 550.1852 Da (+0.12 ppm ), which is 
consistent w ith  addition of one carbon, tw o hydrogens and  
an oxygen atom. The proposed dissociation pattern and LTQ  
O rbitrap  H C D -M S  product ion spectrum for both adducts 
(Fig. 4) revealed diagnostic product ions m/z 186.1121, 
126.0911 and 98.096.3. The product ion m/z 186.1121 
corresponded to the addition of 30 Da to m/z 156.1018 
observed in the M S /M S  spectrum of C P A Q O P , and accurate 
mass confirmed addition of one carbon, tw o hydrogens and  
an oxygen to the m ethylpiperidylethanone group. Detection 
of the m ethylpiperazine product ion (m/z 98.0963, also 
observed in C P A Q O P ) confirmed the piperazine ring was 
unchanged and addition of C H 20  occurred on the 
hydroxyacetamide side chain. Tire m/z 126.0911 product ion 
represents loss of C 2H 4O 2 from  this side chain, confirm ing it 
as the site o f methanol addition.
The observation of tw o distinct I .C /U V /M S  peaks both w ith  
measured accurate masses w ith in  2 ppnr o f the theoretical 
exact mass of C P A Q O P  + C H ;0  ([M  + H ]* = 550.1854 Da) 
and identical M S /M S  fragmentation (Fig. 4) suggested 
form ation of isomers. The addition o f m ethanol to the term inal 
carbon on the hydroxyacetamide side chain creates a second 
chiral centre and therefore diastereoisomers, which could be 
separated chromatographically (Fig. 5(a)).
The data (the observation of the hydrate and the hemiacetal) 
suggested that the potential reactive interm ediate had  
undergone structural changes on the hydroxyacetyl side 
chain, producing a reactive aldehyde, w h ils t the form ation  
of the acid indicated further oxidation of this functional group.
Glutathione (GSH) and methoxyamine trapping experiments
To confirm the reactive interm ediate, the proposed reactive 
aldehyde, two trapping experiments in H L M  were  
undertaken. The first invo lved G SH , the routine industry  
standard for trapping soft electrophilic reactive metabolites. 
G SH  does not routinely adduct w ith  aldehydes, though some 
literature data suggests this can occur/ ’ 1 Saturated aldehydes  
generally require a nitrogen-based trapping agent, such as 
m ethoxyam ine, which forms a stable Schiff base adduct.1*’-81 
The incubation of C P A Q O P  w ith  G SH  did  not produce an 
adduct (data not shown); instead, only the m ethanol adducts 
were detected, confirm ing that the reactive in term ediate was  
not a soft electrophilic species. In contrast, the second involved  
incubation of C P A Q O P  w ith  m ethoxyam ine and generated  
the corresponding m ethoxyam ine adduct, w hilst the m ethanol 
adducts were not detected. Incubation of C P A Q O P  in H L M  
showed almost complete turnover of the C P A Q O P  at 
t -  60 m in (Fig. 5(a)); how ever, when co-incubating w ith  
m ethoxyam ine, the overall m etabolic turnover was reduced, 
resulting in a significant am ount of C P A Q O P  rem aining  
unmetabolised (Fig. 5(b)). A dd ition ally , hydroxyl metabolites 
of the m ethoxyam ine adduct were detected at significantly  
greater concentration than the m ethoxyam ine adduct itself 
(Fig. 5(b)). It was therefore decided to repeat the 
m ethoxyam ine trapping experim ent, this tim e spiking the
w ile yon lin e lib ra ry .com /jou rn a l/rcm Copyright © 2016 John Wiley & Sons, Ltd. Rapid Commun. Mass Spectrum. 2017,37,145-151
127
Methanol adducts reveal reactive aldehyde metabolite by LC/MS
Rap'd
a y  ) Communications in
Mass Spectrometry
Methanol
adducts
/ \  
7.09 7.20
6.34
100^ Acid
metabolite5 0 -
o -
-50 -I
6.85 Methoxyamine 
adduct + 0
100-1
CPAQOP
5 0 - 6.9!
o -
7.36
1 00n
Methoxyamine
adduct6.345 0 -
6.4 6.6 6.8 7.0 7.2 7
Time (min)
Figure 5. Extracted UV absorbance chromatograms (330 nm) 
of CPAQOP incubated in (a) HLM, (b) HLM + methoxyamine, 
and (c) HLM with addition of methoxyamine post-quench.
methoxyamine post-incubation into the HLM immediately 
after quenching (at t = 60 min). This resulted in increased 
metabolic turnover of CPAQOP and the formation of only 
one methoxyamine adduct with significantly increased yield, 
simplifying the data interpretation (Fig. 5(c)).
Structural characterisation of the methoxyamine adduct by 
LC/MS/MS
In positive ion mode the methoxyamine adduct yielded a 
protonated molecule displaying a characteristic chlorine 
pattern with a measured accurate mass of 
[M + H]+ = 547.1855 Da (+0.35 ppm mass error), which is 
consistent with addition of one carbon, one hydrogen and 
one nitrogen (CHN). The addition of CHN was an expected 
modification upon reaction of an aldehyde with 
methoxyamine. The proposed dissociation pattern and the 
LTQ Orbitrap HCD-MS spectrum (Fig. 6) revealed diagnostic 
product ions m/z 183.1124,152.0942,123.0552 and 96.0808. The 
product ion m/z 186.1121 corresponded to the addition of 
27 Da to m/z 156.1018 observed in the MS/MS spectrum of 
CPAQOP and accurate mass measurement confirmed 
addition of CHN to the methylpiperidylethanone group. The 
m/z 152.0942 ion corresponded to the loss of a methanol radical 
from the m/z 183.1124 ion.
The adduct formation with methoxyamine provided 
evidence of the presence of an aldehydic functional group, 
and therefore confirmed the formation of a reactive aldehyde 
intermediate following oxidation of the terminal hydroxyl 
group.
■ o c o
[M + H]*= 547.1855 
Error = +0.35pm
u
U II HU
Radical
Cation
m/z= 96.0808 m/z= 123.0553 m/z= 152.0944
Error = -0.27ppm Error = -0.48ppm Error = -1.3ppm
m/z= 183.1128 
Error = -2.0pm
96 .0 80 8  1—'—*—'—I—
10 100
123 05 52  
' ' V  '—120 140
m/z
Figure 6. Accurate mass HCD-MS positive product ion mass 
spectrum of the methoxyamine adduct (bottom) and proposed 
product ions with theoretical exact mass and mass error in 
ppm (top).
The metabolic fate of CPAQOP, the formation of the 
methanol adduct and the methoxyamine adduct are 
summarised in Fig. 7.
DISCUSSION
This study demonstrated that the compound CPAQOP on 
incubation with HLM generated a reactive aldehyde 
metabolite that subsequently formed two methanol adduct 
isomers (Fig. 7). Whilst the reactive aldehyde metabolite was 
not directly detected and therefore could not be structurally 
characterised by UHPLC/MS, the methoxyamine trapping 
experiment verified the presence of an aldehyde. MS/MS 
experiments carried out on the methoxyamine adduct 
confirmed that addition occurred on the hydroxyacetamide 
side chain. Detection of the hydrate product gave further 
support for metabolism of the hydroxyacetamide side chain 
to the corresponding oxoacetamide (reactive aldehyde). The 
identification of two chromatographically distinct methanol 
adduct peaks with identical accurate masses (within 
±1 ppm) and dissociation patterns was indicative of the 
formation of diastereoisomers. Chemical addition of methanol 
to the reactive aldehyde metabolite created an additional 
chiral centre and resulted in the formation of diastereoisomers, 
which were easily separated by UHPLC (Fig. 5(a)). Ov erall, the 
metabolic profile of CPAQOP incubated in HLM showed that 
CPAQOP was readily metabolised, with little evidence of the 
parent CPAQOP in the LC/UV chromatograms (Fig. 5). The 
aldehyde, hydrate and methanol adducts were likely to be in 
equilibrium. In acidified methanol/water mobile phase the 
methanol adducts appeared to be the predominant products, 
with the hydrate detected only at trace levels and the 
reactive aldehyde not detected. However, in acidified 
acetonitrile/water mobile phase, only a single hydrate 
product was detected. Chemical reactions of methanol with 
aldehydes forming hemiacetals have been reported previously
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Figure 7. The proposed metabolic profile  of C P A Q O P  generated in H L M , together w ith  the 
analytical artifact, the m ethanol adduct, as w ell as the m ethoxyam ine incubation product. The  
proposed reactive aldehyde interm ediate is shown in the centre.
by Bateman et who observed methanol addition to
numerous components of secondary organic aerosol 
(a mixture of polyfunctional compounds containing alcohol, 
carbonyl, nitro and other functionalities) when methanol 
was used for extraction and/or storage. They also observed 
an increased rate of methanol adduct formation in acidified 
solutions. A series of publications have reported the formation 
of artefacts when methanol was used as a diluent to spike test 
compounds into microsomal incubations. Yin et a/.11"1 and Li 
et a / . 1" 1 described the formation of +12 Da artefacts (having 
gained one carbon atom over the incubated parent compound) 
from microsomal incubations, where methanol was present in 
the spiking diluent at 1% (v/v). Similarly, Cunningham 
et a/.112i reported the formation of an unusual -CH? bridged 
dimer of 2,4-diaminotoluene again through the presence of 
methanol in the diluent. In these examples, methanol in the 
spiking solution was metabolised in the microsomal 
incubation to formaldehyde, which subsequently reacted 
with the test compounds containing 1,2-diamino-, 
1,2-aminohydroxyl- or 2,4-diaminotoluene. This is in 
contrast to this study, where methanol had not been added 
to the incubation or the sample extract prior to injection 
onto the LC/UV/MS system, confirming the addition 
occurred post-injection on the LC column, with the mobile 
phase the source of the methanol.
The initial methoxyamine-HLM incubation with CPAQOP 
resulted in a significant reduction in metabolic turnover of 
parent compared to the control (incubation without 
methoxyamine, as shown in Fig. 5(a)) and the generation of 
additional products due to further metabolism of the 
methoxyamine adduct. The reduction in metabolic turnover
was almost certainly due to enzyme inhibition by addition 
of methoxyamine to the incubation. Zhang et fli.11 1 reported 
on the inhibitor properties of methoxyamine against P450 
enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and 
CYP3A4/5 at concentrations up to 10 mM. To improve data 
quality and yield of the methoxyamine adduct the experiment 
was repeated, adding methoxyamine 'post-quench' then 
incubating for a further 10 min at 37°C. The result was a much 
cleaner metabolic profile, with no reduction in metabolic 
turnover and a significant increase in yield of the 
methoxyamine adduct (shown in Fig. 5). Although the 
aldehyde metabolite is reactive, it was present at a high 
enough concentration immediately post-incubation to 
produce the methoxyamine adduct. This is in agreement with 
the facile reaction of the reactive aldehyde and methanolic 
mobile phase on column forming the isomeric methanol 
adducts. Aldehyde metabolites are capable of reacting with 
macromolecules such as proteins, forming covalent adducts 
potentially triggering direct cell toxicity or an immune 
response and have been implicated in adverse drug reactions 
observed in the clinic. Several drugs are suspected of 
generating reactive aldehyde metabolites implicated 
in adverse drug reactions, which include acyclovir 
nephrotoxicity,1141 abacavir idiosyncratic hypersensitivity 
with increased risk of cardiac dysfunction,11"1 and felbamate 
aplastic anaemia and hepatotoxicity.,u'1 It is therefore prudent 
to identify compounds or structural moieties that form 
reactive aldehyde metabolites early in drug discovery to 
modify or change the chemistry' and remove the liability. It 
is also important to note that CPAQOP did not form an adduct 
in the HLM GSH trapping experiment, thus escaping detection
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from the early routine in-house reactive m etabolite screen. 
W ithout the form ation of the m ethanol adducts, the aldehyde  
m ay not have been identified until much later in drug  
discovery.
In conclusion, analytical artefacts (such as methanol 
adducts) are not desired and can complicate the analysis or 
lead to m isinterpretation. H ow ever, here w e presented an 
exam ple where the m ethanol adducts were diagnostic and  
pivotal in identify ing a reactive aldehyde metabolite, thus 
highlighting the im portance of fu lly  investigating any unusual 
adducts observed in m etabolite identification studies.
W hilst the reactive aldehyde m etabolite could be proposed 
from  the detection o f m ethanol adducts, the hydrate  
m etabolite was sim ply addition o f oxygen (+16 Da) to the 
parent com pound, wh ich is a very  com m on biotransform ation  
reaction. If  the in itial analysis had been undertaken in 
acetonitrile it is likely that the hydrate w o u ld  have been 
reported as a hvdroxylated m etabolite and the reactive 
aldehyde liab ility  for the chemical series missed.
CONCLUSIONS
The proposed bioactivation of C P A Q O P  occurred via  the 
reactive aldehyde interm ediate, w h ich readily  reacted w ith  
m ethanol in the m obile phase to form  a pair o f isomeric 
hemiacetal m ethanol adducts. In  acidified m ethanol the 
equilibrium  favoured the m ethanol adduct and in acidified 
acetonitrile it favoured the hydrate; therefore, the reactive 
aldehyde m etabolite was not detected and could not be 
structurally characterised directly.
The aldehyde did  not form  an adduct w ith  G S H , escaping 
detection in our conventional in  v itro  trapping screen; 
however, it was trapped w ith  m ethoxyam ine. A  significant 
gain in efficiency ( > 20-fold increase in  yield  o f adduct) was 
observed when m ethoxyam ine was added im m ediately  
post-incubation over the traditional m ethod, where  
m ethoxyam ine is added pre-incubation.
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7. SUMMARY AND CONCLUSIONS
7.1 Fenclozic acid
Fenclozic acid (Myalex™) was developed by ICI pharmaceuticals in the 1960s 
for the treatment of rheumatoid arthritis, it was a promising compound with good 
pre-clinical safety profile and efficacy. Whilst it did not show adverse hepatic 
effects in pre-clinical animal tests or initial studies in man134,135 it was later 
withdrawn from clinical development due to hepatotoxicity in humans at daily 
doses of 400 mg. One of the more recent theories for the cause of the 
observed hepatoxicity in the clinic is the formation of RMs. The original 
metabolite identification work by Foulkes136,133 and by Bradbury137 showed fairly 
extensive metabolism, but did not detect any potential RMs other than an acyl- 
glucuronide.
7.1.1 In vitro studies
More recently AstraZeneca investigated this hepatotoxicity using a variety of 
modern in vitro approaches, which have been used to explore potential 
underlying mechanisms138. 14C radiolabelled Fenclozic acid (Figure 31) in vitro 
CVB experiments were undertaken to determine the potential for Fenclozic acid 
to be bioactivated in rat, dog and human liver microsomes and hepatocytes.
Figure 31 14C Radiolabelled Fenclozic acid
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Cl
CVB was observed for Fenclozic acid in both the hepatocytes and microsomes 
incubations indicating the formation of a RM. The CVB in microsomes and 
reduced CVB in hepatocytes in the presence of a P450 inhibitor, strongly 
suggested phase I metabolism was responsible for the CVB and not the 
previously identified acyl-glucuronide. To investigate the potential RM, several 
HLM trapping experiments were undertaken with 14C Fenclozic acid using a
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variety of nucleophilic trapping agents for CVB and metabolite identification. 
The most significant drop in CVB was observed for the Cys and GSH trapping 
experiments, suggesting GSH/Cys were conjugating with an electrophilic RM in 
preference to it covalently binding to protein. The metabolite identification work 
was undertaken as a part of this thesis and formed the initial metabolism 
investigation into Fenclozic acid prior to the in vivo studies (Chapter 2 & 3). 
Analysis of each of the trapping agents by flow radio chemical detection did not 
show the presence of any metabolites and the only radio peak observed in each 
trapping experiment was Fenclozic acid (Figure 32).
Figure 32 Radio chromatogram from a Fenclozic acid GSH trapping 
experiment.
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This was unusual considering the position of the 14C in Fenclozic acid (Figure 
31), as it is highly unlikely that the label was lost through metabolism. However, 
the samples were also analysed extensively by LC-UV-MS using a number of 
the MS scan/MS data stripping techniques (Section 1.3.2) and no metabolites or 
parent related products could be identified. Whilst there were no metabolites 
detected, the measured CVB in HLM and the reduction in CVB in the presence 
of GSH or Cys strongly suggests the presence of an electrophilic RM. The in 
vitro metabolic turnover in HLM was low with a measured Cljnt < 3 pL/mL/mg 
(unpublished Astrazeneca data) which may help to explain the lack of 
metabolites. It is therefore possible that low levels of RM were formed, but 
were below the detection limits of the analytical instruments. In summary, all of 
the in vitro data pointed towards CYP bioactivation to a RM, however no RMs 
were detected. Whilst extensive analytical work was undertaken to identify 
metabolites from the microsomal in vitro trapping experiments there was only 
minimal contribution to the overall Fenclozic acid in vitro investigation paper138,
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therefore it was decided not include it in this thesis, even though this work 
formed the basis for the subsequent in vivo investigations.
7.1.2 Fenclozic acid metabolism study in HRN mice (Chapter 2)
The in vitro CVB observed was shown to be phase I mediated, but CVB of a 
drug or its metabolites does not necessarily lead to in vivo toxicity. To 
investigate the contribution of phase II metabolism to Fenclozic acid toxicity, an 
in vivo study in hepatic reductase null mice (HRN) was conducted to examine 
the disposition, metabolism and in vivo CVB of 14C Fenclozic acid. The 
metabolite identification work for this paper (Chapter 2) was undertaken as a 
part of this thesis. HRN mice have no functional hepatic CYP enzymes139 and 
have been shown to produce only phase II conjugation metabolites for 
diclofenac140.
The histopathological examination did not reveal any evidence of adverse 
hepatic effects for Fenclozic acid in HRN mice after a single dose of 10 mg/kg. 
In vivo CVB measured in plasma and the tissues examined was much less than 
50 pmol per mg of protein, with the highest binding observed in the kidney 
(twice what was observed in the liver). This suggested that phase II conjugation 
biotransformations of Fenclozic acid in the liver did not produce a large extent of 
CVB. The two major metabolites detected in faeces and urine were taurine and 
glycine amino acid conjugates, whilst the acyl glucuronide was only detected as 
a minor metabolite. The taurine, glycine and acyl-glucuronide imply the 
formation of a coenzyme A intermediate. Coenzyme A intermediates have 
been associated with the toxicity of carboxylic acid containing xenobiotics141, 
however no evidence of toxicity was observed in the HRN mice in this study. 
Both the in vitro and HRN in vivo experiments suggested the CVB and toxicity 
were not due to phase II metabolism; however due to the use of HRN mice it 
was not possible to identify any phase I metabolites from these studies.
7.1.3 Fenclozic acid metabolism study in bile duct cannulated rats 
(Chapter 3)
To better characterise the metabolism of Fenclozic acid it was decided to 
conduct a bile duct cannulated metabolite identification study using Han Wistar
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rats. Unfortunately due to the amount of radioactive material remaining it was 
not possible to dose rats with 14C labelled Fenclozic acid, so only cold material 
was dosed. Using bile duct cannulated animals it is possible to collect 
excretory metabolites in bile and urine rather than faeces and urine. Faeces is 
a difficult matrix to analyse and will generally require extraction of the 
metabolites prior to analysis, whereas bile can be injected on to LC-MS without 
any need for extraction, reducing the potential loss or degradation of 
metabolites. Rat was chosen as it produces more sample than mouse and is a 
direct comparison to the original work by Foulkes and Bradbury136,137 who had 
previously profiled the metabolites in rat.
The product ions of Fenclozic acid and it’s metabolites identified in the rat bile 
duct cannulated study can be found in Appendix B.
Fenclozic acid was extensively metabolised in vivo in the rat with a total of 18 
metabolites detected including several previously unreported metabolites. 
Earlier studies by Foulkes and Bradbury136,137 in the rat showed fairly extensive 
metabolism, however there was a significant difference in the type and number 
of metabolite identified compared to this study. A likely explanation for these 
differences was the extraction and chromatographic conditions employed by 
Foulkes and Bradbury. It is possible that a number of metabolites degraded 
under their extraction and chromatographic conditions, which were far harsher 
than the ones used in this study. For example Foulkes reported a reductive 
decarboxylation metabolite, but also described degradation of Fenclozic acid to 
this metabolite when extracted in chloroform. The reductive decarboxylation 
product was not detected in this study, so it is likely an analytical artefact from 
the extraction procedure. Foulkes and Bradbury did not detect any GSH-related 
conjugates, while several GSFI related conjugates were detected in this study. 
This would suggest that the analytical methodology applied during the 
development of Fenclozic acid was unsuitable for the detection of GSH adducts. 
Apart from the differences in sample preparation, the vastly improved 
chromatography and sensitivity of modern high resolution MS instruments 
undoubtedly aided the detection of a larger number of metabolites. Unlike the 
HRN mouse study seven new metabolites were identified (not including the 
multiple GSH related product) including an unusual carnitine conjugate and
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additional amino acid conjugates. The carnitine conjugate is not a common 
biotransformation for xenobiotics, but it has been reported as a metabolite for 
valproic acid142. The carnitine conjugate in Figure 33 is zwitterionic and is likely 
to have a low pKa (<3) compared to Fenclozic acid and was demonstrated by 
changing the mobile phase from pH 6.5 to pH 4.0.
Figure 33 Fenclozic acid carnitine conjugate
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At pH 4.0 Fenclozic acid would likely start to become unionised and less polar, 
so retain longer on a reverse phase column, whereas the carnitine conjugate 
will not change ionisation state or retention characteristics (Figure 34).
Figure 34 Selected ion mass chromatograms for Fenclozic acid and the 
carnitine metabolite at pH 6.5 (ammonium acetate) (top) and pH 4.0 
(formic acid) (bottom).
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This test could be used in future to confirm the presence of a carnitine 
conjugate, if MS spectra are unrevealing.
The GSH related conjugates detected pointed towards a single phase I epoxide 
metabolite on the chlorobenzene ring, which is likely responsible for the CVB 
observed in rat microsomes. Whilst the CVB results indicated that a GSH 
conjugate was likely, the in vitro GSH trapping experiments contradicted this
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theory. If an epoxide metabolite was the cause of the CVB, then a conjugate 
should have been detected in either the Cys or GSH trapping experiments, 
which both had almost identical analytical conditions and LC-MS 
instrumentation to the rat bile duct cannulated study. The low metabolic 
turnover of Fenclozic acid in HLM (Clint <3 uL/mL/mg) would be consistent with 
the formation of low levels of the epoxide RM and the subsequent GSH 
adducts. The formation of four isomeric GSH conjugates (Figure 35) (positional 
and diastereoisomers) would further reduce LC-MS sensitivity, indicating that 
these GSH-conjugates were not present at sufficiently high concentrations to be 
detected.
Figure 35 Fenclozic acid Glutathione conjugate isomers
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GSH conjugates can be further metabolised through enzymatic degradation of 
the GSH (Figure 36), often leading to multiple GSH related adducts from one 
RM. Many of these GSH degradation products were identified for Fenclozic and 
there were up to four isomers for each GSH product, so in total there were up to 
16 GSH related conjugates generated from a single epoxide RM.
Figure 36 In vivo enzymatic degradation of GSH conjugates
HO
n h  o  0 H  -G lu ta m y l 0  -G ly c in e  Q N -A c e ty la t io n  0 ;X 0 0
°Xna-V >° — *W S n r°H — » s v ~°h — * s/"SJ'~(  H NH2 NH2 H 0  R M - A h2 r m . - - - S H
RM GSH Cysteineglycine Cysteine N-Acetyl cysteine
Based on all of the data it is proposed that the reactive epoxide 
intermediate/metabolite is the agent responsible for the observed CVB in rat 
microsome and that it is likely to be the cause of CVB in human microsomes. 
While the intact GSH adducts were not detected in previous studies the 
identification of oxidation metabolites on the chloro-benzene ring by Foulkes136, 
is consistent with the formation of an epoxide intermediate.
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In conclusion, the reactive epoxide metabolite identified here is likely formed in 
humans and therefore could have contributed to the Fenclozic acid 
hepatotoxicity observed in the clinic.
7.2 Reaction of Homopioerazine with endogenous formaldehyde
(Chapter 4)
A new series of homopiperazine compounds were introduced into a discovery 
project to replace a piperazine series that had a RM liability, similar to that 
reported by Doss et a/.143. No RMs were detected in vitro and the series of 
compounds had low to moderate metabolic turnover in vitro. However, when 
compounds were dosed to rats the in vivo CL was higher than expected from 
the IVIVe, suggesting there might be additional metabolic routes in vivo. Rat 
urine and plasma were collected from an AZX i.v. dosed rat, to identify 
additional in vivo routes specifically looking for RMs that may not be formed in 
vitro. Subsequent metabolite identification uncovered an unexpected major 
parent related peak with a ion arising from a molecular species at m/z 488 (not 
observed in vitro) in the 0-24 hour pooled urine sample, whilst only low levels of 
AZX were detected by UPLC-UV-MS. Surprisingly the AZX spiked pre-dose 
control urine also produced this m/z 488 product and only a minor LC-UV peak 
for AZX was observed. It was initially assumed that either the wrong compound 
was dosed or that the parent had either degraded/formed chemical adducts, as 
the [M+H]+, i.e. the mass addition, could not be explained. Analysis of the dose 
solution and solvent stocks confirmed AZX ([M+H]+ 476) was >95% pure and no 
m/z 488 was observed so this was ruled out.
Product ion spectra of m/z 488 confirmed the transformation had occurred on 
the homopiperazine ring and elemental composition analysis confirmed the 
molecular formula to be AZX +carbon. It was not possible to identify the exact 
position of the carbon addition however, due to the limited possibilities on the 
homopiperazine ring a carbon bridged structure was proposed (Figure 37). The 
presence of quaternary nitrogen was confirmed by reaction with cyanide.
137
Figure 37 AZX homopiperazine -CH2 bridged structure
The proposed bridged structure equated to the addition of one carbon and one 
hydrogen atom, i.e. a gain of 13 Da which is not consistent with apparent +12 
Da product observed by MS. However, the bridged structure has a fixed 
permanent positive charge (M+) (Figure 37) and cannot produce a protonated 
molecule ([M+H]+ ion ) by positive ion electrospray (+ESI). Whilst the calculated 
MW of AZX is 475 Da and the observed [M+H]+ was m/z 476, the calculated 
mass of the bridged homopiperazine and M+ ion are 488 Da and m/z 488 
respectively. Therefore the MW difference between AZX and the bridged 
homopiperazine is 13 Da (+1xC and +1xH), while the measured m/z difference 
is 12 Da (1xC).
Formaldehyde was identified as a potential candidate to react with AZX and 
form the proposed bridged homopiperazine via the Mannich reaction through a 
reactive schiff base intermediate, which is intramolecularly stabilised by forming 
the bridged homopiperazine. To test this hypothesis formaldehyde was spiked 
into a test solution of AZX and the +13 Da product was formed immediately at 
nearly 100%. This provided an easy method to scale up for NMR analysis, 
which subsequently confirmed the product was in fact the carbon bridged 
homopiperazine. Several experiments ruled out methanol or other analytical 
solvents as the source of the formaldehyde, so the question remained whether 
this could occur in vivo. The +13 Da product was also detected in rat plasma, 
which is highly unlikely to come into contact with formaldehyde prior to analysis. 
Formaldehyde occurs naturally in the body and it is present in rat blood at 
approximately 0.1 mM144. It is therefore proposed that AZX scavenges 
endogenous formaldehyde in vivo, similar to aminoguanidine which was 
reported by Kazachkov et a/.145.
Formaldehyde is known to be responsible for cross linking proteins146,147 and 
some xenobiotics148 via the Mannich reaction through a Schiff base 
intermediate. Considering that basic amine groups are ubiquitous on many
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xenobiotics and proteins, it is worth noting the potential for formaldehyde to 
cause cross linking between xenobiotics and proteins in vivo. Hence, 
susceptibility to formaldehyde addition via a direct or metabolic route could lead 
to the formation of covalently bound protein adducts.
Additionally compounds with this susceptibility are likely to generate poor IVIVe, 
as the formaldehyde reaction products are not formed when incubated in 
hepatocytes or microsomes under AstraZeneca’s standard incubation 
conditions. For these reasons compounds/chemical series with this liability 
should be avoided and structures containing homopiperazine rings should be 
tested for formaldehyde reactivity prior to any in vivo studies.
7.3 Bioactivation of a homomomholine (Chapter 5)
The lead compound for drug research programme carried out within 
Astrazeneca had a RM liability and was shown to generate significant CVB in 
vitro. A homomorpholine backup series was investigated to mediate this RM 
risk, initial GSH HLM trapping results were negative in the Astrazeneca GSH 
screening assay. However, initial in vitro metabolite identification studies 
uncovered an unexpected cysteinglycine adduct. A representative compound 
was selected for a detailed investigation, AZX, which will be referred to as AZXa 
to avoid confusion with the compounds discussed in Chapter 4 and 6. To 
generate enough of the cysteineglycine adduct for NMR analysis, incubations of 
AZXa were scaled up using cytochrome P450 (CYP) variants of CYP102A1 
from Bacillus megaterium (BM3) with GSH. The metabolite was isolated by 
fraction collection and initial LC-MS analysis confirmed the cysteineglycine 
product (m/z 662) had been isolated, however subsequent analysis by NMR 
showed the metabolite degraded during isolation. Therefore isolation of the 
metabolite was not possible, so more detailed MS product ion work on an LTQ- 
Orbitrap was undertaken on a fresh sample of AZXa to gain more structural 
information. It was possible to identify the molecular formula for each fragment 
ion using elemental composition software. Restricting the molecular formula 
parameters to the number and type of elements possible from the theoretical 
exact mass [M+H]+ ion of the cysteineglycine conjugate, ensured only the 
correct molecular formulae were reported for each product ion.
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From the product ion data it was possible to postulate a structure for the 
cysteineglycine adduct (Figure 38), and from this structure propose a 
mechanism of formation via a reactive aldehyde metabolite.
Figure 38 Proposed structure for the AZXa cysteineglycine adduct
A methoxyamine FILM trapping experiment confirmed the presence of an 
aldehyde metabolite, however MS3 product ion spectra were required to confirm 
the methoxyamine addition to the homopiperazine ring. There were two 
possible mechanisms of formation, the first involving the reaction of the 
aldehyde with the amine on the Cys moiety of GSFI, forming an imine 
intermediate (similar to the mechanism discussed in Chapter 2), which reacts 
with the thiol to form the thiazolidine-glycine proposed structure. The second 
mechanism is via reaction of the thiol in GSH with the aldehyde, the resulting 
mercaptomethanol undergoes an intermolecular reaction eliminating water and 
forming the proposed thiazolidine-glycine product. Both mechanisms involved 
the loss of the glutamyl from GSH prior or in the process of reacting with the 
aldehyde metabolite. The loss of the glutamyl made this GSH related adduct 
invisible to the LC-MS GSH -129 NL & m/z 272 PIS screening method (Section 
1.5.1.1) employed at the time of this work, thus highlighting the importance of 
early metabolite identification studies for the identification of RMs, rather than 
relying on automated LC-MS screening methods. It is recommended that 
homomorpholine rings are avoided in drug design if possible; if not that they are 
fully investigated for the formation of reactive aldehyde metabolites.
0
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7.4 Methanol adducts leading to the identification of a reactive
aldehyde metabolite (Chapter 6)
Through routine metabolite identification in HLM, two unexpected methanol 
adduct products were detected by LC-UV-MS for a chemical series in a drug 
discovery programme. Methanol adducts are common in mass spectrometry 
and are normally identified as analytical artefacts of the parent drug, generated 
during the positive ion ESI process and are therefore often ignored. In this 
example both methanol adducts were chromatographically separated from each 
other and the parent compound, so must have been generated prior to 
introduction into the MS ESI source. The T=0 control sample did not contain 
these adducts, so they were likely formed through a metabolic process, 
however addition of CH30  metabolically is very unusual. The methanol adducts 
disappeared on re-analysis when acetonitrile replaced methanol as eluent B, 
which inferred a metabolite was reacting with methanol on column. A 
representative compound was selected for a detailed investigation, AZX, which 
will be referred to as AZXb to avoid confusion with the compounds discussed in 
Chapter 4 & 5. AZXb generated several metabolites in HLM including the two 
methanol adducts, which were major products. Interpretation of the methanol 
adduct from AZXb product ion spectra confirmed the addition of methanol to the 
hydroxyacetamide side chain and that both methanol adducts generated 
identical product ion spectra. Therefore the likely site of methanol addition was 
the terminal hydroxy methyl, which created a pair of diastereisomers (Figure 
39).
Figure 39 AZXb methanol adduct diastereoisomers
HO
A plausible explanation for the chemical addition of methanol to the terminal 
hydroxy methyl would be metabolic oxidation of the terminal hydroxy to a 
reactive aldehyde that forms a hemiacetal with methanol. A methoxyamine
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trapping experiment confirmed the presence of an aldehyde metabolite, so 
bioactivation of AZXb had occurred via a reactive aldehyde intermediate, which 
subsequently reacted with methanol to form a pair of isomeric hemiacetal 
methanol adducts. The reactive aldehyde metabolite was not detected and 
could not be structurally characterized directly, as the equilibrium favoured the 
methanol adduct in acidified methanol and the hydrate in acidified acetonitrile.
The initial methoxyamine trapping experiment with AZXb in HLM reduced the 
metabolic turnover of AZXb and produced hydroxylated metabolites of the 
methoxyamine adduct. This was likely caused by the P450 inhibitory properties 
of methoxyamine121. Repeating the methoxyamine experiment, this time adding 
the methoxyamine post incubation, resulted in a much cleaner metabolic profile; 
with no reduction in metabolic turnover and a significant increase in yield of the 
methoxyamine adduct. The increase in yield of the methoxyamine adduct 
inferred there was a significant concentration of the aldehyde post incubation, 
this is in agreement that the aldehyde reacted with the methanol mobile phase 
on column forming the isomeric methanol adducts.
Whilst the reactive aldehyde metabolite could be proposed from the detection of 
methanol adducts, the hydrate metabolite is simply addition of Oxygen (+16 
amu) to parent compound, which is a very common biotransformation reaction. 
If the initial analysis had been undertaken in acetonitrile, it is likely that the 
hydrate would have been reported as a simple hydroxylated metabolite and the 
reactive aldehyde liability for the chemical series missed. This is especially true 
for AZXb, which when incubated in HLM fortified with GSH did not yield any 
GSH related conjugates. This is in contrast to the AZXb aldehyde metabolite 
discussed in Chapter 6 that formed a rearranged GSH adduct, but did not 
appear to react with the methanol mobile phase. The absence of methanol 
adducts for AZXa is likely due to the aldehyde forming an adduct with GSH, 
considering the excess GSH present, it is unlikely any aldehyde would be 
present at the time of the LC-MS analysis. Both AZXa and AZXb generated 
reactive aldehyde metabolites in HLM, which would not have been detected 
through the standard AZ RM trapping screens (GSH & KCN). Methoxyamine 
was successfully employed to trap both AZXa and AZXb reactive aldehyde 
metabolites. For these reasons compounds/chemical series with this liability
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should be avoided and structures containing a side chain with a terminal 
hydroxy should be tested for aldehyde formation with methoxyamine or 
semicarbazide.
7.5 Limitations of GSH LC-MS trapping screening assay
There are a number of trapping experiments available to capture and detect 
RMs (Section 1.5.1), however the most common within drug research are HLM 
incubations fortified with GSH for soft electrophiles and cyanide for hard 
electrophiles. They are often employed in early drug discovery in LC-MS RM 
trapping screening assays that utilise PIS, NLS or/and automated data 
processing to generate a quick yes/no answer (Section 1.5.1.1). The 
advantage of these early RM trapping screens is their ability to process 
relatively large numbers of compounds quickly and inexpensively, feeding back 
data within design make test cycles. Adducts are generally detected based on 
expected precursor ions, product ions or neutral losses from the GSH or 
cyanide adduct. However, none of the RM examples described in this thesis 
were detected by the current AZ GSH or cyanide RM LC-MS screening assays. 
From these studies there were 4 limitations highlighted;
7.5.1 Detectability of RMs from compounds with little or no in vitro
metabolic turnover
When a compound or chemical series have little or no in vitro metabolic 
turnover (Low Clint) in HLM, they are not likely to generate enough RM to be 
trapped and detected by LC-MS, even if bioactivation was a major metabolic 
route in vivo (e.g. Fenclozic acid). Prior to submission for RM trapping 
experiments the HLM Clint should have been determined for the test compound 
or chemical series, if the Clint is low then alternative studies to assess potential 
bioactivation should be considered. Cultured cells such as the HpREL system 
149 remain viable for much longer than human hepatocytes or HLM during 
incubations with test compounds. Thus compounds with low in vitro metabolic 
turnover can be incubated for days rather than hours, generating a more 
accurate Cljnt and significantly higher concentrations of metabolites.
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An in vitro radiolabelled CVB experiment is likely to be more sensitive and 
would indicate the presence of a RM (Fenclozic acid), however these studies 
require a radiolabelled analogue of the test compound. For that reason they are 
often only conducted when a compound has been selected for progression into 
development. For an earlier investigation in vivo metabolite identification may 
provide further information, however the animal species used for the in vivo 
metabolite identification may generate a completely different metabolic profile to 
humans.
7.5.2 Bioactivation to a RM in vivo is not represented in vitro
When a compound generates a RM in vivo, but the RM is not generated in vitro, 
RM trapping assays will generate a false negative. This is difficult to address 
as the RM may only be detected from detailed in vivo metabolite identification 
studies and it is not possible to predict what will occur in vivo in humans until 
later in the drugs development after considerable investment. Flowever, it was 
possible to detect a potential human RM of AZX (Chapter 4) through in vivo 
metabolite identification studies in preclinical species. It is therefore 
recommended that an in vivo metabolite identification is conducted alongside an 
in vitro incubation to determine if there is an in vitro/\n vivo RM disconnect prior 
to candidate selection for progression in to development. This is not a perfect 
solution as the animal species used for the in vivo metabolite identification may 
generate a different metabolic profile to humans, but it could be valuable to 
identify potential bioactivation reactions not represented in vitro.
7.5.3 GSH or cyanide trapping agents are unsuitable for the RM
Whilst GSH successfully trapped the AZXa reactive aldehyde metabolite 
(Chapter 4), it did form an adduct with the AZXb reactive aldehyde that was 
formed in significant quantities in HLM and subsequently reacted with methanol 
(Chapter 6). There are alternative nucleophilic trapping agents available to trap 
aldehyde metabolites such as methoxyamine or semicarbazide.
Methoxyamine successfully trapped both the AZXa and AZXb reactive aldehyde 
metabolites, however, methoxyamine’s inhibitory properties against P450 
enzymes121 significantly reduced the metabolic turnover for AZXb in HLM
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(Chapter 6). Spiking methoxyamine post incubation in HLM would prevent any 
inhibition from the trapping agent or further metabolism of the trapped adduct. 
Whilst this experiment successfully trapped the AZXb reactive aldehyde, the 
aldehyde was expected to be present post incubation at a significant 
concentration, due to its subsequent reaction with methanol from the LC-MS 
analysis. Therefore this may not work for all reactive aldehyde metabolites 
which could bind to microsomal protein during the incubation, resulting in little or 
no aldehyde metabolite remaining to adduct with the trapping agent post 
incubation. Semicarbazide adducts do not produce consistent straightforward 
product ions or neutral losses, so it is not possible to use automated LC-MS 
screening scan functions such as PIS/NLS or data processing to detect and find 
them.
Therefore it is unlikely that methoxyamine or semicarbazide would become part 
of the routine trapping screening assays employed, however they are useful for 
specific experiments to investigate a mechanism of bioactivation. Detailed 
metabolite identification experiments in vitro and in vivo are the most likely 
studies to identify RMs not trapped by cyanide or GSH, prior to in vitro 
radiolabelled CVB experiments conducted in late drug design. Trapping assays 
are useful tools for an early RM flag, but it is suggested that these do not 
replace more detailed metabolite identification studies for the investigation of 
RM liability.
7.5.4 Unexpected or unusual GSH rearrangement products not
detectable by current LC-MS GSH trapping screening assays.
RMs can form rearrangement products with GSH143 (Chapter 5) that do not 
generate expected [M+H]+ or [M-H]' ions, product ions or neutral loss by LC-MS 
and thus not detected by LC-MS GSH screening assays utilising -129 NLS/m/z 
272 PIS or predicted [M+H]+/[M-H]‘ ions (Section 1.5.1.1). It is very difficult to 
screen for these types of RMs by LC-MS detection, and an expert metabolite 
identification scientist utilising high resolution accurate mass instrumentation 
would often be required to identify these unusual GSH rearrangements. These 
studies are low throughput and time consuming, so it would be impossible to do
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this in replacement of routine RM trapping. However checking a representative 
compound from a chemical series in conjunction with RM trapping is feasible.
7.6 LC-UV-MS methodology
The application of UHPLC, UV and high resolution accurate mass data was 
critical for the identification, separation, isolation and structural elucidation of all 
metabolites and products. All of the compounds studied in this thesis contained 
reasonable chromophores, so absorbed UV at higher more selective 
wavelengths. Therefore it was easy to generate relatively clean UV 
chromatograms at selected wavelength ranges, that were extremely useful to 
help find and semi-quantify metabolites.
All MS data were acquired on either a Q-ToF operated in MSE mode or an LTQ- 
Orbitrap. Whilst the Q-ToF methodology was useful, accurate mass data 
acquired on the LTQ-Orbitrap was far superior, so superseded all Q-ToF data. 
The initial LTQ-Orbitrap MS analysis for all studies consisted of positive ion 
DDA with full scan and AIF in the orbitrap (accurate mass). Due to the scan 
time and LC peak widths it was not possible to acquire DDA orbitrap scans, so 
they were acquired in parallel in the ion trap with nominal mass. This method 
was successful and several metabolites were detected by post acquisition 
processing such as accurate mass common fragment searching using a narrow 
mass window (Figure 40), MDF and precursor/neutral loss searching of the 
DDA MS2 acquisitions.
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Figure 40 Selected ion mass chromatograms (+/-5 ppm narrow mass 
window) of Fenclozic acid (survey scan) and Fenclozic acid product ions 
(AIF) in rat urine.
254.0037
(+./-5ppm)
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207.9982 Fenclozic acid 
(+/-5ppm) metabolites _
138.0105
(+/-5ppm)
XX AIFscan
70.99450
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It was also possible to gain a reasonable amount of spectral information on the 
metabolites using accurate mass AIF and nominal mass DDA product ion scans 
in combination. Once all the positive ion metabolites were identified, additional 
runs were required to generate discrete accurate mass MS2 data that were 
acquired using DDA with a targeted m/z list. Due to the complexity of the bile 
and urine matrix analysed for Fenclozic acid, multiple runs were required to 
generate product ion spectra for all metabolites. It is not possible to acquire 
positive/negative switching data on a LTQ-Orbitrap or Q-ToF MS, so all 
negative ion data had to be acquired in separate runs. Acquiring both IT and 
collision cell based dissociation product ion spectra for every discrete MS2 
generated more product ions than each technique on its own and reduced the 
need for additional MSn experiments. However, it was still necessary to 
generate IT MS3 data to confirm the site of methoxyamine addition on the AZXa 
reactive aldehyde.
Whilst the LC-MS methodology was successfully employed for the detection 
and structural elucidation of all metabolites, several repeat LC-MS analyses 
were required to generate sufficient data for metabolite assignment. This is a 
significant limitation of the LC-MS methodology especially for early discovery
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work where results are time critical and small sample volumes are the norm. An 
optimal method would ideally, acquire negative and positive ion, AIF, DDA with 
CID and HCD MS2 accurate mass data in a single analysis and multiple scan 
cycles of these across the within the width of a UHPLC peak (~ 3 seconds 
wide). This would significantly reduce repeat analysis, sample usage, 
instrument time and the number of data files simplifying interpretation. This 
method is beyond the capability of most LC-MS systems including; Q-ToF, LTQ- 
Orbitrap and Q-Exactive mass spectrometers, in fact the Fusion MS is the only 
instrument with this capability.
7.7 Overall conclusion
The LC-MS methodology and bespoke trapping experiments were successfully 
employed to determine the structure and propose a mechanism of formation for 
all the RMs reported in this thesis. The limitations of conventional GSH trapping 
assays were identified for these RM examples and potential improvements to 
the LC-MS methodology for metabolite identification studies were highlighted.
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